<SEC-DOCUMENT>0001144204-11-052645.txt : 20110913
<SEC-HEADER>0001144204-11-052645.hdr.sgml : 20110913
<ACCEPTANCE-DATETIME>20110913140859
ACCESSION NUMBER:		0001144204-11-052645
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20110731
FILED AS OF DATE:		20110913
DATE AS OF CHANGE:		20110913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS ONCOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		111087742

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS BIOTECHNOLOGY, INC.
		DATE OF NAME CHANGE:	20070220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v234451_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Form 10-Q</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Mark One)</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt;" face="Wingdings">&#254;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">QUARTERLY REPORT PURSUANT TO SECTION 13</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">OR 15(d)</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">OF THE SECURITIES EXCHANGE ACT OF 1934</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">For the quarterly period ended</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">July 31, 2011</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Or</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt;" face="Wingdings">&#168;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">TRANSITION REPORT PURSUANT TO</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">SECTION 13 OR 15(d)</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">OF THE SECURITIES EXCHANGE ACT OF 1934</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">For the transition period from</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">to</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission file number 0-17263</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Exact name of registrant as defined in its charter)</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Delaware</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52-1401755</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(State or other jurisdiction of</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(I.R.S. Employer</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">incorporation or organization)</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Identification No.)</font></div>
</td>
</tr><tr>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">855 North Wolfe Street, Suite 619</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21205</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Baltimore, Maryland</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(Zip Code)</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(Address of principal executive offices)</font></div>
</td>
<td valign="top" width="4%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
</td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(410) 369-0365</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;Yes <font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">&#254;</font>&#160;&#160;&#160;&#160;&#160;No <font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports).&#160;&#160;Yes <font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">&#254;</font>&#160;&#160;&#160;&#160;&#160;No <font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="21%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Large accelerated filer <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td valign="top" width="16%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accelerated filer <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td valign="top" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-accelerated filer <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td align="right" nowrap valign="top" width="21%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Smaller reporting company <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
</tr><tr>
<td valign="top" width="21%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td nowrap valign="top" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Do not check if a smaller reporting company)</font></div>
</td>
<td valign="top" width="21%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;Yes <font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;No <font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">&#254;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The number of Common Shares of the Registrant outstanding as of August 31, 2011 was 46,268,436.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DOCUMENTS INCORPORATED BY REFERENCE - None</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INDEX TO FORM 10-Q</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR THE QUARTERLY PERIOD ENDED JULY 31, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td colspan="3" valign="bottom" width="100%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PART I - FINANCIAL INFORMATION</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Financial Statements.</font></div>
</td>
<td align="left" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" colspan="2" valign="bottom" width="94%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Condensed Consolidated Balance Sheets as of July 31, 2011 (unaudited) and April 30, 2011</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" colspan="2" valign="bottom" width="94%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended July 31, 2011 and 2010</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" colspan="2" valign="bottom" width="94%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended July 31, 2011 and 2010</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" colspan="2" valign="bottom" width="94%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to Unaudited Condensed Consolidated Financial Statements</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 3.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quantitative and Qualitative Disclosures About Market Risk</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 4.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Controls and Procedures</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#160;</font></div>
</td>
<td align="left" valign="bottom" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td colspan="3" valign="bottom" width="10%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PART II - OTHER INFORMATION</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Legal Proceedings</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1A.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk Factors</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unregistered Sales of Equity Securities and Use of Proceeds</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 3.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Defaults Upon Senior Securities</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 4.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other Information</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 5.</font></div>
</td>
<td align="left" valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibits</font></div>
</td>
<td valign="bottom" width="6%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20</font></div>
</td>
</tr></table>
</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART I &#8211; FINANCIAL INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 1. Financial Statements</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(unaudited)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ASSETS</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current assets:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,839,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,457,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts receivable</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,236,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">585,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant receivable</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">504,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">517,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">341,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">276,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current assets</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,920,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,835,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property and equipment, net</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">212,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">146,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">669,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">669,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">11,801,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,650,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LIABILITIES, COMMITMENTS AND CONTINGENCIES,</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,498,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,580,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">264,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">302,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred revenue</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,077,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,618,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,839,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant liability</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">795,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">972,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total liabilities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,634,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,472,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Commitments and contingencies</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Redeemable common stock; $0.001 par value; 12,533,333 contingently puttable common shares outstanding as of July 31, 2011 and April 30, 2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,159,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,159,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stockholders' equity (deficit):</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of July 31, 2011 and April 30, 2011</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common stock, $.001 par value; 125,000,000 shares authorized, including redeemable common stock, 36,971,667 and 36,956,667 shares issued and 33,930,103 and 33,870,000 shares outstanding as of July 31, 2011 and April 30, 2011, respectively</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Treasury stock, at cost, 3,236,000 common shares as of July 31, 2011 and April 30, 2011</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,252,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,252,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional paid-in capital</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,802,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,784,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accumulated deficit</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(18,519,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(16,482,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accumulated other comprehensive loss</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(60,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(68,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stockholders' equity (deficit)</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(992,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">19,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total liabilities, redeemable common stock and stockholders' equity (deficit)</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">11,801,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,650,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three Months Ended July 31,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating revenue:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Personalized oncology solutions</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">601,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,109,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Translational oncology solutions</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,033,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">491,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total operating revenue</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,634,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,600,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Costs and operating expenses:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost of personalized oncology solutions</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">483,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">324,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost of translational oncology solutions</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">419,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">222,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">541,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">919,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sales and marketing</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">688,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">134,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,717,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">604,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and operating expenses</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,848,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,203,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss from operations</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(2,214,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(603,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other income (expense):</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in fair value of warrant liability</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">177,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other income</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total other income</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">177,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss before provision for income taxes</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,037,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(591,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Provision for income taxes</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(2,037,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(591,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss per common share outstanding, including redeemable common stock, basic and diluted</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.04</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.02</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding, including redeemable common stock, basic and diluted</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">46,420,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">33,774,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td colspan="9" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,037,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(591,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Foreign currency translation adjustment</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Comprehensive loss</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(2,029,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(587,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three Months Ended July 31,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating activities:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,037,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(591,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments to reconcile net loss to net cash used in operating activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation expense</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,014,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">170,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation expense</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in fair value of warrant liability</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(177,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Changes in operating assets and liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts receivable</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(651,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant receivable</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses, deposits and other</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(65,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">109,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(82,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">165,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(38,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred revenue</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">459,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(355,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash used in operating activities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,535,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(436,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Investing activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Purchase of property and equipment</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(95,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(20,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash used in investing activities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(95,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(20,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Financing activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Purchase of treasury stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(31,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from exercise of options and warrants</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash provided by (used in) financing activities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(31,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exchange rate effect on cash and cash equivalents</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Decrease in cash and cash equivalents</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,618,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(484,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents, beginning of period</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">10,457,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,572,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents, end of period</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,839,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,088,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 1.&#160;&#160;Organization, Use of Estimates and Basis of Presentation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Champions Oncology, Inc. (the &#8220;Company&#8221;), is a company that is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company&#8217;s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice. The Company uses this technology to derive revenue for two customer groups: Personalized Oncology Solutions (&#8220;POS&#8221;), and Translational Oncology Solutions (&#8220;TOS&#8221;). Personal Oncology Solutions assist physicians in developing personalized treatment options for their cancer patients through access to panels of expert medical professionals and tumor specific data. The Company&#8217;s Translational Oncology Solutions offer a technology platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries:&#160;&#160;Biomerk, Inc, Champions Biotechnology U.K., Limited and Champions Oncology (Israel) Ltd., which was established in November 2010.&#160;&#160;All material intercompany transactions have been eliminated in consolidation.</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">The financial statements of the Company&#8217;s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for each period presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss. The Company is subject to foreign exchange rate fluctuations in connection with the Company&#8217;s international operations.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). All significant intercompany transactions and accounts have been eliminated. Certain information related to the Company&#8217;s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company&#8217;s annual consolidated financial statements for the year ended April&#160;30, 2011, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended April&#160;30, 2011.&#160;&#160;Certain reclassifications have been made to the prior period financial statement amounts to conform to current presentation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation assumptions used for share-based compensation and warrant liability, expenses related to personalized oncology solutions and the carrying amounts of long-lived assets and deferred taxes.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the period.&#160;&#160;Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the period, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method.&#160;&#160;Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable.&#160;&#160;Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.&#160;&#160;Due to the net losses for the three months ended July 31, 2011 and 2010, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table reflects the potential weighted average incremental shares of common stock that have been excluded from the computation of diluted loss per common share since their effect would be anti-dilutive.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three Months Ended July 31,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">437,054</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">650,385</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">431,668</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">462,273</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Restricted stock</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,974</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total common stock equivalents</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">868,722</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,115,632</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 2. Recently Issued Accounting Pronouncements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June 2011, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2011-05, &#8220;Presentation of Comprehensive Income&#8221; (&#8220;ASU 2011-05&#8221;).&#160;&#160;ASU 2011-05 provides for the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income (&#8220;OCI&#8221;) either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Regardless of which format is chosen, the amendments establish a requirement for entities to present on the face of the financial statements reclassification adjustments for items that are reclassified from OCI to net income in the statement(s) where the components of net income and the components of OCI are presented. The amendments in ASU 2011-05 are effective, on a retrospective basis, for public entities for interim and annual periods beginning after December 15, 2011. The adoption of this guidance will not have any impact on the Company&#8217;s financial position and results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In May 2011, the FASB issued ASU No. 2011-04, &#8220;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs&#8221; (&#8220;ASC 2011-05&#8221;).&#160;&#160;The amendments in ASC 2011-05 were issued in order to align the fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards.&#160;&#160;Consequently, the amendments change the wording used to describe many of the requirements in GAAP for measuring fair value and for disclosing information about fair value measurements.&#160;&#160;However, many of the amendments in ASC 2011-05 will not result in a change in the application of the requirements in ASC 820, Fair Value Measurement. The amendments in ASU 2011-04 are effective, on a prospective basis, for public entities for interim and annual periods beginning after December 15, 2011. The adoption of this guidance will not have any impact on the Company&#8217;s financial position and results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During December&#160;2010, the FASB issued ASU No.&#160;2010-28, Intangibles - Goodwill and Other (&#8220;ASU 2010-28&#8221;). ASU 2010-28 addresses questions about entities with reporting units with zero or negative carrying amounts because some entities concluded that Step 1 of the goodwill impairment test is passed in those circumstances because the fair value of their reporting unit will generally be greater than zero. The amendments in this update do not provide guidance on how to determine the carrying amount or measure the fair value of the reporting unit. The amendments in this update modify Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. This update was effective for fiscal years beginning after December 15, 2010. The Company does not anticipate that the adoption of this standard will have a&#160;&#160;material impact on the Company&#8217;s financial position and results of operations. The Company tests for goodwill impairment annually during its fourth quarter, or more frequently if circumstances indicate potential impairment.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 3. Property and Equipment</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following:</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(unaudited)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Furniture and fixtures</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Computer equipment and software</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">167,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">119,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Laboratory equipment</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">67,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Leasehold improvements</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Software in-progress</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">26,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">24,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total property and equipment</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">306,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">211,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less: Accumulated depreciation</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(94,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(65,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property and equipment, net</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">212,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">146,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation expense was $29,000 and $10,000 for the three months ended July&#160;31, 2011 and 2010, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 4. Share-Based Payments</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has in place a 2010 Equity Incentive Plan, a 2008 Equity Incentive Plan and a Director Compensation Plan of 2010, all of which are described in more detail in the Company&#8217;s Annual Report on Form 10-K for the year ended April&#160;30, 2011. In general, these plans provide for stock-based compensation in the form (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company&#8217;s employees, directors and non-employees.&#160;&#160;The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock-based compensation in the amount of $1,014,000 and $170,000 was recognized for the three months ended July 31, 2011 and 2010, respectively.&#160;&#160;Stock-based compensation expense was recognized as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three Months Ended July 31,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">916,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">140,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sales and marketing</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">24,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">22,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stock-based compensation expense</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,014,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">170,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stock Option Grants</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2011 and 2010 were as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three Months Ended July 31,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected term in years</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.75</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk-free interest rates</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.9% - 2.2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Volatility</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">107.1% - 107.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">104</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividend yield</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The weighted average fair value of stock options granted during the three months ended July 31, 2011 and 2010 was $0.74 and $0.75, respectively. The Company&#8217;s stock options activity for the three months ended July 31, 2011 is as follows:</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Directors</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">and</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intrinsic</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Employees</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Employees</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Total</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Life (Years)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Value</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding, May 1, 2011</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,610,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,710,948</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,320,948</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.88</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.44</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">245,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">245,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.92</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(50,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(50,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expired</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in employee status</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding, July 31, 2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,610,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,905,948</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">14,515,948</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.88</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.13</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">653,643</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested and expected to vest as of July 31, 2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,610,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,879,281</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">14,489,281</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.88</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.13</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">652,310</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercisable as of July 31, 2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,533,333</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,859,250</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5,392,583</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.86</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.33</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">442,526</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Restricted Stock Grants</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of the activity related to restricted stock grants is as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant</font></div>
</td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date Fair</font></div>
</td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Value Per</font></div>
</td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Shares</font></font></div>
</td>
<td nowrap valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Share</font></font></div>
</td>
<td nowrap valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nonvested as of May 1, 2011</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100,000</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.90</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,000</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.90</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited</font></div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nonvested as of July 31, 2011</font></div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">50,000</font></font></td>
<td nowrap valign="bottom" width="2%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.90</font></td>
<td nowrap valign="bottom" width="2%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The aggregate fair value of shares vested during the three months ended July 31, 2011 was $43,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stock Purchase Warrants</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of July 31, 2011, the Company has warrants outstanding for the purchase of 1,897,019 shares of its common stock, all of which are exercisable.&#160;&#160;Of these warrants, 1,266,667 were issued in connection with the April 2011 financing arrangement and are accounted for as liabilities as further discussed in Note 5. 15,000 warrants were exercised on July 11, 2011.&#160;&#160;As of July 31, 2011, the weighted average exercise price of these warrants was $0.73 and the weighted average contractual life was 3.46 years.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 5. Redeemable Common Stock and Stock Purchase Warrant</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale to the investors of an aggregate 12,533,333 shares of the Company&#8217;s Common Stock at a purchase price of $0.75 per share, or an aggregate of $9,400,000, of which, $500,000 was sold to officers and directors of the Company.&#160;&#160;As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667&#160;&#160;shares of Common Stock at an exercise price of $0.90 per share.&#160;&#160;These warrants expire five years after the closing date, which occurred on April 4, 2011.&#160;&#160;The Securities Purchase Agreement contains certain anti-dilution protections for the investors and certain registration rights with respect to the shares of Common Stock issued to the investors.&#160;&#160;Furthermore, investors will have the right to require the Company to redeem the purchased common shares held by such investors (the &#8220;Put Option&#8221;) for cash for $0.75 per share upon a change of control or sale of substantially all of the company&#8217;s assets.&#160;&#160;The Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The warrants issued in connection with the Securities Purchase Agreement contain certain exercise price reset provisions.&#160;&#160;Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants.&#160;&#160;These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period.&#160;&#160;If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists.&#160;&#160;The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement is $41,000 for each 30-day period in which a registration default exists; however, as of the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has accounted for the warrants issued in connection with the Securities Purchase Agreement as liabilities based on the exercise price reset provisions described above.&#160;&#160;This liability, which is recorded at fair value on the accompanying unaudited condensed consolidated balance sheets, totaled $936,000 at the time of the close of the Securities Purchase Agreement.&#160;&#160;As of April 30, 2011, the fair value of these warrants increased $36,000 to $972,000.&#160;&#160;During the quarter ended July 31, 2011, the fair value of these warrants decreased by $177,000 to $794,000.&#160;&#160;The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company&#8217;s unaudited condensed consolidated Statements of Operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected term in years</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk-free interest rates</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Volatility</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">103</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">102</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividend yield</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due to the Put Option described above, the Company has accounted for&#160;&#160;Common Stock issued under the Securities Purchase Agreement as temporary equity, which is reflected under the caption &#8220;Redeemable common stock&#8221; on the accompanying Condensed Consolidated Balance Sheets.&#160;&#160;The total amount allocated to these common shares was $8,159,000.&#160;&#160;This allocation is equal to the total proceeds of $9,400,000, less the amount allocated to the warrants of $936,000 and is also net of direct and incremental costs associated with the Securities Purchase Agreement of $305,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 6. Related Party Transactions</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Related party transactions include transactions between the Company and certain of its shareholders, management and affiliates.&#160;&#160;The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Consulting Services</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the three months ended July 31, 2011 and 2010, the Company paid one of its directors and former Chief Executive Officer, $18,000 and $15,000, respectively, in consulting fees.&#160;&#160;During the three months ended July 31, 2011 and 2010, the Company paid certain members of its Board of Directors $16,000 and $10,000, respectively, for consulting services unrelated to their duties as board members.&#160;&#160;The Company incurred $4,000 in expenses for the three months ended July 31, 2011 from a substantial stockholder of the Company for consulting fees. $2,000 was payable to this stockholder as of July 31, 2011. As of the date of this filing, the Company has satisfied this obligation. No such expenses were incurred for the three months ended July 31, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Revenue</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the three months ended July 31, 2011, the Company recognized $20,000 in revenues from companies whose board members were also members of the Company&#8217;s Board of Directors. These revenues are still receivable as of the date of this filing. No such revenues were incurred for the three months ended July 31, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 7. Commitments and Contingencies</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Operating Leases</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of July 31, 2011, the Company leases office and laboratory space under a non-cancelable operating lease in Baltimore, Maryland, which expires in April 2014, office space under a non-cancelable operating lease in Ra&#8217;anana, Israel, which expires in July 2012, and office space in Hackensack, New Jersey under a non-cancellable operating lease, which expires in 2014.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Rent expense under all lease agreements was approximately $36,700 and $14,200 for the three months ended July 31, 2011 and 2010, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Research and Development Materials Purchase Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In February 2010, the Company entered into a research and development materials purchase agreement with a foreign hospital for the acquisition of Tumorgrafts.&#160;&#160;Under the agreement, the Company makes monthly payments to the foreign hospital of approximately $37,000 for 18 months, commencing March 1, 2010.&#160;&#160;Future payments due under the agreement total $144,000 at July 31, 2011 and are due during&#160;the remainder of the fiscal year ending April 30, 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Legal Matters</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is party to certain legal matters arising in the ordinary course of its business.&#160;&#160;The Company has evaluated its potential exposure to these legal matters, and has concluded that there were no reasonably possible or probable liabilities at July 31, 2011 and April 30, 2011.&#160;&#160;The Company is not aware of any other matters that would have a material impact on the Company&#8217;s financial position or results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Registration Payment Arrangements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has entered into registration rights agreements in connection with a private placement of its securities, which closed during April 2011 and is discussed more fully in Note 5.&#160;&#160;This registration rights agreement contains provisions that may call for the Company to pay penalties in certain circumstances.&#160;&#160;This registration payment arrangement primarily relates to the Company&#8217;s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period.&#160;&#160;The Company does not believe it is probable that penalty payments will be made for the registration rights agreement discussed above and, accordingly, has not accrued for such potential penalties as of July 31, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 8. Licensing Agreements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During fiscal 2011, the Company was a party to several different licensing agreements, all of which are described in more detail in the Company&#8217;s Annual Report on Form 10-K for the year ended April&#160;30, 2011.&#160;&#160;During April 2011, the Company terminated all of these licensing agreements with the exception of the Liposome Option Agreement, which is described further below.&#160;&#160;All rights related to all other licensing agreements that were terminated during April 2011 were returned to the underlying companies and no amounts were due under these other agreements as of April 30, 2011.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In February 2010, the Company entered into an exclusive option agreement with a Canadian company for which it paid and expensed $40,000 during the Company&#8217;s fiscal 2010 year.&#160;&#160;The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast and lung cancer through April 2011.&#160;&#160;During the option year, the Company performed various tumorgraft testing on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. Under the terms of the agreement, the company&#8217;s exercise of the option resulted in amounts due to the Canadian company of $85,000 comprised of the option exercise price and reimbursement to the Canadian company for past patent costs, which is recorded as a liability as of July 31, 2011 and April 30, 2011.&#160;&#160;As of the date of this filing, the Company has satisfied this obligation.&#160;&#160;Under the terms of the license agreement, the Company will be required to pay up to $3 million in development milestones.&#160;&#160;Upon commercialization, the Company would also be required to make royalty payments and sales milestone based upon revenues.&#160;&#160;&#160;Commencing with the second anniversary of the agreement (March 2013), the Company will be obligated to pay a minimum annual royalty of $10,000 (Canadian).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 9. Cephalon Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March&#160;16, 2011, the Company entered into an agreement with Cephalon, Inc., (&#8220;Cephalon&#8221;), pursuant to which the Company will conduct low Tumorgraft studies on proprietary chemical compounds provided by Cephalon to determine the activity or response of a compound in potential clinical indications. In April 2011, Cephalon paid an initiation fee of $1,390,000 to the Company which is reflected within deferred revenue on the Condensed Consolidated Balance Sheets as of July 31, 2011 and April 30, 2011. The Company anticipates that the studies will be completed within 12 months of the execution of the agreement.&#160;&#160;As models, along with required reports, are delivered, the deferred revenue will be recognized on a proportionate basis in accordance with the Company&#8217;s revenue recognition policies. No revenue was recognized in the quarter ended July 31, 2011, as no models were delivered. The Company expects the models will begin being delivered in the second quarter of our fiscal year ending April 30, 2012. Cephalon will, under certain conditions, also pay the Company various amounts upon achieving certain milestones. Potential milestone payments under the Agreement total $27&#160;million. In addition, under certain conditions, Cephalon will pay the Company royalties on any commercialized products developed under the Agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 10. Supplemental Cash Flow Information</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There was no cash paid for interest or income taxes during the three months ended July 31, 2011 and 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note 11. Grant Income</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 29, 2010, the Company was notified that it was awarded total cash grants of approximately $1.5 million under the Qualifying Therapeutic Discovery Project program administered under section 48D of the Internal Revenue Code, of which approximately $1.0 million related to qualifying expenses the Company had previously incurred during fiscal 2010 and $0.5 million related to qualifying expenses which the Company expected to incur during fiscal 2011.&#160;&#160;In November 2010, the Company received approximately $1.0 million and expects to receive $0.5 million related to the 2011 expenditures during the Company&#8217;s fiscal year.&#160;&#160;To date, the $0.5 million has not been received.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Item 2.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Management&#8217;s Discussion and Analysis of Financial Condition and</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">Results of Operations</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">Forward-Looking Statements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This Quarterly Report on Form 10-Q, including Item&#160;2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contains certain &#8220;forward-looking statements,&#8221; which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management&#8217;s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates&#8221; and similar expressions, as well as statements in future tense, identify forward-looking statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management&#8217;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of our Annual Report on Form 10-K for the fiscal year ended April&#160;30, 2011, as updated in our subsequent reports filed with the SEC, including any updates found in Part&#160;II, Item&#160;1A of this or other reports on Form 10-Q. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Overview and Recent Developments</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As explained in Item 1, &#8220;Business&#8221; of our Form 10-K for the year ended April 30, 2011, our operations have recently been refocused to emphasize our Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS) lines of business.&#160;&#160;We also plan to continue our research and development efforts to expand our Tumorgraft Technology Platform in order to expand our TOS program.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating Results</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes our operating results for the periods presented below:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="18" nowrap valign="bottom" width="48%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">For the Three Months Ended July 31,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">% of</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">% of</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Revenue</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Revenue</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Change</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating revenue:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Personalized oncology solutions</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">601,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,109,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">69.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(45.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)%</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Translational oncology solutions</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,033,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">63.2</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">491,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">30.7</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">110.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total operating revenue</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,634,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">100.0</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,600,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">100.0</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Costs and operating expenses:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost of personalized oncology solutions</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">483,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">324,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost of translational oncology solutions</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">419,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">222,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">88.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">541,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">919,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">57.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(41.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sales and marketing</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">688,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">42.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">134,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">413.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,717,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">105.1</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">604,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">37.8</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">184.3</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and operating expenses</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,848,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">235.5</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,203,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">137.7</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74.7</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating loss</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(2,214,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(135.5</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)%</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(603,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(37.7</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)%</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="7%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">267.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Operating Revenues</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating revenues were $1.6 million for each of the three month periods ended July 31, 2011 and 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Personalized oncology solutions revenues were $0.6 million and $1.1 million for the three months ended July 31, 2011 and 2010, respectively, a decrease of $0.5 million, or 46%.&#160;&#160;This decrease was the result of the Company&#8217;s strategic decision to re-engineer its products to facilitate lower price points which are expected to result in higher volumes. During the quarter, the Company did generate significantly higher volumes, but these were not yet sufficient to overcome the impact of the price decreases.&#160;&#160;These decreases were partially offset by an increase in gene sequencing revenue over the prior year first quarter.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Translational oncology solutions revenues were $1.0 million and $0.5 million for the three months ended July 31, 2011 and 2010, respectively, an increase of $0.5 million or 110%.&#160;&#160;The increase in TOS&#160;revenues was due primarily to an increase in the number of contracts over the prior year first quarter, driven by the Company&#8217;s increased sales efforts.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Cost of Personalized Oncology Solutions</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost of POS for the three months ended July 31, 2011 and 2010 was $0.5 million and $0.3 million, respectively, an increase of $0.2 million, or 49%.&#160; For the three months ended July 31, 2011 and 2010, gross margins for POS were 20% and 71%, respectively.&#160;&#160;The decrease in gross margin was due to declines in pricing.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Cost of Translational Oncology Solutions</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost of TOS for the three months ended July 31, 2011 and 2010 was $0.4 million and $0.2 million, respectively, an increase of $0.2 million, or 89%.&#160;&#160;The increase in costs was due to the increased volume of TOS business.&#160;&#160;For the three months ended July 31, 2011 and 2010, gross margins for TOS were 59% and 55%, respectively.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Research and Development</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research and development expenses for the three months ended July 31, 2011 and 2010 were $0.5 million and $0.9 million, respectively, a decrease of $0.4 million, or 41%.&#160;&#160;The decrease from prior year first quarter was primarily related to lower spending on our technology platform and tumorgraft testing on the in-licensed compounds.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Sales and Marketing</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sales and marketing expenses for the three months ended July 31, 2011 and 2010 were $0.7 million and $0.1 million, respectively, an increase of $0.6 million, or 413%.&#160;&#160;The increase is primarily related to the increase in Company sales force personnel and increased marketing and promotional expenses.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">General and Administrative</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General and administrative expenses for the three months ended July 31, 2011 and 2010 were $1.7 million and $0.6 million, respectively, an increase of $1.1 million, or 184%.&#160;&#160;The increase is primarily related to an increase in stock-based compensation and an increase in Company personnel due to growth.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Other Income (Expense)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other income for the three months ended July 31, 2011 and 2010 was $177,000 and $12,000 respectively, an increase of $165,000.&#160;&#160;During the three months ended July 31, 2011, the Company recognized income of $177,000 for the change in fair value of warrants that are accounted for as liabilities and are described further below and in Note 5 to the accompanying unaudited condensed consolidated financial statements. The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. This change in fair value of warrant liability was a result of revaluing the warrant liability based on the Monte Carlo simulation valuation model, impacted primarily by the quoted price of the Company's common stock. The revaluation of the warrant liability has no impact on our cash balances.<a name="FIS_LIQUIDITY_CAPITAL"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Liquidity and Capital Resources</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements and other strategic initiatives.&#160;&#160;In the past, we have met these cash requirements through our cash and cash equivalents, working capital management and proceeds from certain private placements of our securities.&#160;&#160;As of July 31, 2011, we had working capital of $7.1 million and cash and cash equivalents of $8.8 million.&#160;&#160;We believe that our cash and cash equivalents on hand at July 31, 2011 are adequate to fund operations for at least the next twelve months.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 24, 2011, we entered into a Securities Purchase Agreement with several accredited investors for the sale to the investors of an aggregate 12,533,333 shares of the Company&#8217;s common stock at a purchase price of $0.75 per share, or an aggregate of $9,400,000, of which, $500,000 was sold to officers and directors of the Company.&#160;&#160;As part of this transaction, we issued warrants to purchase an aggregate 1,010,000 shares of common stock at an exercise price of $0.90 per share.&#160;&#160;These warrants expire five years after the closing date, which occurred on April 4, 2011.&#160;&#160;The Securities Purchase Agreement contains certain anti-dilution protections for the investors and certain registration rights with respect to the shares of common stock issued to the investors.&#160;&#160;Furthermore, investors will have the right to require the Company to repurchase the purchased common shares held (the &#8220;Put Option&#8221;) for cash for $0.75 per share upon a change of control or sale of substantially all of the company&#8217;s assets.&#160;&#160;The Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The warrants issued in connection with the Securities Purchase Agreement contain certain exercise price reset provisions.&#160;&#160;Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its common stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has accounted for the warrants issued in connection with the Securities Purchase Agreement as liabilities based on the exercise price reset provisions described above.&#160;&#160;This liability, which is recorded at fair value on the accompanying Condensed Consolidated Balance Sheets, totaled $746,000 at the time of the close of the Securities Purchase Agreement.&#160;&#160;As of April 30, 2011, the fair value of these warrants increased $36,000 to $782,000.&#160;&#160;During the quarter ended July 31, 2011, the fair value of these warrants decreased by $177,000 to $794,000.&#160;&#160;The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company&#8217;s Statement of Operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. Changes in the liability from period to period are recorded in the statements of operations under the caption "Change in fair value of warrants."</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due to the Put Option described above, the Company has accounted for the Common Stock issued under the Securities Purchase Agreement as temporary equity, which is reflected under the caption &#8220;Redeemable common stock&#8221; on the consolidated balance sheet, at April 30, 2011 included in Item 15.&#160;&#160;The total amount allocated to these common shares was $8,159,000.&#160;&#160;This allocation is equal to the total proceeds of $9,400,000, less the amount allocated to the warrants of $936,000 and is net of direct and incremental costs associated with the Securities Purchase Agreement of $305,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If we require additional cash, there can be no assurance that management will be successful in raising additional capital on terms acceptable to us, if at all.&#160;&#160;Our ability to successfully complete a raise of capital will depend on the conditions of the capital markets and our financial condition and prospects.&#160;&#160;Even if we are able to successfully raise additional capital, such capital could be in the form of debt and could be at high interest rates and/or require us to comply with restrictive covenants that limit financial and business activities.&#160;&#160;In addition, even if we are able to successfully raise equity capital, this could dilute the interest of existing shareholders and/or be issued with preferential liquidation, dividend or voting rights to those currently held by our common stockholders.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Cash Flows</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following discussion relates to the major components of our cash flows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Cash Flows from Operating Activities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net cash used in operating activities was $1.5 million and $0.4 million for the three months ended July 31, 2011 and 2010, respectively.&#160;&#160;The increase of $1.1 million cash used in operations relates to the net loss and the increase in accounts receivable, offset primarily by an increase in stock-based compensation expense.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Cash Flows from Investing Activities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net cash used in investing activities was $95,000 and $20,000 for the three months ended July 31, 2011 and 2010, respectively.&#160;&#160;Cash used for the quarter ended July 31, 2011 relates to the purchase of property and equipment.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Cash Flows from Financing Activities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net cash provided by financing activities was $4,000 for the three months ended July 31, 2011, due to the exercise of 15,000 warrants.&#160;&#160;Net cash used in financing activities were $31,000 for the three months ended July 31, 2010, due to the purchase of treasury stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Critical Accounting Estimates and Policies</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We believe that of our significant accounting policies, the following may involve a higher degree of judgment and complexity:</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">General</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).&#160;&#160;The preparation of the consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities.&#160;&#160;On an ongoing basis, we evaluate our estimates, including those related to areas that require a significant level of judgment or are otherwise subject to an inherent degree of uncertainty.&#160;&#160;These areas include carrying amounts of long-lived assets and deferred taxes.&#160;&#160;We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources.&#160;&#160;Actual amounts could differ significantly from amounts previously estimated.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Revenue Recognition</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We derive revenue from POS and TOS.&#160;&#160;Personalized oncology solutions assist physicians by providing information that may enhance personalized treatment options for their cancer patients through access to expert medical information panels and tumor specific data.&#160;&#160;Translational oncology solutions offer a preclinical tumorgraft platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.&#160;&#160;We recognize revenue when the following four basic criteria are met: (i) a contract has been entered into with our customers; (ii) delivery has occurred or services have been rendered to our customers; (iii) the fee charged is fixed and determinable as noted in the contract; and (iv) collectability is reasonably assured, as fees for services are remitted in full upon execution of the contract.&#160;&#160;We utilize a proportional performance revenue recognition model for its translational oncology solutions under which we recognize revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to our customers documenting the results of our testing protocols.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">When a personalized oncology solution or translational oncology solution arrangement involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting.&#160;&#160;We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered.&#160;&#160;Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) has standalone value to the customer, (ii) if we have given the customer a general right of return relative to the delivered item(s), and (iii) delivery or performance of the undelivered item(s) or service(s) is probable and substantially in our control. Revenue on multiple element arrangements is recognized using a proportional method for each separately identified element.&#160;&#160;All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or if there is no predominant deliverable upon delivery of the final element of the arrangement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Share-Based Payments</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We typically recognize expense for share-based payments based on the fair value of awards on the date of grant.&#160;&#160;We use the Black-Scholes option pricing model to estimate fair value.&#160;&#160;The option pricing model requires us to estimate certain key assumptions such as expected life, volatility, risk free interest rates, and dividend yield to determine the fair value of share-based awards.&#160;&#160;These assumptions are based on historical information and management judgment.&#160;&#160;We expense share-based payments over the period that the awards are expected to vest, net of estimated forfeitures.&#160;&#160;If the actual forfeitures differ from management&#8217;s estimates, compensation expense is adjusted.&#160;&#160;We report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Warrant Liability</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Warrant liability represents the fair value of warrants issued in connection with the Securities Purchase Agreement as liabilities based on the certain exercise price reset provisions.&#160;&#160;The&#160;&#160;liability, which is recorded at fair value on the accompanying consolidated balance sheet, is calculated by the Monte Carlo simulation valuation method.&#160;&#160;The change in fair value of these warrants is recognized as other expense in the consolidated statement of operations.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Research and Development</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="V228749_10K_HTM_PAGE18"><!--EFPlaceholder--></a>&#160;Research and development costs represent costs incurred internally for research and development activities, costs of licensing drug compounds as well as costs incurred externally to fund research activities.&#160;&#160;All research and development costs are expensed as incurred.&#160;&#160;Non-refundable advance payments are capitalized and recorded as expense when the respective product or services are delivered.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Recently Issued Accounting Pronouncements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See Note 2 of our Notes to Unaudited Condensed Consolidated Financial Statements included in Item 1 of this Form 10-Q.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Off-Balance Sheet Financing</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have no off-balance sheet debt or similar obligations. We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position. We do not guarantee any third-party debt.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 4.&#160;&#160;Controls and Procedures</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Evaluation of Disclosure Controls and Procedures</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It is management&#8217;s responsibility to establish and maintain &#8220;disclosure controls and procedures&#8221; as such term is defined in Rule&#160;13a-15 under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;). Our management, with the participation of our Chief Executive Officer and our Acting Principal Financial Officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of a date within ninety (90)&#160;days of the filing date of this Form 10-Q quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Acting Principal Financial Officer, have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Acting Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Changes in Internal Control Over Financial Reporting</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule&#160;13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART II &#8211; OTHER INFORMATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 1. Legal Proceedings</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">From time to time we are involved in litigation incidental to the conduct of our business. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 1A. Risk Factors</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There have been no material changes in risk factors previously disclosed in our Form 10-K for the year ended April 30, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 3. Defaults Upon Senior Securities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 4. Other Information</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 5. Exhibits</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">No.</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="92%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exhibit</font></font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.1</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8650 Section 302 Certification of Chief Executive Officer</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.2</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8650 Section 302 Certification of Chief Financial Officer</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.1</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="92%" style="TEXT-ALIGN: justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of&#160;&#160;2002</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press Release dated September 13, 2011</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="92%" style="TEXT-ALIGN: justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interactive data files providing financial information from the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2011 in XBRL (eXtensible Business Reporting Language) pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Balance Sheets, July 31, 2011 and April 30, 2011, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended July 31, 2011 and 2010, (iii) Condensed Consolidated Statements of Cash Flows for the three months ended July 31, 2011 and 2010, and (v) Notes to Consolidated Financial Statements</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CHAMPIONS ONCOLOGY, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CHAMPIONS ONCOLOGY, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: September 13, 2011</font></div>
</td>
<td valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;&#160;</font></div>
</td>
<td valign="top" width="45%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160;/s/ Joel Ackerman</font></font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Joel Ackerman&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer and</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Acting Chief Financial Officer&#160;</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v234451_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT 31.1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section&#160;302 Certification</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Joel Ackerman, certify that:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">I have reviewed this Quarterly Report on Form 10-Q of Champions Oncology, Inc., a Delaware corporation;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(a)</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(b)</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(c)</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(d)</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting; and</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(a)</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(b)</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: September 13, 2011</font></div>
</td>
<td align="left" valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ Joel Ackerman</font></font></div>
</td>
<td valign="top" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Joel Ackerman</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer (Principal Executive</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Officer) and Acting Principal Financial Officer</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>v234451_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT 32.1<a name="FIS_CERTIFICATION_2"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the Quarterly Report of Champions Biotechnology, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending July 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: September 13, 2011&#160;</font></div>
</td>
<td valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ Joel Ackerman</font></font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Joel Ackerman&#160;</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer (Principal Executive</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Officer) and Acting Principal Financial Officer</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>v234451_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT 99.1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Champions Oncology, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">NEWS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Tel. 410-369-0365</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">For Immediate Release</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Champions Oncology Reports Fiscal 2012 First Quarter Financial Results</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Baltimore, MD, September 13, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Champions Oncology, Inc. formerly Champions Biotechnology, Inc. (OTC: CSBR) reported the following results:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Fiscal Year 2012 First Quarter Financial Results:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Total operating revenues for the first quarter of fiscal 2012 were $1.63 million compared to $1.60 million in the first quarter of fiscal 2011.&#160;&#160;Total operating expenses for the first quarter of fiscal 2012 were $3.85 million compared to $2.20 million in the first quarter of fiscal 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Champions reported a net loss of $2.04 million, or ($0.04) per share, compared to a net loss of $0.59 million, or ($0.02) per share, in the corresponding prior year quarter.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Champions recognized a net loss of $1.03 million excluding stock based compensation* of $1.01 million, or ($0.02) per share for the first quarter of fiscal 2012 compared to a net loss of $0.42 million excluding stock based compensation* of $0.17 million, or ($0.01) per share for the first quarter of fiscal 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Services Revenues</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Revenues from Translational Oncology Solutions (TOS) were $1.03 million for the quarter compared to $0.49 million in the corresponding quarter of the prior year, an increase of 110%.&#160;&#160;The increase in TOS revenues was driven by an increase in the number of contracts over the prior period, resulting from the company&#8217;s increased sales efforts.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Cost of TOS services for the first quarter of fiscal 2012 was $0.42 million which resulted in a gross margin of 59% as compared to 55% in the corresponding 2011 fiscal quarter.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #00000a">Revenues from Personalized Oncology Solutions (POS) were $0.60 million compared to $1.11 million in the corresponding prior year quarter. This decrease was the result of the company&#8217;s strategic decision to re-engineer its products to facilitate lower price points which are expected to result in higher volumes</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">. During the quarter, the company did generate significantly higher volumes but these were not yet sufficient to overcome the impact of the price decreases.&#160;&#160;These decreases were partially offset by an increase in sequencing revenue over the prior year first quarter.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Cost of POS for the first quarter of 2012 was $0.48 million which resulted in a gross margin of 20% as compared to 71% in the corresponding 2011 fiscal quarter.&#160;&#160;The decrease in gross margin can be attributed to declines in pricing.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #00000a; FONT-FAMILY: Times New Roman">Research and development (&#8220;R&amp;D&#8221;) expenses for the first quarter of</font><font style="DISPLAY: inline; COLOR: #00000a"> fiscal 2012 were $0.54 million as compared to $0.92 million in the first quarter of fiscal 2011.&#160;&#160;</font>The decrease from 2011 to 2012 was primarily related to lower spending on our technology platform and tumorgraft testing on the in-licensed compounds.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Sales and marketing expenses for first quarter of fiscal 2012 were $0.69 million as compared to $0.13 million in the first quarter of fiscal 2011.&#160;&#160;The increase is primarily related to the increase in Company sales force personnel and increased marketing and promotional expenses.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">General and administrative expenses for first quarter of fiscal 2012 were $1.72 million as compared to $0.60 million in the first quarter of fiscal 2011.&#160;&#160;The increase is primarily related to the increase in Company personnel due to growth and stock-based compensation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">For the first quarter of fiscal 2012, the Company reported a net loss of $2.04 million, or ($0.04) per share, compared to a net loss of $0.59 million, or ($0.02) per share, in the corresponding quarter of fiscal 2011.&#160;&#160;In addition to the factors described above, the Company&#8217;s net losses reflect non-cash expenses, i.e., share-based compensation and depreciation, of $1.04 million or ($0.02) per share, in the first quarter of 2012 compared to $0.18 million, or ($0.01) per share, in the first quarter of 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">The Company&#8217;s cash position on July 31, 2011 was $8.84 million.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">* Non-GAAP Financial Information</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">See the attached Reconciliation of GAAP Net Loss to Non-GAAP Net Loss for an explanation of the amounts excluded to arrive at non-GAAP net loss and related non-GAAP loss per share amounts for the fiscal first quarter ended, 2012 and 2011, respectively.&#160;&#160;Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis.&#160;&#160;Certain unusual or non-recurring items that management does not believe affect the Company&#8217;s basic operations do not meet the GAAP definition of unusual or non-recurring items.&#160;&#160;Non-GAAP net loss and non-GAAP loss per share are not, and should not be viewed as a substitute for similar GAAP items.&#160;&#160;We define non-GAAP diluted loss per share amounts as non-GAAP net loss divided by the weighted average number of diluted shares outstanding.&#160;&#160;Our definition of non-GAAP net loss and non-GAAP diluted loss per share may differ from similarly named measures used by others.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #00000a">Full details of the Company&#8217;s financial results will be available in the Company&#8217;s Form 10-Q at</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">www.championsoncology.com</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About Champions Oncology, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Champions Oncology, Inc. (formerly Champions Biotechnology, Inc) is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.&#160;&#160;The Company&#8217;s Tumorgraft<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8482;</font> Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8482;</font>, in a manner that preserves the biological characteristics of the original human tumor.&#160;&#160;The Company uses this technology in conjunction with related services to offer solutions for two customer groups:&#160;&#160;Personalized Oncology Solutions (&#8220;POS&#8221;) in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions (&#8220;TOS&#8221;) in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Company&#8217;s Tumorgraft<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8482;</font> Technology Platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs.&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">The Company is building its Tumorgraft&#8482; Technology Platform through the procurement, development and characterization of numerous Tumorgrafts&#8482; within each of several cancer types.&#160;&#160;Tumorgrafts&#8482; are procured through agreements with a number of institutions in the U.S. and overseas as well as through its POS business.&#160;&#160;The Tumorgrafts&#8482; are developed and tested through agreement with a United States-based preclinical facility.</font></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company provides POS to oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients&#8217; cancer tissues, as appropriate.&#160;&#160;Additionally, the Company offers Personalized Tumorgraft&#8482; development, drug studies and genome sequencing as part of its POS whereby physicians can evaluate the effects of cancer drugs on their patients&#8217; tumorgrafts and understand the genetic make-up of their patient&#8217;s tumor enabling them to better select treatment regimens that may be efficacious to the patient.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.&#160;&#160;Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.&#160;&#160;One should not place undue reliance on these forward-looking statements.&#160;&#160;The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.&#160;&#160;See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2011 for a discussion of such risks, uncertainties and other factors.&#160;&#160;Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.&#160;&#160;The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Champions Oncology, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #00000a; FONT-FAMILY: Times New Roman">Reconciliation of GAAP to Non-GAAP Net Loss</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #00000a; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Amounts in millions except for loss per share amounts)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three&#160;Months&#160;Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">July&#160;31,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss attributable to Champions &#8211; GAAP</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2.04</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.59</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1.01</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">0.17</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss attributable to Champions-non-GAAP:</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1.03</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.42</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss per common share attributable to Champions &#8211; non GAAP:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and diluted</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.02</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.01</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>csbr-20110731.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- XBRL document created with Ez-XBRL version 3.0.1.5  -->
<!-- Based on XBRL 2.1  -->
<xbrli:xbrl xmlns:csbr="http://championsoncology.com/2011-07-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="csbr-20110731.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_3ME_31-Jul-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-05-01
</xbrli:startDate>
<xbrli:endDate>
2010-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_31-Jul-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-01
</xbrli:startDate>
<xbrli:endDate>
2011-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Jul-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Aug-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Apr-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Jul-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_3ME_31-Jul-2011">CHAMPIONS ONCOLOGY, INC.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_3ME_31-Jul-2011">0000771856</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Context_3ME_31-Jul-2011">--04-30</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_3ME_31-Jul-2011">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:TradingSymbol contextRef="Context_3ME_31-Jul-2011">csbr</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_31-Aug-2011" unitRef="Shares" decimals="0">46268436</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_3ME_31-Jul-2011">10-Q</dei:DocumentType>
<dei:AmendmentFlag contextRef="Context_3ME_31-Jul-2011">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="Context_3ME_31-Jul-2011">2011-07-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="Context_3ME_31-Jul-2011">Q1</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="Context_3ME_31-Jul-2011">2012</dei:DocumentFiscalYearFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">10457000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">8839000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Apr-2010" unitRef="USD" decimals="0">2572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Jul-2010" unitRef="USD" decimals="0">2088000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">585000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">1236000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:GrantsReceivableCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">517000</us-gaap:GrantsReceivableCurrent>
<us-gaap:GrantsReceivableCurrent contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">504000</us-gaap:GrantsReceivableCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">276000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">341000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">11835000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">10920000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">146000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">212000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Goodwill contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">669000</us-gaap:Goodwill>
<us-gaap:Goodwill contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">669000</us-gaap:Goodwill>
<us-gaap:Assets contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">12650000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">11801000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">1580000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">1498000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">302000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">264000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">1618000</us-gaap:DeferredRevenueCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">2077000</us-gaap:DeferredRevenueCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">3500000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">3839000</us-gaap:LiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">972000</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">795000</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">4472000</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">4634000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">0</us-gaap:CommitmentsAndContingencies>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">0</us-gaap:CommitmentsAndContingencies>
<us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">8159000</us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount>
<us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">8159000</us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">37000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">37000</us-gaap:CommonStockValue>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">1252000</us-gaap:TreasuryStockValue>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">1252000</us-gaap:TreasuryStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">17784000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">18802000</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">-16482000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">-18519000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">-68000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">-60000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">19000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">-992000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30-Apr-2011" unitRef="USD" decimals="0">12650000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Jul-2011" unitRef="USD" decimals="0">11801000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_30-Apr-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_31-Jul-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_30-Apr-2011" unitRef="Shares" decimals="0">12533333</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_31-Jul-2011" unitRef="Shares" decimals="0">12533333</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Apr-2011" unitRef="USDPerShare" decimals="0">10</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Jul-2011" unitRef="USDPerShare" decimals="0">10</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30-Apr-2011" unitRef="Shares" decimals="0">56075</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Jul-2011" unitRef="Shares" decimals="0">56075</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30-Apr-2011" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Jul-2011" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30-Apr-2011" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Jul-2011" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Apr-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Jul-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30-Apr-2011" unitRef="Shares" decimals="0">125000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Jul-2011" unitRef="Shares" decimals="0">125000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30-Apr-2011" unitRef="Shares" decimals="0">36956667</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Jul-2011" unitRef="Shares" decimals="0">36971667</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30-Apr-2011" unitRef="Shares" decimals="0">33870000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Jul-2011" unitRef="Shares" decimals="0">33930103</us-gaap:CommonStockSharesOutstanding>
<us-gaap:TreasuryStockShares contextRef="Context_As_Of_30-Apr-2011" unitRef="Shares" decimals="0">3236000</us-gaap:TreasuryStockShares>
<us-gaap:TreasuryStockShares contextRef="Context_As_Of_31-Jul-2011" unitRef="Shares" decimals="0">3236000</us-gaap:TreasuryStockShares>
<csbr:PersonalizedOncologySolutions contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">1109000</csbr:PersonalizedOncologySolutions>
<csbr:PersonalizedOncologySolutions contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">601000</csbr:PersonalizedOncologySolutions>
<csbr:TranslationalOncologySolutions contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">491000</csbr:TranslationalOncologySolutions>
<csbr:TranslationalOncologySolutions contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">1033000</csbr:TranslationalOncologySolutions>
<us-gaap:SalesRevenueServicesNet contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">1600000</us-gaap:SalesRevenueServicesNet>
<us-gaap:SalesRevenueServicesNet contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">1634000</us-gaap:SalesRevenueServicesNet>
<csbr:CostOfPersonalizedOncologySolutions contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">324000</csbr:CostOfPersonalizedOncologySolutions>
<csbr:CostOfPersonalizedOncologySolutions contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">483000</csbr:CostOfPersonalizedOncologySolutions>
<csbr:CostOfTranslationalOncologySolutions contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">222000</csbr:CostOfTranslationalOncologySolutions>
<csbr:CostOfTranslationalOncologySolutions contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">419000</csbr:CostOfTranslationalOncologySolutions>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">919000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">541000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:SellingAndMarketingExpense contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">134000</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">688000</us-gaap:SellingAndMarketingExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">604000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">1717000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">2203000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">3848000</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-603000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-2214000</us-gaap:OperatingIncomeLoss>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">177000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">12000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">0</us-gaap:OtherNonoperatingIncome>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">12000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">177000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-591000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-2037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-591000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-2037000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_31-Jul-2010" unitRef="USDPerShare" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_31-Jul-2011" unitRef="USDPerShare" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
<csbr:WeightedAvergageNumberOfSharesBasicAndDiluted contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">33774000</csbr:WeightedAvergageNumberOfSharesBasicAndDiluted>
<csbr:WeightedAvergageNumberOfSharesBasicAndDiluted contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">46420000</csbr:WeightedAvergageNumberOfSharesBasicAndDiluted>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">4000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">8000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-587000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-2029000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">170000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">1014000</us-gaap:ShareBasedCompensation>
<us-gaap:Depreciation contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">10000</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">29000</us-gaap:Depreciation>
<csbr:IncreaseDecreaseInAccountReceivable contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-13000</csbr:IncreaseDecreaseInAccountReceivable>
<csbr:IncreaseDecreaseInAccountReceivable contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">651000</csbr:IncreaseDecreaseInAccountReceivable>
<csbr:IncreaseOrDecreaseInGrantReceivable contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">0</csbr:IncreaseOrDecreaseInGrantReceivable>
<csbr:IncreaseOrDecreaseInGrantReceivable contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-13000</csbr:IncreaseOrDecreaseInGrantReceivable>
<csbr:IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-109000</csbr:IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets>
<csbr:IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">65000</csbr:IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">165000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-82000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">43000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-38000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-355000</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">459000</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-436000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-1535000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">20000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">95000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-20000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-95000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">31000</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">4000</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-31000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">4000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">3000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">8000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME_31-Jul-2010" unitRef="USD" decimals="0">-484000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME_31-Jul-2011" unitRef="USD" decimals="0">-1618000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 1.&amp;#160;&amp;#160;Organization, Use of Estimates and Basis of Presentation
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Champions Oncology, Inc. (the &amp;#8220;Company&amp;#8221;), is a company that is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company&amp;#8217;s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice. The Company uses this technology to derive revenue for two customer groups: Personalized Oncology Solutions (&amp;#8220;POS&amp;#8221;), and Translational Oncology Solutions (&amp;#8220;TOS&amp;#8221;). Personal Oncology Solutions assist physicians in developing personalized treatment options for their cancer patients through access to panels of expert medical professionals and tumor specific data. The Company&amp;#8217;s Translational Oncology Solutions offer a technology platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries:&amp;#160;&amp;#160;Biomerk, Inc, Champions Biotechnology U.K., Limited and Champions Oncology (Israel) Ltd., which was established in November 2010.&amp;#160;&amp;#160;All material intercompany transactions have been eliminated in consolidation.
&lt;/font&gt; &lt;font style="display:inline;font-size:10pt;" &gt;The financial statements of the Company&amp;#8217;s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for each period presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss. The Company is subject to foreign exchange rate fluctuations in connection with the Company&amp;#8217;s international operations.
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). All significant intercompany transactions and accounts have been eliminated. Certain information related to the Company&amp;#8217;s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company&amp;#8217;s annual consolidated financial statements for the year ended April&amp;#160;30, 2011, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company&amp;#8217;s Annual Report on Form 10-K for the year ended April&amp;#160;30, 2011.&amp;#160;&amp;#160;Certain reclassifications have been made to the prior period financial statement amounts to conform to current presentation.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation assumptions used for share-based compensation and warrant liability, expenses related to personalized oncology solutions and the carrying amounts of long-lived assets and deferred taxes.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the period.&amp;#160;&amp;#160;Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the period, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method.&amp;#160;&amp;#160;Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable.&amp;#160;&amp;#160;Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.&amp;#160;&amp;#160;Due to the net losses for the three months ended July 31, 2011 and 2010, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.
&lt;/font&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The
 following table reflects the potential weighted average incremental shares of common stock that have been excluded from the computation of diluted loss per common share since their effect would be anti-dilutive.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="22%" colspan="6" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Three Months Ended July 31,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Stock options
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;437,054
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;650,385
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Warrants
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;431,668
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;462,273
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font
 style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Restricted stock
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;2,974
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Total common stock equivalents
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;868,722
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1,115,632
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 2. Recently Issued Accounting Pronouncements
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In June 2011, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2011-05, &amp;#8220;Presentation of Comprehensive Income&amp;#8221; (&amp;#8220;ASU 2011-05&amp;#8221;).&amp;#160;&amp;#160;ASU 2011-05 provides for the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income (&amp;#8220;OCI&amp;#8221;) either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Regardless of which format is chosen, the amendments establish a requirement for entities to present on the face of the financial statements reclassification adjustments for items that are reclassified from OCI to net income in the statement(s) where the components of net income and the components of OCI are presented. The amendments in ASU 2011-05 are effective, on a retrospective basis, for public entities for interim and annual periods beginning after December 15, 2011. The adoption of this guidance will not have any impact on the Company&amp;#8217;s financial position and results of operations.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In May 2011, the FASB issued ASU No. 2011-04, &amp;#8220;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs&amp;#8221; (&amp;#8220;ASC 2011-05&amp;#8221;).&amp;#160;&amp;#160;The amendments in ASC 2011-05 were issued in order to align the fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards.&amp;#160;&amp;#160;Consequently, the amendments change the wording used to describe many of the requirements in GAAP for measuring fair value and for disclosing information about fair value measurements.&amp;#160;&amp;#160;However, many of the amendments in ASC 2011-05 will not result in a change in the application of the requirements in ASC 820, Fair Value Measurement. The amendments in ASU 2011-04 are effective, on a prospective basis, for public entities for interim and annual periods beginning after December 15, 2011. The adoption of this guidance will not have any impact on the Company&amp;#8217;s financial position and results of operations.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;During December&amp;#160;2010, the FASB issued ASU No.&amp;#160;2010-28, Intangibles - Goodwill and Other (&amp;#8220;ASU 2010-28&amp;#8221;). ASU 2010-28 addresses questions about entities with reporting units with zero or negative carrying amounts because some entities concluded that Step 1 of the goodwill impairment test is passed in those circumstances because the fair value of their reporting unit will generally be greater than zero. The amendments in this update do not provide guidance on how to determine the carrying amount or measure the fair value of the reporting unit. The amendments in this update modify Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. This update was effective for fiscal years beginning after December 15, 2010. The Company does not anticipate that the adoption of this standard will have a&amp;#160;&amp;#160;material impact on the Company&amp;#8217;s financial position and results of operations. The Company tests for goodwill impairment annually during its fourth quarter, or more frequently if circumstances indicate potential impairment.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 3. Property and Equipment
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;July 31,
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;April 30,
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;(unaudited)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Furniture and fixtures
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;44,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;10,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom"
 width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Computer equipment and software
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;167,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;119,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Laboratory equipment
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;67,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;56,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Leasehold improvements
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Software in-progress
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;26,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;24,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;"
 &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Total property and equipment
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;306,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;211,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Less: Accumulated depreciation
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(94,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(65,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Property and equipment, net
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;212,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;"
 &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;146,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Depreciation expense was $29,000 and $10,000 for the three months ended July&amp;#160;31, 2011 and 2010, respectively.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 4. Share-Based Payments
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company has in place a 2010 Equity Incentive Plan, a 2008 Equity Incentive Plan and a Director Compensation Plan of 2010, all of which are described in more detail in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended April&amp;#160;30, 2011. In general, these plans provide for stock-based compensation in the form (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company&amp;#8217;s employees, directors and non-employees.&amp;#160;&amp;#160;The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Stock-based compensation in the amount of $1,014,000 and $170,000 was recognized for the three months ended July 31, 2011 and 2010, respectively.&amp;#160;&amp;#160;Stock-based compensation expense was recognized as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="22%" colspan="6" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Three Months Ended July 31,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;General and administrative
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;916,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;140,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td
 valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Sales and marketing
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;74,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;8,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Research and development
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;24,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;22,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Total stock-based compensation expense
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1,014,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;170,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Stock Option Grants
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div
 style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2011 and 2010 were as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="22%" colspan="6" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Three Months Ended July 31,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected term in years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;5.75
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;6.0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Risk-free interest rates
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.9% - 2.2
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new
 roman;font-size:10pt;" &gt;2.0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Volatility
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" nowrap="nowrap" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;107.1% - 107.3
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;104
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Dividend yield
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The weighted average fair value of stock options granted during the three months ended July 31, 2011 and 2010 was $0.74 and $0.75, respectively. The Company&amp;#8217;s stock options activity for the three months ended July 31, 2011 is as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="40%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Weighted
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td
 valign="bottom" width="40%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Weighted
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Average
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="40%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Directors
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Average
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Remaining
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Aggregate
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="40%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2"
 nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Non-
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;and
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Exercise
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Contractual
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Intrinsic
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="40%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Employees
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Employees
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Total
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Life (Years)
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom"
 width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Value
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="40%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="40%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Outstanding, May 1, 2011
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,610,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;12,710,948
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;14,320,948
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.88
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;8.44
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom"
 width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="40%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Granted
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;245,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;245,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.92
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="40%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Exercised
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"
 style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="40%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Forfeited
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;(50,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;(50,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="40%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expired
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font
 style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="40%" style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Change in employee status
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="40%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;"
 &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="8%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="40%" style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Outstanding, July 31, 2011
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1,610,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;12,905,948
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;14,515,948
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.88
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;8.13
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new
 roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;653,643
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="40%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="40%" style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:-9pt;display:block;margin-left:9pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Vested and expected to vest as of July 31, 2011
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1,610,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;12,879,281
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;14,489,281
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;"
 &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.88
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;8.13
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;652,310
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="40%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="40%" style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:-9pt;display:block;margin-left:9pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Exercisable as of July 31, 2011
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1,533,333
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"
 style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;3,859,250
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;5,392,583
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.86
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;6.33
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;442,526
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Restricted Stock Grants
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;A summary of the activity related to restricted stock grants is as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="70%" style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="64%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Weighted
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="64%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Average
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="64%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new
 roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Grant
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="64%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Date Fair
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="64%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Total
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Value Per
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="64%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Shares
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Share
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="64%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="64%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Nonvested as of May 1, 2011
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;"
 &gt;100,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.90
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="64%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Granted
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="64%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Vested
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;50,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.90
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="64%" style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Forfeited
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="64%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr
 style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="64%" style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Nonvested as of July 31, 2011
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;50,000
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="12%" style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.90
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The aggregate fair value of shares vested during the three months ended July 31, 2011 was $43,000.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Stock Purchase Warrants
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;As of July 31, 2011, the Company has warrants outstanding for the purchase of 1,897,019 shares of its common stock, all of which are exercisable.&amp;#160;&amp;#160;Of these warrants, 1,266,667 were issued in connection with the April 2011 financing arrangement and are accounted for as liabilities as further discussed in Note 5. 15,000 warrants were exercised on July 11, 2011.&amp;#160;&amp;#160;As of July 31, 2011, the weighted average exercise price of these warrants was $0.73 and the weighted average contractual life was 3.46 years.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<csbr:RedeemableCommonStockAndStockPurchaseWarrantTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 5. Redeemable Common Stock and Stock Purchase Warrant
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale to the investors of an aggregate 12,533,333 shares of the Company&amp;#8217;s Common Stock at a purchase price of $0.75 per share, or an aggregate of $9,400,000, of which, $500,000 was sold to officers and directors of the Company.&amp;#160;&amp;#160;As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667&amp;#160;&amp;#160;shares of Common Stock at an exercise price of $0.90 per share.&amp;#160;&amp;#160;These warrants expire five years after the closing date, which occurred on April 4, 2011.&amp;#160;&amp;#160;The Securities Purchase Agreement contains certain anti-dilution protections for the investors and certain registration rights with respect to the shares of Common Stock issued to the investors.&amp;#160;&amp;#160;Furthermore, investors will have the right to require the Company to redeem the purchased common shares held by such investors (the &amp;#8220;Put Option&amp;#8221;) for cash for $0.75 per share upon a change of control or sale of substantially all of the company&amp;#8217;s assets.&amp;#160;&amp;#160;The Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The warrants issued in connection with the Securities Purchase Agreement contain certain exercise price reset provisions.&amp;#160;&amp;#160;Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants.&amp;#160;&amp;#160;These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period.&amp;#160;&amp;#160;If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists.&amp;#160;&amp;#160;The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement is $41,000 for each 30-day period in which a registration default exists; however, as of the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company has accounted for the warrants issued in connection with the Securities Purchase Agreement as liabilities based on the exercise price reset provisions described above.&amp;#160;&amp;#160;This liability, which is recorded at fair value on the accompanying unaudited condensed consolidated balance sheets, totaled $936,000 at the time of the close of the Securities Purchase Agreement.&amp;#160;&amp;#160;As of April 30, 2011, the fair value of these warrants increased $36,000 to $972,000.&amp;#160;&amp;#160;During the quarter ended July 31, 2011, the fair value of these warrants decreased by $177,000 to $794,000.&amp;#160;&amp;#160;The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company&amp;#8217;s unaudited condensed consolidated Statements of Operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;July 31,
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;April 30,
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;"
 &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected term in years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;4.7
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;5.0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Risk-free interest rates
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.4
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2.0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Volatility
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;103
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;"
 &gt;102
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Dividend yield
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Due to the Put Option described above, the Company has accounted for&amp;#160;&amp;#160;Common Stock issued under the Securities Purchase Agreement as temporary equity, which is reflected under the caption &amp;#8220;Redeemable common stock&amp;#8221; on the accompanying Condensed Consolidated Balance Sheets.&amp;#160;&amp;#160;The total amount allocated to these common shares was $8,159,000.&amp;#160;&amp;#160;This allocation is equal to the total proceeds of $9,400,000, less the amount allocated to the warrants of $936,000 and is also net of direct and incremental costs associated with the Securities Purchase Agreement of $305,000.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</csbr:RedeemableCommonStockAndStockPurchaseWarrantTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 6. Related Party Transactions
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Related party transactions include transactions between the Company and certain of its shareholders, management and affiliates.&amp;#160;&amp;#160;The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;br /&gt;
Consulting Services
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;During the three months ended July 31, 2011 and 2010, the Company paid one of its directors and former Chief Executive Officer, $18,000 and $15,000, respectively, in consulting fees.&amp;#160;&amp;#160;During the three months ended July 31, 2011 and 2010, the Company paid certain members of its Board of Directors $16,000 and $10,000, respectively, for consulting services unrelated to their duties as board members.&amp;#160;&amp;#160;The Company incurred $4,000 in expenses for the three months ended July 31, 2011 from a substantial stockholder of the Company for consulting fees. $2,000 was payable to this stockholder as of July 31, 2011. As of the date of this filing, the Company has satisfied this obligation. No such expenses were incurred for the three months ended July 31, 2010.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Revenue
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;During the three months ended July 31, 2011, the Company recognized $20,000 in revenues from companies whose board members were also members of the Company&amp;#8217;s Board of Directors. These revenues are still receivable as of the date of this filing. No such revenues were incurred for the three months ended July 31, 2010.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 7. Commitments and Contingencies
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Operating Leases
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;As of July 31, 2011, the Company leases office and laboratory space under a non-cancelable operating lease in Baltimore, Maryland, which expires in April 2014, office space under a non-cancelable operating lease in Ra&amp;#8217;anana, Israel, which expires in July 2012, and office space in Hackensack, New Jersey under a non-cancellable operating lease, which expires in 2014.&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;Rent expense under all lease agreements was approximately $36,700 and $14,200 for the three months ended July 31, 2011 and 2010, respectively.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Research and Development Materials Purchase Agreement
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In February 2010, the Company entered into a research and development materials purchase agreement with a foreign hospital for the acquisition of Tumorgrafts.&amp;#160;&amp;#160;Under the agreement, the Company makes monthly payments to the foreign hospital of approximately $37,000 for 18 months, commencing March 1, 2010.&amp;#160;&amp;#160;Future payments due under the agreement total $144,000 at July 31, 2011 and are due during&amp;#160;the remainder of the fiscal year ending April 30, 2012.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Legal Matters
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company is party to certain legal matters arising in the ordinary course of its business.&amp;#160;&amp;#160;The Company has evaluated its potential exposure to these legal matters, and has concluded that there were no reasonably possible or probable liabilities at July 31, 2011 and April 30, 2011.&amp;#160;&amp;#160;The Company is not aware of any other matters that would have a material impact on the Company&amp;#8217;s financial position or results of operations.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Registration Payment Arrangements
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company has entered into registration rights agreements in connection with a private placement of its securities, which closed during April 2011 and is discussed more fully in Note 5.&amp;#160;&amp;#160;This registration rights agreement contains provisions that may call for the Company to pay penalties in certain circumstances.&amp;#160;&amp;#160;This registration payment arrangement primarily relates to the Company&amp;#8217;s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period.&amp;#160;&amp;#160;The Company does not believe it is probable that penalty payments will be made for the registration rights agreement discussed above and, accordingly, has not accrued for such potential penalties as of July 31, 2011.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<csbr:LicensingagreementsdisclosuretextblockTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 8. Licensing Agreements
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;During fiscal 2011, the Company was a party to several different licensing agreements, all of which are described in more detail in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended April&amp;#160;30, 2011.&amp;#160;&amp;#160;During April 2011, the Company terminated all of these licensing agreements with the exception of the Liposome Option Agreement, which is described further below.&amp;#160;&amp;#160;All rights related to all other licensing agreements that were terminated during April 2011 were returned to the underlying companies and no amounts were due under these other agreements as of April 30, 2011.
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;br /&gt;
In February 2010, the Company entered into an exclusive option agreement with a Canadian company for which it paid and expensed $40,000 during the Company&amp;#8217;s fiscal 2010 year.&amp;#160;&amp;#160;The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast and lung cancer through April 2011.&amp;#160;&amp;#160;During the option year, the Company performed various tumorgraft testing on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. Under the terms of the agreement, the company&amp;#8217;s exercise of the option resulted in amounts due to the Canadian company of $85,000 comprised of the option exercise price and reimbursement to the Canadian company for past patent costs, which is recorded as a liability as of July 31, 2011 and April 30, 2011.&amp;#160;&amp;#160;As of the date of this filing, the Company has satisfied this obligation.&amp;#160;&amp;#160;Under the terms of the license agreement, the Company will be required to pay up to $3 million in development milestones.&amp;#160;&amp;#160;Upon commercialization, the Company would also be required to make royalty payments and sales milestone based upon revenues.&amp;#160;&amp;#160;&amp;#160;Commencing with the second anniversary of the agreement (March 2013), the Company will be obligated to pay a minimum annual royalty of $10,000 (Canadian).
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</csbr:LicensingagreementsdisclosuretextblockTextBlock>
<csbr:CephalonAgreementTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 9. Cephalon Agreement
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On March&amp;#160;16, 2011, the Company entered into an agreement with Cephalon, Inc., (&amp;#8220;Cephalon&amp;#8221;), pursuant to which the Company will conduct low Tumorgraft studies on proprietary chemical compounds provided by Cephalon to determine the activity or response of a compound in potential clinical indications. In April 2011, Cephalon paid an initiation fee of $1,390,000 to the Company which is reflected within deferred revenue on the Condensed Consolidated Balance Sheets as of July 31, 2011 and April 30, 2011. The Company anticipates that the studies will be completed within 12 months of the execution of the agreement.&amp;#160;&amp;#160;As models, along with required reports, are delivered, the deferred revenue will be recognized on a proportionate basis in accordance with the Company&amp;#8217;s revenue recognition policies. No revenue was recognized in the quarter ended July 31, 2011, as no models were delivered. The Company expects the models will begin being delivered in the second quarter of our fiscal year ending April 30, 2012. Cephalon will, under certain conditions, also pay the Company various amounts upon achieving certain milestones. Potential milestone payments under the Agreement total $27&amp;#160;million. In addition, under certain conditions, Cephalon will pay the Company royalties on any commercialized products developed under the Agreement.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;
&lt;/div&gt;</csbr:CephalonAgreementTextBlock>
<csbr:GrantIncomeTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 11. Grant Income
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On October 29, 2010, the Company was notified that it was awarded total cash grants of approximately $1.5 million under the Qualifying Therapeutic Discovery Project program administered under section 48D of the Internal Revenue Code, of which approximately $1.0 million related to qualifying expenses the Company had previously incurred during fiscal 2010 and $0.5 million related to qualifying expenses which the Company expected to incur during fiscal 2011.&amp;#160;&amp;#160;In November 2010, the Company received approximately $1.0 million and expects to receive $0.5 million related to the 2011 expenditures during the Company&amp;#8217;s fiscal year.&amp;#160;&amp;#160;To date, the $0.5 million has not been received.
&lt;/font&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;/div&gt;</csbr:GrantIncomeTextBlock>
<us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="Context_3ME_31-Jul-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Note 10. Supplemental Cash Flow Information
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;There was no cash paid for interest or income taxes during the three months ended July 31, 2011 and 2010.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>

</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>csbr-20110731.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<schema targetNamespace="http://championsoncology.com/2011-07-31" elementFormDefault="qualified" xmlns:csbr="http://championsoncology.com/2011-07-31" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://championsoncology.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>01 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/StatementOfFinancialPositionClassified" id="StatementOfFinancialPositionClassified">
<link:definition>02 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>03 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/StatementOfIncomeAlternative" id="StatementOfIncomeAlternative">
<link:definition>04 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome" id="StatementOfOtherComprehensiveIncome">
<link:definition>05 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/StatementOfCashFlowsIndirect" id="StatementOfCashFlowsIndirect">
<link:definition>06 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentation" id="OrganizationUseOfEstimatesAndBasisOfPresentation">
<link:definition>07 - Disclosure - Organization, Use of Estimates and Basis of Presentation (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/RecentlyIssuedAccountingPronouncements" id="RecentlyIssuedAccountingPronouncements">
<link:definition>08 - Disclosure - Recently Issued Accounting Pronouncements (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>09 - Disclosure - Property and Equipment (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/ShareBasedPayments" id="ShareBasedPayments">
<link:definition>10 - Disclosure - Share-Based Payments (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrant" id="RedeemableCommonStockAndStockPurchaseWarrant">
<link:definition>11 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>12 - Disclosure - Related Party Transactions (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/Commitmentsandcontingencies" id="Commitmentsandcontingencies">
<link:definition>13 - Disclosure - Commitments and Contingencies (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/LicensingAgreements" id="LicensingAgreements">
<link:definition>14 - Disclosure - Licensing Agreements (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/CephalonAgreement" id="CephalonAgreement">
<link:definition>15 - Disclosure - Cephalon Agreement (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/SupplementalCashFlowInformation" id="SupplementalCashFlowInformation">
<link:definition>16 - Disclosure - Supplemental Cash Flow Information (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://championsoncology.com/role/GrantIncome" id="GrantIncome">
<link:definition>17 - Disclosure - Grant Income (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="csbr-20110731_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="csbr-20110731_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="csbr-20110731_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="csbr-20110731_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="csbr_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BalanceSheetParentheticalAbstract" id="csbr_BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PersonalizedOncologySolutions" id="csbr_PersonalizedOncologySolutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TranslationalOncologySolutions" id="csbr_TranslationalOncologySolutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CostOfPersonalizedOncologySolutions" id="csbr_CostOfPersonalizedOncologySolutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CostOfTranslationalOncologySolutions" id="csbr_CostOfTranslationalOncologySolutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WeightedAvergageNumberOfSharesBasicAndDiluted" id="csbr_WeightedAvergageNumberOfSharesBasicAndDiluted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseOrDecreaseInGrantReceivable" id="csbr_IncreaseOrDecreaseInGrantReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RedeemableCommonStockAndStockPurchaseWarrantAbstract" id="csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RedeemableCommonStockAndStockPurchaseWarrantTextBlock" id="csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicensingAgreementsAbstract" id="csbr_LicensingAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicensingagreementsdisclosuretextblockTextBlock" id="csbr_LicensingagreementsdisclosuretextblockTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CephalonAgreementAbstract" id="csbr_CephalonAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CephalonAgreementTextBlock" id="csbr_CephalonAgreementTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantIncomeAbstract" id="csbr_GrantIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantIncomeTextBlock" id="csbr_GrantIncomeTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantIncome" id="csbr_GrantIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInAccountReceivable" id="csbr_IncreaseDecreaseInAccountReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" nillable="true"/>
<element name="IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" id="csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>csbr-20110731_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfFinancialPositionClassified" roleURI="http://championsoncology.com/role/StatementOfFinancialPositionClassified"/>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" order="60" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="120" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="60" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfIncomeAlternative" roleURI="http://championsoncology.com/role/StatementOfIncomeAlternative"/>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_PersonalizedOncologySolutions" xlink:label="loc_csbr_PersonalizedOncologySolutions"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueServicesNet" xlink:to="loc_csbr_PersonalizedOncologySolutions" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_TranslationalOncologySolutions" xlink:label="loc_csbr_TranslationalOncologySolutions"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueServicesNet" xlink:to="loc_csbr_TranslationalOncologySolutions" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CostOfPersonalizedOncologySolutions" xlink:label="loc_csbr_CostOfPersonalizedOncologySolutions"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_csbr_CostOfPersonalizedOncologySolutions" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CostOfTranslationalOncologySolutions" xlink:label="loc_csbr_CostOfTranslationalOncologySolutions"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_csbr_CostOfTranslationalOncologySolutions" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingAndMarketingExpense" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="100" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="40" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfCashFlowsIndirect" roleURI="http://championsoncology.com/role/StatementOfCashFlowsIndirect"/>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" order="120" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:label="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" order="140" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseOrDecreaseInGrantReceivable" xlink:label="loc_csbr_IncreaseOrDecreaseInGrantReceivable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_csbr_IncreaseOrDecreaseInGrantReceivable" order="160" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseDecreaseInAccountReceivable" xlink:label="loc_csbr_IncreaseDecreaseInAccountReceivable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_csbr_IncreaseDecreaseInAccountReceivable" order="180" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="200" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" order="40" use="optional" weight="-1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>csbr-20110731_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#DocumentAndEntityInformation" roleURI="http://championsoncology.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfFinancialPositionClassified" roleURI="http://championsoncology.com/role/StatementOfFinancialPositionClassified"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfIncomeAlternative" roleURI="http://championsoncology.com/role/StatementOfIncomeAlternative"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfOtherComprehensiveIncome" roleURI="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfCashFlowsIndirect" roleURI="http://championsoncology.com/role/StatementOfCashFlowsIndirect"/>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_8" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_11" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_12" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_13" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_14" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_GrantsReceivableCurrent_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_InventoryNet_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_8" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Goodwill_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Assets_11" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccountsPayableCurrent_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_DeferredRevenueCurrent_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_Liabilities_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_CommitmentsAndContingencies_19" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount_20" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_StockholdersEquityAbstract_21" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_PreferredStockValue_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommonStockValue_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_TreasuryStockValue_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AdditionalPaidInCapital_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquity_28" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_29" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_11" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_12" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_13" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TreasuryStockShares_14" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingIncomeLossAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_PersonalizedOncologySolutions" xlink:label="loc_csbr_PersonalizedOncologySolutions_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_2" xlink:to="loc_csbr_PersonalizedOncologySolutions_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_TranslationalOncologySolutions" xlink:label="loc_csbr_TranslationalOncologySolutions_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_2" xlink:to="loc_csbr_TranslationalOncologySolutions_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_2" xlink:to="loc_us-gaap_SalesRevenueServicesNet_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CostOfPersonalizedOncologySolutions" xlink:label="loc_csbr_CostOfPersonalizedOncologySolutions_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_csbr_CostOfPersonalizedOncologySolutions_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CostOfTranslationalOncologySolutions" xlink:label="loc_csbr_CostOfTranslationalOncologySolutions_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_csbr_CostOfTranslationalOncologySolutions_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_SellingAndMarketingExpense_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_OperatingExpenses_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_2" xlink:to="loc_us-gaap_OperatingIncomeLoss_13" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_GrantIncome" xlink:label="loc_csbr_GrantIncome_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_csbr_GrantIncome_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_OtherNonoperatingIncome_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_22" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_WeightedAvergageNumberOfSharesBasicAndDiluted" xlink:label="loc_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_14" xlink:to="loc_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted_23" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetIncomeLoss_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_ShareBasedCompensation_5" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_Depreciation_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseDecreaseInAccountReceivable" xlink:label="loc_csbr_IncreaseDecreaseInAccountReceivable_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8" xlink:to="loc_csbr_IncreaseDecreaseInAccountReceivable_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseOrDecreaseInGrantReceivable" xlink:label="loc_csbr_IncreaseOrDecreaseInGrantReceivable_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8" xlink:to="loc_csbr_IncreaseOrDecreaseInGrantReceivable_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:label="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_23" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_24" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" order="60" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>csbr-20110731_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_DocumentAndEntityInformationAbstract" xlink:label="loc_csbr_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_DocumentAndEntityInformationAbstract" xlink:to="lab_csbr_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xml:lang="en-US">Grants Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xml:lang="en-US">Grant receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivableCurrent" xlink:to="lab_us-gaap_GrantsReceivableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES, COMMITMENTS AND CONTINGENCIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xml:lang="en-US">Redeemable common stock; $0.001 par value; 12,533,333 contingently puttable common shares outstanding as of July 31, 2011 and April 30, 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xml:lang="en-US">Redeemable common stock; $0.001 par value; 12,533,333 contingently puttable common shares outstanding as of July 31, 2011 and April 30, 2011</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity (deficit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of July 31, 2011 and April 30, 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $.001 par value; 125,000,000 shares authorized, including redeemable common stock, 36,971,667 and 36,956,667 shares issued and 33,930,103 and 33,870,000 shares outstanding as of July 31, 2011 and April 30, 2011, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost, 3,236,000 common shares as of July 31, 2011 and April 30, 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost, 3,236,000 common shares as of July 31, 2011 and April 30, 2011</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders Equity Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, redeemable common stock and stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, redeemable common stock and stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_BalanceSheetParentheticalAbstract" xlink:label="loc_csbr_BalanceSheetParentheticalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet [Parenthetical] [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet [Parenthetical] [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_BalanceSheetParentheticalAbstract" xlink:to="lab_csbr_BalanceSheetParentheticalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Redeemable common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Redeemable common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLossAbstract" xml:lang="en-US">Operating Income (Loss) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLossAbstract" xml:lang="en-US">Operating revenue:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract" xlink:to="lab_us-gaap_OperatingIncomeLossAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_PersonalizedOncologySolutions" xlink:label="loc_csbr_PersonalizedOncologySolutions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_PersonalizedOncologySolutions" xml:lang="en-US">Personalized Oncology Solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_PersonalizedOncologySolutions" xml:lang="en-US">Personalized oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_PersonalizedOncologySolutions" xml:lang="en-US">Aggregate revenue during the period from personalized oncology solutions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_PersonalizedOncologySolutions" xlink:to="lab_csbr_PersonalizedOncologySolutions"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_TranslationalOncologySolutions" xlink:label="loc_csbr_TranslationalOncologySolutions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_TranslationalOncologySolutions" xml:lang="en-US">Translational Oncology Solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_TranslationalOncologySolutions" xml:lang="en-US">Translational oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_csbr_TranslationalOncologySolutions" xml:lang="en-US">Translational oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_TranslationalOncologySolutions" xml:lang="en-US">Aggregate revenue during the period from translational oncology solutions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_TranslationalOncologySolutions" xlink:to="lab_csbr_TranslationalOncologySolutions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueServicesNet" xml:lang="en-US">Sales Revenue, Services, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesRevenueServicesNet" xml:lang="en-US">Total operating revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_SalesRevenueServicesNet" xml:lang="en-US">Total operating revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueServicesNet" xlink:to="lab_us-gaap_SalesRevenueServicesNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Costs and operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CostOfPersonalizedOncologySolutions" xlink:label="loc_csbr_CostOfPersonalizedOncologySolutions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_CostOfPersonalizedOncologySolutions" xml:lang="en-US">Cost Of Personalized Oncology Solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_CostOfPersonalizedOncologySolutions" xml:lang="en-US">Cost of personalized oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_CostOfPersonalizedOncologySolutions" xml:lang="en-US">Total costs related to personalized oncology solutions during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CostOfPersonalizedOncologySolutions" xlink:to="lab_csbr_CostOfPersonalizedOncologySolutions"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CostOfTranslationalOncologySolutions" xlink:label="loc_csbr_CostOfTranslationalOncologySolutions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_CostOfTranslationalOncologySolutions" xml:lang="en-US">Cost Of Translational Oncology Solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_CostOfTranslationalOncologySolutions" xml:lang="en-US">Cost of translational oncology solutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_CostOfTranslationalOncologySolutions" xml:lang="en-US">Total costs related to translational oncology solutions during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CostOfTranslationalOncologySolutions" xlink:to="lab_csbr_CostOfTranslationalOncologySolutions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Sales and marketing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Sales and marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total costs and operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total costs and operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) On Derivative Instruments, Net, Pretax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share outstanding, including redeemable common stock, basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_WeightedAvergageNumberOfSharesBasicAndDiluted" xlink:label="loc_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted" xml:lang="en-US">Weighted Avergage Number Of Shares Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding, including redeemable common stock, basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted" xml:lang="en-US">The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted" xlink:to="lab_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement Of Income and Comprehensive Income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Income and Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xml:lang="en-US">Foreign currency translation adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net Of Tax, Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (Decrease) In Operating Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseDecreaseInAccountReceivable" xlink:label="loc_csbr_IncreaseDecreaseInAccountReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_IncreaseDecreaseInAccountReceivable" xml:lang="en-US">Increase (Decrease) In Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_IncreaseDecreaseInAccountReceivable" xml:lang="en-US">Accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_csbr_IncreaseDecreaseInAccountReceivable" xml:lang="en-US">Accounts receivable</label>
<label xlink:type="resource" xlink:label="lab_csbr_IncreaseDecreaseInAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The (increase) decrease during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_IncreaseDecreaseInAccountReceivable" xlink:to="lab_csbr_IncreaseDecreaseInAccountReceivable"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseOrDecreaseInGrantReceivable" xlink:label="loc_csbr_IncreaseOrDecreaseInGrantReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_IncreaseOrDecreaseInGrantReceivable" xml:lang="en-US">Increase Or Decrease In Grant Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_IncreaseOrDecreaseInGrantReceivable" xml:lang="en-US">Grant receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_IncreaseOrDecreaseInGrantReceivable" xml:lang="en-US">The (increase) decrease in amount due during the reporting period in Governmental, corporate, or foundation grants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_csbr_IncreaseOrDecreaseInGrantReceivable" xml:lang="en-US">Grant receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_IncreaseOrDecreaseInGrantReceivable" xlink:to="lab_csbr_IncreaseOrDecreaseInGrantReceivable"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:label="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xml:lang="en-US">Prepaid expenses, deposits and other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xml:lang="en-US">Prepaid expenses, deposits and other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xml:lang="en-US">Prepaid expenses, deposits and other</label>
<label xlink:type="resource" xlink:label="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The (increase) decrease during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:to="lab_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) In Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (Decrease) In Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments For Repurchase Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Purchase of treasury stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Purchase of treasury stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds From Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from exercise of options and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from exercise of options and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect Of Exchange Rate On Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Exchange rate effect on cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Exchange rate effect on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Decrease in cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Decrease in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xml:lang="en-US">Accounting Changes and Error Corrections [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xml:lang="en-US">Accounting Changes and Error Corrections [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xlink:label="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xml:lang="en-US">Redeemable Common Stock and Stock Purchase Warrant [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xml:lang="en-US">Redeemable Common Stock and Stock Purchase Warrant [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xml:lang="en-US">Equity-based compensation plans and award types, including multiple equity-based payment arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xlink:to="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xlink:label="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xml:lang="en-US">Redeemable Common Stock and Stock Purchase Warrant [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xml:lang="en-US">Redeemable Common Stock and Stock Purchase Warrant [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xml:lang="en-US">Equity-based compensation plans and award types, including multiple equity-based payment arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xlink:to="lab_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_LicensingAgreementsAbstract" xlink:label="loc_csbr_LicensingAgreementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_LicensingAgreementsAbstract" xml:lang="en-US">Licensing Agreements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_LicensingAgreementsAbstract" xml:lang="en-US">Licensing Agreements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_LicensingAgreementsAbstract" xml:lang="en-US">The entire concept related to several different licensing agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_LicensingAgreementsAbstract" xlink:to="lab_csbr_LicensingAgreementsAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_LicensingagreementsdisclosuretextblockTextBlock" xlink:label="loc_csbr_LicensingagreementsdisclosuretextblockTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_LicensingagreementsdisclosuretextblockTextBlock" xml:lang="en-US">Licensingagreementsdisclosuretextblock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_LicensingagreementsdisclosuretextblockTextBlock" xml:lang="en-US">Licensing Agreements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_LicensingagreementsdisclosuretextblockTextBlock" xml:lang="en-US">The entire concept related to several different licensing agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_LicensingagreementsdisclosuretextblockTextBlock" xlink:to="lab_csbr_LicensingagreementsdisclosuretextblockTextBlock"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CephalonAgreementAbstract" xlink:label="loc_csbr_CephalonAgreementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_CephalonAgreementAbstract" xml:lang="en-US">Cephalon Agreement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_CephalonAgreementAbstract" xml:lang="en-US">Cephalon Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CephalonAgreementAbstract" xlink:to="lab_csbr_CephalonAgreementAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CephalonAgreementTextBlock" xlink:label="loc_csbr_CephalonAgreementTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_CephalonAgreementTextBlock" xml:lang="en-US">Cephalon Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_CephalonAgreementTextBlock" xml:lang="en-US">Cephalon Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_CephalonAgreementTextBlock" xml:lang="en-US">The entire concept related to Cephalon Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CephalonAgreementTextBlock" xlink:to="lab_csbr_CephalonAgreementTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_GrantIncomeAbstract" xlink:label="loc_csbr_GrantIncomeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_GrantIncomeAbstract" xml:lang="en-US">Grant Income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_GrantIncomeAbstract" xml:lang="en-US">Grant Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_GrantIncomeAbstract" xlink:to="lab_csbr_GrantIncomeAbstract"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_GrantIncomeTextBlock" xlink:label="loc_csbr_GrantIncomeTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_GrantIncomeTextBlock" xml:lang="en-US">Grant Income [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_GrantIncomeTextBlock" xml:lang="en-US">Grant Income [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_GrantIncomeTextBlock" xml:lang="en-US">The entire concept related to grant Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_GrantIncomeTextBlock" xlink:to="lab_csbr_GrantIncomeTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Statement, Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_GrantIncome" xlink:label="loc_csbr_GrantIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_csbr_GrantIncome" xml:lang="en-US">Grant Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_csbr_GrantIncome" xml:lang="en-US">Grant income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_csbr_GrantIncome" xml:lang="en-US">The aggregate amount of other income amounts, resulting from grant income.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_GrantIncome" xlink:to="lab_csbr_GrantIncome"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>csbr-20110731_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#DocumentAndEntityInformation" roleURI="http://championsoncology.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfFinancialPositionClassified" roleURI="http://championsoncology.com/role/StatementOfFinancialPositionClassified"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfIncomeAlternative" roleURI="http://championsoncology.com/role/StatementOfIncomeAlternative"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfOtherComprehensiveIncome" roleURI="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#StatementOfCashFlowsIndirect" roleURI="http://championsoncology.com/role/StatementOfCashFlowsIndirect"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#OrganizationUseOfEstimatesAndBasisOfPresentation" roleURI="http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentation"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#RecentlyIssuedAccountingPronouncements" roleURI="http://championsoncology.com/role/RecentlyIssuedAccountingPronouncements"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#PropertyAndEquipment" roleURI="http://championsoncology.com/role/PropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#ShareBasedPayments" roleURI="http://championsoncology.com/role/ShareBasedPayments"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#RedeemableCommonStockAndStockPurchaseWarrant" roleURI="http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrant"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#RelatedPartyTransactions" roleURI="http://championsoncology.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#Commitmentsandcontingencies" roleURI="http://championsoncology.com/role/Commitmentsandcontingencies"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#LicensingAgreements" roleURI="http://championsoncology.com/role/LicensingAgreements"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#CephalonAgreement" roleURI="http://championsoncology.com/role/CephalonAgreement"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#SupplementalCashFlowInformation" roleURI="http://championsoncology.com/role/SupplementalCashFlowInformation"/>
<roleRef xlink:type="simple" xlink:href="csbr-20110731.xsd#GrantIncome" roleURI="http://championsoncology.com/role/GrantIncome"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_DocumentAndEntityInformationAbstract" xlink:label="loc_csbr_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityRegistrantName_5" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityFilerCategory_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_TradingSymbol_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentType_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AmendmentFlag_12" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_13" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_14" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_15" order="100" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AssetsAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_GrantsReceivableCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_InventoryNet_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsCurrent_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Goodwill_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Assets_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_DeferredRevenueCurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_PreferredStockValue_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_CommonStockValue_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_TreasuryStockValue_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AdditionalPaidInCapital_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquity_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_30" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_BalanceSheetParentheticalAbstract" xlink:label="loc_csbr_BalanceSheetParentheticalAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_BalanceSheetParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CommonStockSharesIssued_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_TreasuryStockShares_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingIncomeLossAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_PersonalizedOncologySolutions" xlink:label="loc_csbr_PersonalizedOncologySolutions_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_3" xlink:to="loc_csbr_PersonalizedOncologySolutions_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_TranslationalOncologySolutions" xlink:label="loc_csbr_TranslationalOncologySolutions_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_3" xlink:to="loc_csbr_TranslationalOncologySolutions_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_3" xlink:to="loc_us-gaap_SalesRevenueServicesNet_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CostOfPersonalizedOncologySolutions" xlink:label="loc_csbr_CostOfPersonalizedOncologySolutions_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_csbr_CostOfPersonalizedOncologySolutions_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CostOfTranslationalOncologySolutions" xlink:label="loc_csbr_CostOfTranslationalOncologySolutions_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_csbr_CostOfTranslationalOncologySolutions_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_SellingAndMarketingExpense_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OperatingExpenses_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_3" xlink:to="loc_us-gaap_OperatingIncomeLoss_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_GrantIncome" xlink:label="loc_csbr_GrantIncome_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_csbr_GrantIncome_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_OtherNonoperatingIncome_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_NetIncomeLoss_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_23" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_WeightedAvergageNumberOfSharesBasicAndDiluted" xlink:label="loc_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_15" xlink:to="loc_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted_24" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfOtherComprehensiveIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLoss_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetIncomeLoss_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_Depreciation_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseDecreaseInAccountReceivable" xlink:label="loc_csbr_IncreaseDecreaseInAccountReceivable_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_9" xlink:to="loc_csbr_IncreaseDecreaseInAccountReceivable_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseOrDecreaseInGrantReceivable" xlink:label="loc_csbr_IncreaseOrDecreaseInGrantReceivable_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_9" xlink:to="loc_csbr_IncreaseOrDecreaseInGrantReceivable_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets" xlink:label="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/RecentlyIssuedAccountingPronouncements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0" xlink:to="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/ShareBasedPayments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrant">
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract" xlink:label="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract_0"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock" xlink:label="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract_0" xlink:to="loc_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/Commitmentsandcontingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/LicensingAgreements">
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_LicensingAgreementsAbstract" xlink:label="loc_csbr_LicensingAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_LicensingagreementsdisclosuretextblockTextBlock" xlink:label="loc_csbr_LicensingagreementsdisclosuretextblockTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_LicensingAgreementsAbstract_0" xlink:to="loc_csbr_LicensingagreementsdisclosuretextblockTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/CephalonAgreement">
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CephalonAgreementAbstract" xlink:label="loc_csbr_CephalonAgreementAbstract_0"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_CephalonAgreementTextBlock" xlink:label="loc_csbr_CephalonAgreementTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_CephalonAgreementAbstract_0" xlink:to="loc_csbr_CephalonAgreementTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/SupplementalCashFlowInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://championsoncology.com/role/GrantIncome">
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_GrantIncomeAbstract" xlink:label="loc_csbr_GrantIncomeAbstract_0"/>
<loc xlink:type="locator" xlink:href="csbr-20110731.xsd#csbr_GrantIncomeTextBlock" xlink:label="loc_csbr_GrantIncomeTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_GrantIncomeAbstract_0" xlink:to="loc_csbr_GrantIncomeTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EBHAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable common stock, shares outstanding</a></td>
        <td class="nump">12,533,333<span></span></td>
        <td class="nump">12,533,333<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 10<span></span></td>
        <td class="nump">$ 10<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">56,075<span></span></td>
        <td class="nump">56,075<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="nump">125,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">36,971,667<span></span></td>
        <td class="nump">36,956,667<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">33,930,103<span></span></td>
        <td class="nump">33,870,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
        <td class="nump">3,236,000<span></span></td>
        <td class="nump">3,236,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of stock classified as temporary equity; generally not indicative of the fair market value per share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquitySharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E5YAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating revenue:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_PersonalizedOncologySolutions', window );">Personalized oncology solutions</a></td>
        <td class="nump">$ 601,000<span></span></td>
        <td class="nump">$ 1,109,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_TranslationalOncologySolutions', window );">Translational oncology solutions</a></td>
        <td class="nump">1,033,000<span></span></td>
        <td class="nump">491,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Total operating revenue</a></td>
        <td class="nump">1,634,000<span></span></td>
        <td class="nump">1,600,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CostOfPersonalizedOncologySolutions', window );">Cost of personalized oncology solutions</a></td>
        <td class="nump">483,000<span></span></td>
        <td class="nump">324,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CostOfTranslationalOncologySolutions', window );">Cost of translational oncology solutions</a></td>
        <td class="nump">419,000<span></span></td>
        <td class="nump">222,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">541,000<span></span></td>
        <td class="nump">919,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
        <td class="nump">688,000<span></span></td>
        <td class="nump">134,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">1,717,000<span></span></td>
        <td class="nump">604,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and operating expenses</a></td>
        <td class="nump">3,848,000<span></span></td>
        <td class="nump">2,203,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(2,214,000)<span></span></td>
        <td class="num">(603,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">177,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">12,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
        <td class="nump">177,000<span></span></td>
        <td class="nump">12,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
        <td class="num">(2,037,000)<span></span></td>
        <td class="num">(591,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(2,037,000)<span></span></td>
        <td class="num">(591,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)</a></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted', window );">Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)</a></td>
        <td class="nump">$ 46,420,000<span></span></td>
        <td class="nump">$ 33,774,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CostOfPersonalizedOncologySolutions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to personalized oncology solutions during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_CostOfPersonalizedOncologySolutions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CostOfTranslationalOncologySolutions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to translational oncology solutions during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_CostOfTranslationalOncologySolutions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_PersonalizedOncologySolutions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from personalized oncology solutions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_PersonalizedOncologySolutions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_TranslationalOncologySolutions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from translational oncology solutions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_TranslationalOncologySolutions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_WeightedAvergageNumberOfSharesBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_WeightedAvergageNumberOfSharesBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 10<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 109<br> -Paragraph 45<br> -Subparagraph a, b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLossAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Audit and Accounting Guide (AAG)<br> -Number AAG-BRD<br> -Chapter 4<br> -Paragraph 80<br> -Subparagraph Exhibit 4-4<br> -IssueDate 2006-05-01<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141<br> -Paragraph 51<br> -Subparagraph g<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 2<br> -Paragraph 12, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 86<br> -Paragraph 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueServicesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingAndMarketingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2DAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">CHAMPIONS ONCOLOGY, INC.<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000771856<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--04-30<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">csbr<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">46,268,436<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jul. 31,
         2011<span></span></td>
        <td class="text"><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
        <td class="text"><div><div><div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 6. Related Party Transactions
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div><div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Related party transactions include transactions between the Company and certain of its shareholders, management and affiliates.&#160;&#160;The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.
</font>
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font>
</font>
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font>
</font>
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div>
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font>
</font>
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div><div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><br />
Consulting Services
</font>
</div>
</div>
</div>
</div>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >During the three months ended July 31, 2011 and 2010, the Company paid one of its directors and former Chief Executive Officer, $18,000 and $15,000, respectively, in consulting fees.&#160;&#160;During the three months ended July 31, 2011 and 2010, the Company paid certain members of its Board of Directors $16,000 and $10,000, respectively, for consulting services unrelated to their duties as board members.&#160;&#160;The Company incurred $4,000 in expenses for the three months ended July 31, 2011 from a substantial stockholder of the Company for consulting fees. $2,000 was payable to this stockholder as of July 31, 2011. As of the date of this filing, the Company has satisfied this obligation. No such expenses were incurred for the three months ended July 31, 2010.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Revenue
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >During the three months ended July 31, 2011, the Company recognized $20,000 in revenues from companies whose board members were also members of the Company&#8217;s Board of Directors. These revenues are still receivable as of the date of this filing. No such revenues were incurred for the three months ended July 31, 2010.
</font>
</div>
</div>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 3A<br> -Section 04<br> -Paragraph b<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 57<br> -Paragraph 1-4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph k<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Grant Income (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_GrantIncomeAbstract', window );"><strong>Grant Income [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_GrantIncomeTextBlock', window );">Grant Income [Text Block]</a></td>
        <td class="text"><div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 11. Grant Income
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On October 29, 2010, the Company was notified that it was awarded total cash grants of approximately $1.5 million under the Qualifying Therapeutic Discovery Project program administered under section 48D of the Internal Revenue Code, of which approximately $1.0 million related to qualifying expenses the Company had previously incurred during fiscal 2010 and $0.5 million related to qualifying expenses which the Company expected to incur during fiscal 2011.&#160;&#160;In November 2010, the Company received approximately $1.0 million and expects to receive $0.5 million related to the 2011 expenditures during the Company&#8217;s fiscal year.&#160;&#160;To date, the $0.5 million has not been received.
</font>
</div><br />
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_GrantIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_GrantIncomeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_GrantIncomeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire concept related to grant Income</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_GrantIncomeTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Recently Issued Accounting Pronouncements (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">Accounting Changes and Error Corrections [Text Block]</a></td>
        <td class="text"><div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 2. Recently Issued Accounting Pronouncements
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In June 2011, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2011-05, &#8220;Presentation of Comprehensive Income&#8221; (&#8220;ASU 2011-05&#8221;).&#160;&#160;ASU 2011-05 provides for the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income (&#8220;OCI&#8221;) either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Regardless of which format is chosen, the amendments establish a requirement for entities to present on the face of the financial statements reclassification adjustments for items that are reclassified from OCI to net income in the statement(s) where the components of net income and the components of OCI are presented. The amendments in ASU 2011-05 are effective, on a retrospective basis, for public entities for interim and annual periods beginning after December 15, 2011. The adoption of this guidance will not have any impact on the Company&#8217;s financial position and results of operations.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In May 2011, the FASB issued ASU No. 2011-04, &#8220;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs&#8221; (&#8220;ASC 2011-05&#8221;).&#160;&#160;The amendments in ASC 2011-05 were issued in order to align the fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards.&#160;&#160;Consequently, the amendments change the wording used to describe many of the requirements in GAAP for measuring fair value and for disclosing information about fair value measurements.&#160;&#160;However, many of the amendments in ASC 2011-05 will not result in a change in the application of the requirements in ASC 820, Fair Value Measurement. The amendments in ASU 2011-04 are effective, on a prospective basis, for public entities for interim and annual periods beginning after December 15, 2011. The adoption of this guidance will not have any impact on the Company&#8217;s financial position and results of operations.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >During December&#160;2010, the FASB issued ASU No.&#160;2010-28, Intangibles - Goodwill and Other (&#8220;ASU 2010-28&#8221;). ASU 2010-28 addresses questions about entities with reporting units with zero or negative carrying amounts because some entities concluded that Step 1 of the goodwill impairment test is passed in those circumstances because the fair value of their reporting unit will generally be greater than zero. The amendments in this update do not provide guidance on how to determine the carrying amount or measure the fair value of the reporting unit. The amendments in this update modify Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. This update was effective for fiscal years beginning after December 15, 2010. The Company does not anticipate that the adoption of this standard will have a&#160;&#160;material impact on the Company&#8217;s financial position and results of operations. The Company tests for goodwill impairment annually during its fourth quarter, or more frequently if circumstances indicate potential impairment.
</font>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingChangesAndErrorCorrectionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 1.N.Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6369664&amp;loc=d3e30840-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=6368906&amp;loc=d3e21914-107793<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 154<br> -Paragraph 17, 22, 25, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 1<br> -Section N<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22644-107794<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Licensing Agreements (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_LicensingagreementsdisclosuretextblockTextBlock', window );">Licensing Agreements Disclosure [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 8. Licensing Agreements
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >During fiscal 2011, the Company was a party to several different licensing agreements, all of which are described in more detail in the Company&#8217;s Annual Report on Form 10-K for the year ended April&#160;30, 2011.&#160;&#160;During April 2011, the Company terminated all of these licensing agreements with the exception of the Liposome Option Agreement, which is described further below.&#160;&#160;All rights related to all other licensing agreements that were terminated during April 2011 were returned to the underlying companies and no amounts were due under these other agreements as of April 30, 2011.
</font>
</div><div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><br />
In February 2010, the Company entered into an exclusive option agreement with a Canadian company for which it paid and expensed $40,000 during the Company&#8217;s fiscal 2010 year.&#160;&#160;The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast and lung cancer through April 2011.&#160;&#160;During the option year, the Company performed various tumorgraft testing on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. Under the terms of the agreement, the company&#8217;s exercise of the option resulted in amounts due to the Canadian company of $85,000 comprised of the option exercise price and reimbursement to the Canadian company for past patent costs, which is recorded as a liability as of July 31, 2011 and April 30, 2011.&#160;&#160;As of the date of this filing, the Company has satisfied this obligation.&#160;&#160;Under the terms of the license agreement, the Company will be required to pay up to $3 million in development milestones.&#160;&#160;Upon commercialization, the Company would also be required to make royalty payments and sales milestone based upon revenues.&#160;&#160;&#160;Commencing with the second anniversary of the agreement (March 2013), the Company will be obligated to pay a minimum annual royalty of $10,000 (Canadian).
</font>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_LicensingAgreementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire concept related to several different licensing agreements</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_LicensingAgreementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_LicensingagreementsdisclosuretextblockTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire concept related to several different licensing agreements</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_LicensingagreementsdisclosuretextblockTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cephalon Agreement (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CephalonAgreementAbstract', window );"><strong>Cephalon Agreement [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CephalonAgreementTextBlock', window );">Cephalon Agreement [Text Block]</a></td>
        <td class="text"><div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 9. Cephalon Agreement
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On March&#160;16, 2011, the Company entered into an agreement with Cephalon, Inc., (&#8220;Cephalon&#8221;), pursuant to which the Company will conduct low Tumorgraft studies on proprietary chemical compounds provided by Cephalon to determine the activity or response of a compound in potential clinical indications. In April 2011, Cephalon paid an initiation fee of $1,390,000 to the Company which is reflected within deferred revenue on the Condensed Consolidated Balance Sheets as of July 31, 2011 and April 30, 2011. The Company anticipates that the studies will be completed within 12 months of the execution of the agreement.&#160;&#160;As models, along with required reports, are delivered, the deferred revenue will be recognized on a proportionate basis in accordance with the Company&#8217;s revenue recognition policies. No revenue was recognized in the quarter ended July 31, 2011, as no models were delivered. The Company expects the models will begin being delivered in the second quarter of our fiscal year ending April 30, 2012. Cephalon will, under certain conditions, also pay the Company various amounts upon achieving certain milestones. Potential milestone payments under the Agreement total $27&#160;million. In addition, under certain conditions, Cephalon will pay the Company royalties on any commercialized products developed under the Agreement.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CephalonAgreementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_CephalonAgreementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CephalonAgreementTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire concept related to Cephalon Agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_CephalonAgreementTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
        <td class="text"><div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 7. Commitments and Contingencies
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Operating Leases
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >As of July 31, 2011, the Company leases office and laboratory space under a non-cancelable operating lease in Baltimore, Maryland, which expires in April 2014, office space under a non-cancelable operating lease in Ra&#8217;anana, Israel, which expires in July 2012, and office space in Hackensack, New Jersey under a non-cancellable operating lease, which expires in 2014.<font style="display:inline;font-size:10pt;" >&#160;
</font>Rent expense under all lease agreements was approximately $36,700 and $14,200 for the three months ended July 31, 2011 and 2010, respectively.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Research and Development Materials Purchase Agreement
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In February 2010, the Company entered into a research and development materials purchase agreement with a foreign hospital for the acquisition of Tumorgrafts.&#160;&#160;Under the agreement, the Company makes monthly payments to the foreign hospital of approximately $37,000 for 18 months, commencing March 1, 2010.&#160;&#160;Future payments due under the agreement total $144,000 at July 31, 2011 and are due during&#160;the remainder of the fiscal year ending April 30, 2012.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Legal Matters
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company is party to certain legal matters arising in the ordinary course of its business.&#160;&#160;The Company has evaluated its potential exposure to these legal matters, and has concluded that there were no reasonably possible or probable liabilities at July 31, 2011 and April 30, 2011.&#160;&#160;The Company is not aware of any other matters that would have a material impact on the Company&#8217;s financial position or results of operations.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Registration Payment Arrangements
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company has entered into registration rights agreements in connection with a private placement of its securities, which closed during April 2011 and is discussed more fully in Note 5.&#160;&#160;This registration rights agreement contains provisions that may call for the Company to pay penalties in certain circumstances.&#160;&#160;This registration payment arrangement primarily relates to the Company&#8217;s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period.&#160;&#160;The Company does not believe it is probable that penalty payments will be made for the registration rights agreement discussed above and, accordingly, has not accrued for such potential penalties as of July 31, 2011.
</font>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Interpretation (FIN)<br> -Number 14<br> -Paragraph 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 9, 10, 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EACAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (2,037,000)<span></span></td>
        <td class="num">$ (591,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">1,014,000<span></span></td>
        <td class="nump">170,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">29,000<span></span></td>
        <td class="nump">10,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="num">(177,000)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_IncreaseDecreaseInAccountReceivable', window );">Accounts receivable</a></td>
        <td class="num">(651,000)<span></span></td>
        <td class="nump">13,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_IncreaseOrDecreaseInGrantReceivable', window );">Grant receivable</a></td>
        <td class="nump">13,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets', window );">Prepaid expenses, deposits and other</a></td>
        <td class="num">(65,000)<span></span></td>
        <td class="nump">109,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num">(82,000)<span></span></td>
        <td class="nump">165,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="num">(38,000)<span></span></td>
        <td class="nump">43,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump">459,000<span></span></td>
        <td class="num">(355,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(1,535,000)<span></span></td>
        <td class="num">(436,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(95,000)<span></span></td>
        <td class="num">(20,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(95,000)<span></span></td>
        <td class="num">(20,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(31,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of options and warrants</a></td>
        <td class="nump">4,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="nump">4,000<span></span></td>
        <td class="num">(31,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Exchange rate effect on cash and cash equivalents</a></td>
        <td class="nump">8,000<span></span></td>
        <td class="nump">3,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Decrease in cash and cash equivalents</a></td>
        <td class="num">(1,618,000)<span></span></td>
        <td class="num">(484,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump">10,457,000<span></span></td>
        <td class="nump">2,572,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump">$ 8,839,000<span></span></td>
        <td class="nump">$ 2,088,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_IncreaseDecreaseInAccountReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The (increase) decrease during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_IncreaseDecreaseInAccountReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The (increase) decrease during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_IncreaseOrDecreaseInGrantReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The (increase) decrease in amount due during the reporting period in Governmental, corporate, or foundation grants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_IncreaseOrDecreaseInGrantReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 20<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 17<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 3. Property and Equipment
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following:
</font>
</div><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >July 31,
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >April 30,
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >(unaudited)
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Furniture and fixtures
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >44,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >10,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom"
 width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Computer equipment and software
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >167,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >119,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Laboratory equipment
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >67,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >56,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Leasehold improvements
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Software in-progress
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >26,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >24,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;"
 >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Total property and equipment
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >306,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >211,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Less: Accumulated depreciation
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(94,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(65,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Property and equipment, net
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >212,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;"
 >$
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >146,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Depreciation expense was $29,000 and $10,000 for the three months ended July&#160;31, 2011 and 2010, respectively.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-Based Payments (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 4. Share-Based Payments
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company has in place a 2010 Equity Incentive Plan, a 2008 Equity Incentive Plan and a Director Compensation Plan of 2010, all of which are described in more detail in the Company&#8217;s Annual Report on Form 10-K for the year ended April&#160;30, 2011. In general, these plans provide for stock-based compensation in the form (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company&#8217;s employees, directors and non-employees.&#160;&#160;The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Stock-based compensation in the amount of $1,014,000 and $170,000 was recognized for the three months ended July 31, 2011 and 2010, respectively.&#160;&#160;Stock-based compensation expense was recognized as follows:
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="22%" colspan="6" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Three Months Ended July 31,
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2010
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >General and administrative
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >916,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >140,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td
 valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Sales and marketing
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >74,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >8,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Research and development
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >24,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >22,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Total stock-based compensation expense
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1,014,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >170,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Stock Option Grants
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div
 style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2011 and 2010 were as follows:
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="22%" colspan="6" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Three Months Ended July 31,
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2010
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected term in years
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >5.75
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >6.0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Risk-free interest rates
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.9% - 2.2
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new
 roman;font-size:10pt;" >2.0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Volatility
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" nowrap="nowrap" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >107.1% - 107.3
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >104
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Dividend yield
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The weighted average fair value of stock options granted during the three months ended July 31, 2011 and 2010 was $0.74 and $0.75, respectively. The Company&#8217;s stock options activity for the three months ended July 31, 2011 is as follows:
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="40%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Weighted
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr><td
 valign="bottom" width="40%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Weighted
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Average
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="40%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Directors
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Average
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Remaining
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Aggregate
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="40%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2"
 nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Non-
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >and
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Exercise
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Contractual
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Intrinsic
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="40%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Employees
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Employees
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Total
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Price
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Life (Years)
</font>
</font>
</div>
</td><td valign="bottom"
 width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Value
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="40%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="40%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Outstanding, May 1, 2011
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,610,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >12,710,948
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >14,320,948
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.88
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >8.44
</font>
</td><td valign="bottom"
 width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="40%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Granted
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >245,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >245,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.92
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="40%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Exercised
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"
 style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="40%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Forfeited
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >(50,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >(50,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="40%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expired
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font
 style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="40%" style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Change in employee status
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="40%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;"
 >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="8%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="40%" style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Outstanding, July 31, 2011
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1,610,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >12,905,948
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >14,515,948
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.88
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >8.13
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new
 roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >653,643
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="40%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="40%" style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:-9pt;display:block;margin-left:9pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Vested and expected to vest as of July 31, 2011
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1,610,000
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >12,879,281
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >14,489,281
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;"
 >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.88
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >8.13
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >652,310
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="40%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="40%" style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:-9pt;display:block;margin-left:9pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Exercisable as of July 31, 2011
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1,533,333
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"
 style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >3,859,250
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >5,392,583
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.86
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >6.33
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="7%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >442,526
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Restricted Stock Grants
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >A summary of the activity related to restricted stock grants is as follows:
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="70%" style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="64%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Weighted
</font>
</div>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="64%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Average
</font>
</div>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="64%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new
 roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Grant
</font>
</div>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="64%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Date Fair
</font>
</div>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="64%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Total
</font>
</div>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Value Per
</font>
</div>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="64%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Shares
</font>
</font>
</div>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Share
</font>
</font>
</div>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="64%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="14%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="64%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Nonvested as of May 1, 2011
</font>
</div>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;"
 >100,000
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="12%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.90
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="64%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Granted
</font>
</div>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="64%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Vested
</font>
</div>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >50,000
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.90
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="64%" style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Forfeited
</font>
</div>
</td><td valign="bottom" width="2%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="64%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr
 style="background-color:#ffffff;" ><td valign="bottom" width="64%" style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Nonvested as of July 31, 2011
</font>
</div>
</td><td valign="bottom" width="2%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >50,000
</font>
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="2%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="12%" style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.90
</font>
</td><td valign="bottom" width="2%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The aggregate fair value of shares vested during the three months ended July 31, 2011 was $43,000.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Stock Purchase Warrants
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >As of July 31, 2011, the Company has warrants outstanding for the purchase of 1,897,019 shares of its common stock, all of which are exercisable.&#160;&#160;Of these warrants, 1,266,667 were issued in connection with the April 2011 financing arrangement and are accounted for as liabilities as further discussed in Note 5. 15,000 warrants were exercised on July 11, 2011.&#160;&#160;As of July 31, 2011, the weighted average exercise price of these warrants was $0.73 and the weighted average contractual life was 3.46 years.
</font>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Statement of Position (SOP)<br> -Number 93-6<br> -Paragraph 53<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph 64, 65, A240<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Redeemable Common Stock and Stock Purchase Warrant (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract', window );"><strong>Redeemable Common Stock and Stock Purchase Warrant [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock', window );">Redeemable Common Stock and Stock Purchase Warrant [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 5. Redeemable Common Stock and Stock Purchase Warrant
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale to the investors of an aggregate 12,533,333 shares of the Company&#8217;s Common Stock at a purchase price of $0.75 per share, or an aggregate of $9,400,000, of which, $500,000 was sold to officers and directors of the Company.&#160;&#160;As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667&#160;&#160;shares of Common Stock at an exercise price of $0.90 per share.&#160;&#160;These warrants expire five years after the closing date, which occurred on April 4, 2011.&#160;&#160;The Securities Purchase Agreement contains certain anti-dilution protections for the investors and certain registration rights with respect to the shares of Common Stock issued to the investors.&#160;&#160;Furthermore, investors will have the right to require the Company to redeem the purchased common shares held by such investors (the &#8220;Put Option&#8221;) for cash for $0.75 per share upon a change of control or sale of substantially all of the company&#8217;s assets.&#160;&#160;The Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The warrants issued in connection with the Securities Purchase Agreement contain certain exercise price reset provisions.&#160;&#160;Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants.&#160;&#160;These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period.&#160;&#160;If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists.&#160;&#160;The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement is $41,000 for each 30-day period in which a registration default exists; however, as of the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company has accounted for the warrants issued in connection with the Securities Purchase Agreement as liabilities based on the exercise price reset provisions described above.&#160;&#160;This liability, which is recorded at fair value on the accompanying unaudited condensed consolidated balance sheets, totaled $936,000 at the time of the close of the Securities Purchase Agreement.&#160;&#160;As of April 30, 2011, the fair value of these warrants increased $36,000 to $972,000.&#160;&#160;During the quarter ended July 31, 2011, the fair value of these warrants decreased by $177,000 to $794,000.&#160;&#160;The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company&#8217;s unaudited condensed consolidated Statements of Operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >July 31,
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >April 30,
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" style="padding-bottom:2px;"
 ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected term in years
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >4.7
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >5.0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Risk-free interest rates
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.4
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2.0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Volatility
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >103
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;"
 >102
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Dividend yield
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Due to the Put Option described above, the Company has accounted for&#160;&#160;Common Stock issued under the Securities Purchase Agreement as temporary equity, which is reflected under the caption &#8220;Redeemable common stock&#8221; on the accompanying Condensed Consolidated Balance Sheets.&#160;&#160;The total amount allocated to these common shares was $8,159,000.&#160;&#160;This allocation is equal to the total proceeds of $9,400,000, less the amount allocated to the warrants of $936,000 and is also net of direct and incremental costs associated with the Securities Purchase Agreement of $305,000.
</font>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity-based compensation plans and award types, including multiple equity-based payment arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity-based compensation plans and award types, including multiple equity-based payment arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>csbr</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EAFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (2,037,000)<span></span></td>
        <td class="num">$ (591,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Foreign currency translation adjustment</a></td>
        <td class="nump">8,000<span></span></td>
        <td class="nump">4,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">$ (2,029,000)<span></span></td>
        <td class="num">$ (587,000)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A5<br> -Appendix A<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph c(3)<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 8, 9, 10, 11, 12, 13, 14<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 24<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph c(3)<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 14, 17, 19, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 52<br> -Paragraph 13, 20, 31<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization, Use of Estimates and Basis of Presentation (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 1.&#160;&#160;Organization, Use of Estimates and Basis of Presentation
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Champions Oncology, Inc. (the &#8220;Company&#8221;), is a company that is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company&#8217;s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice. The Company uses this technology to derive revenue for two customer groups: Personalized Oncology Solutions (&#8220;POS&#8221;), and Translational Oncology Solutions (&#8220;TOS&#8221;). Personal Oncology Solutions assist physicians in developing personalized treatment options for their cancer patients through access to panels of expert medical professionals and tumor specific data. The Company&#8217;s Translational Oncology Solutions offer a technology platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries:&#160;&#160;Biomerk, Inc, Champions Biotechnology U.K., Limited and Champions Oncology (Israel) Ltd., which was established in November 2010.&#160;&#160;All material intercompany transactions have been eliminated in consolidation.
</font> <font style="display:inline;font-size:10pt;" >The financial statements of the Company&#8217;s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for each period presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss. The Company is subject to foreign exchange rate fluctuations in connection with the Company&#8217;s international operations.
</font>
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). All significant intercompany transactions and accounts have been eliminated. Certain information related to the Company&#8217;s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company&#8217;s annual consolidated financial statements for the year ended April&#160;30, 2011, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended April&#160;30, 2011.&#160;&#160;Certain reclassifications have been made to the prior period financial statement amounts to conform to current presentation.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation assumptions used for share-based compensation and warrant liability, expenses related to personalized oncology solutions and the carrying amounts of long-lived assets and deferred taxes.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the period.&#160;&#160;Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the period, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method.&#160;&#160;Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable.&#160;&#160;Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.&#160;&#160;Due to the net losses for the three months ended July 31, 2011 and 2010, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.
</font><br />
</div><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><div>
</div>
</div><div style="text-align:justify;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The
 following table reflects the potential weighted average incremental shares of common stock that have been excluded from the computation of diluted loss per common share since their effect would be anti-dilutive.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="90%" style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="22%" colspan="6" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Three Months Ended July 31,
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2010
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" nowrap="nowrap" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Stock options
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >437,054
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >650,385
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Warrants
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >431,668
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >462,273
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font
 style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Restricted stock
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >2,974
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Total common stock equivalents
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >868,722
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1,115,632
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Name Statement of Position (SOP)<br> -Publisher AICPA<br> -Number 94-6<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Staff Position (FSP)<br> -Number FAS140-4/FIN46(R)-8<br> -Paragraph 8, C1, C7<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Name FASB Interpretation (FIN)<br> -Publisher FASB<br> -Number 46R<br> -Paragraph 4, 14, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 2-6<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 915<br> -SubTopic 235<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Supplemental Cash Flow Information (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Cash Flow, Supplemental Disclosures [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Note 10. Supplemental Cash Flow Information
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:left;text-indent:9pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >There was no cash paid for interest or income taxes during the three months ended July 31, 2011 and 2010.
</font>
</div>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 32<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowSupplementalDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowElementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>29
<FILENAME>0001144204-11-052645-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-11-052645-xbrl.zip
M4$L#!!0````(`"EQ+3_KF`^48D$``*K;`P`1`!P`8W-B<BTR,#$Q,#<S,2YX
M;6Q55`D``TZ<;TY.G&].=7@+``$$)0X```0Y`0``[%U9<]M&MGY/5?X#KJ9N
M*JDB*8*[9#M3M"Q[E#B2QI+O9)Y23:!)=H*%Z08D,;_^GM.-G0`!D*`M._2#
M;:*7\_79>T'CY3^?;$M[H%PPUWEUHG>Z)QIU#-=DSN+5R<?[M^W)R3]__/:;
ME__3;FN_OO[P7C-=P[>IXVD&I\2CIO;(O*5V^5=;E@8]:?U.MZ-WAIK6;H>M
M7Q,!M:%,5NQU]+#P:<8M=HY_:P#&$>>&F/%7)TO/6YV?GAI+8J^@2^$"+,M=
MK#N&:Y_VNKK>[H[;??TD:&0QYX^HT>/C8P<[[+A\`76[_5,LG@&"L#J6FBQJ
MD*P\.E6%4=6-KA_[LJY^=G9V*DNCJH+E581.]=-??WE_9RRI3=K,$1YQC!06
MM@5[MCX3[J"GC[>U4#7"!H[K.+Z=7]_T^*FW7M%3J-2&6I0S(VI7WBC=P*0K
M3@U4BT)P9Z>$&]RUZ.F<&%Z;/JTLXA#/Y>NW\#OLB--Y80^C4RB-(%)O"RE)
M!ZJDI.[E2GVHI!Y5-5S?\?@Z75=0H[-P'TZ#PD`-]80:&C[G8$!%[8+2G(8F
M9?EMH""G.GTREOGUL22G`7,>J/#RFZBRG$8.88;(;R.+<IH(9N0W@(*\ZMZ*
M%]2'DIP&OF@O"%E%;>9$S*0,@X+B)FWB><7-H)"SF>]1D6B&.BYRV\B2'%I/
MUA:S_/4]^@KT>>@TSH5T!Q_H7)-.Y#PPC.VNYG3%W17E'@/R":<F.T!0KTX$
MLU=6]&PI30E=:AO1=L=]O?,DS)/3T"]?N(Y'GSSMCAH>NNZ45S:"0@8&'53\
MK?_+Y6]]O?V3;V&/W9.X-H0%YJWCW\S$)W-&N2;'FAY:*.B+JY]/?NS"G_%8
MGPQ'+T^SC;'#TWP*P`GFFO%O<)3<>P,."!XAN'9W"/*)VR?+(]!FJ@$&E23!
ML#1\$I,\3?%H.].FXK>;^6_];GNZ4H)X5FQ3$<93/`"-'K3[W;AU7+H?#]**
M\[PXD%$<O:[BZ`=6G&?*MJSBI'G0E.)$/)CZB^?/@\DA>1`YD.?E=U,\Z![*
M@61MX7GS8!];P,#\T6$%4=G'$F3,W9)P2%A^#)[;E`B?TQ\#ER4+P\[#LO`W
M]I'3X\>[-QO=!;.)<RBKW]LMY1)EU*O)'H"]/R:J7N,D`J<`.Q+>:(\/WU#'
MM9F3UVU5]J2Z.$VCSXP;Y75I43DQ3HKL)63OYY=2<3[0!1,>!QVX)C;5`F%_
MP.RL,$!>_&OZR^W5S?6==G-]<?/^YMU_6]K5]47GY6E1OP@F+KL`/)Q85XY)
MGWZFZVI$D^90V%5(YT+.:+RW3!C$^B\E_%+%O6JDVLI3*#I%7:6'])99E%_`
MXP5,&:M1N;.)!8VT#W3E0N+L+"#GM5?$62?'E^HW)'G/":Z$W*WMF6M5(X:9
MMNHWU3@C%]>V7>?.<XT_E`G?^!ZZ!ZR?2V8S`FJH>K).X`0TDQH,1@KS%?"+
M@U%O-!GTTR+<0C7$]R98WKF'J42U`8.K^[>BDFP;]C>%!R8^?&N1_*%M=#B'
M,5#58ZIU%N*M])^U]"U.4M*(4UUEZ2B%5%7>PC-1C=:_,S0VNLFG@XI?@PK\
MW<NC$W6#5((Y[OD%$<NI8^(_EW_Z[(%84%],O0O"^1J4X/^(Y>=S<G/Z$NL?
MAHRT\NG=P7`,7N3E:2W*C4)-,&D;U,FD?_:9D292NFU(>\-Q[[GPM`1I=S+9
M#^G4D"MLX@,U*%2?6?2:>D%\:$`_AY-A"M\V<DW`JJB+>J\_V@G7.XS^B5H-
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MY2PS*RJAV!"XBMP:GPUW!9>HT`"7!H,,FQ+=[T"UXO`'H_Z@"E5<F&*>+2>%
M,$T$6C`II([1S-B3$]%B0@W@J<B5^G@^4)-26\[_\!24XW'7LJ#F%9#G5'B8
MCX7+>^&<>FIC<&N`?1-]F+;XW=$<?DQ55WT.,R:84JG`(-=8FUI-2\_9L@3V
MH%]?7TOH)Q:8FQI\/[..F*&P*_6JT:XZ]7LN=Y#6C8Y>[PW3;GN3RNX8*J]*
MU<(P-4V&VU_$NB7,O`)K63&/-#$EU,?C229%S:>U)YRJ?)E,LBE\.9P/U"/,
MH>8EX0ZX$`%)MF_[%IZ8A*22&:P)C]W61X-)+^/?RN@VA[(B_]KZ9*AGO7`=
ME(E2N72%FWJ<+JDC(+^Z`B]NT_>N$-?4NYG?DZ<F&#O:F$'607`@\%7Y/=J8
MBN\*7EK^TK5,RH6*C$V8=UH7-FGLCJ`JA\[.>C4P)))92-X.PY.-E:(RHDT!
MW'EUJ0[`>VJO7$[X6A7=$G[#[SS42!E6PJ,CNS`R.G:2P-N'7*;3[>J)4%8-
M0,.8BWC[J3#7.G*0R^#<(P>0*/3Q3R'4W$,'36#,9>@!,*;3WT.KJ]RI*,J]
MJXA]?[AU-+5AN$H04]];NIS]1<UF='0XZHZ'12"S))L!5UTY&P5W)83?%-<*
MQ9HDM3^@ZIQJ!%#C#K`$526G<B"_MQNTQ'SWT\?F"L0;Q+I?3-X=ZV'<'(2Y
M;F:O8`O-!J#5BL!-06O2Q?5'9\/1:#3>@FK3J^R`J#JC`-%8WQM1XTZNWY^,
M2\17[DT.Y.7Z_;,^3$?Z];&EUK14S8;8E3W3E4-I#R`U>%,1")Y?/@>G)7`=
M"TWP)GCO^LZU?%S=JG(P=?OY0%WOJKE^.:W&$)4<_P@FL34`W7/B"(NH];[F
M>30X2R#:3JLY2&7'IOK].IBB511B41%LE=]1_L`,*HK.*=52HU$FCA00:@9+
MV7&%S$[G%BR2?1>N\&[FA[6S?F\0RZL"P8;!E>P-3_K[@#NP^?5ZO2RZBD;8
M$+P2YNEG]>'%J^R"$F[@B>PWH*"6*X_R!>=`]^;<V<::_A9J3<(J.3N<.?U:
M&=8=E1O!4.\7PO^@N$'?%*OTK,\H)-48H)(PF#FW7PW0.^I03BRH-35MYLB7
MT?"(2U-L&F6/?6^GURRTLBW)[/GXZMAN5OC28LS2)IQ6MY]"LT%B7_IE9\,&
MDQWHQWM->W.@/2KB0$QD?PPENTB]GCZH`^(=80X^NW'BXV%7#FB.?)T+LX9;
M3KV"/<`ZW$GJ:46:!\)9NM&?-JH=P,HMS6O7<=.\W]]GIW<("\@T@Z3RL9P*
M*#9+&XMB:8X4$FH*33W=J00GMLNWW+61+'-\:!`8+N1/K^G<Y<&N^#UYHN+R
M"3R[RTWF$+Z^\J@M\@^.[>_2AF?IS.6`8)\/3\I<;#=S,NN3,@6:!TKT&L+]
MO.`TS(Z>N8!$,R@J>Y0**,#M-AFYLVJ>ZGX?NG55J9!P>"HI7-%_300S</[`
M8))5L.J[E05Y>PL]@-3M='LQGA*RS2*LL/L1(!S40B@GJO^A;+&$!],'RA=D
M0:]]>T;YS5PM/N[-SHW%X/$XL?Y1B_C!()>=EQ\$+R;N!CF5#^2<YWH+'I`M
MG(O@%D*Y9$#D92703V(!86K^[@LO>,%/GOY2UQ9`+[AH3-]0]>_^JYR;R=0G
M@/U,655R9/VSLRJ'W-;CB?7<_V3CJ'41L>8PE8:&WMDNH$(G2$UL`+4ER_=/
MM#/[;OED&@%2MA&0F>"6(WDC+X9E#3$BS8=DWWO0+'D'\&PK3>FOL\9SY02O
MF,97%.QO*'IBV;P"P8;!E:P?#O7]P-WPN+:\W:%!SF5Q;:'5,*ZR<_`Y$JT#
M+JX97.D0OIX:KKJE[W9H0`63V[<[HO@$HRC3U4;&D)@PY6M[^'IY`]N=P^R4
M=SO%IN&5J''FC9/]X67>/M\_V>R7`\S0/`#&$B[V)PV#S+RKOK_U]X=E>I@A
MV32^DCE4YLW.6O#P>B4BEK?<Q5L>S=?KCY#37#G1`OX44NF'9K2Q/<B<QZE.
M^V"(RP+5,'-CSVZ0P?[ENOV].S7^]!FGA=?+[+\CELX4JU,^&-Z2RPR&#>`M
MD,J5O.2_827.,+@ZZ8,!+GO%JY(&EP`.Y0*S[0]TY7-CB2G;/''8</_5*SU7
M$XHI-HZO^DOA];!QUZ#4E.OT_R$<<]O+)\H-UL0.>.J8>S&=!O&4!*/L-5J5
M(!4HY5OF$,=HV(#[&ZON%4D?#'`=CNX&]W(^IX9W,[]\`E5U%O0#\>B-DW])
MY?Z&G`)<A_0!(==9:MP5<GZ-`RTDMP>9JP'J4#\@ZM(7]?4J-Z566,;F"^*P
MO^1ZU`5^+,MB)@F6?6$N*Z`7^?-F'M@&L>0[*M)QOV'"L%R\_OP>1O#:JAH?
M?OS.\EZ8[.&[A?=B\[^:\-;X,1MLVB866SCG%IU[+^1OYN`-^^?=%585*XNL
MSV=(]X5-^((Y;:PI2X/?''="Y(,3+:0Q!U@AD;`3YEC,H;*H/2<VL];G'K/!
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MY0M.YIYV'Y.'S-Z;N]Q6PW%<(*&1U8J[Q%BF0<BW9A`^AW\XU6;R^WK^RE5#
MQ8]`D4#S$-;2![YK'A(5R`YFV[Z#@\![-7`(-HPSA18'!`-?`I($?P"#B:>P
MJ,:#&3O`U;Q'5S-`MUP;X"RXZZ_$N98\SQV)5(M/07^?$.GMS5U:G,C1U)GF
MLA[NTSUT(O)Y#8D``_6TU7(M8/A`!5D2"!09NTI"]_!+ATIG5JJY'/*2,AY*
M8`4@9>SUEC#XQ5(C!FB-4AOB4$LZ`_J$DS?-IB8S`!8(=0YUY."4MDGI:&(%
M,0*DHH$')UOTIXPY+@1N#DJ4$-XJU"[$M23<)@:%VH@&Z<^8FZBL;`F3-E](
MGL#DDS/J$;Y.*J_P?!,JM;3')0,=71)0C1FECB:6[J.#E&84VN*@\>">U$7W
M45F'9I,U\EIIO*,9X#@D&D$]G'Z)SM%IECC-*OUEVZ!*^0X!N06G%DQ<W9;_
M"S('^#$/$P7H.<P40$:&Y9O*_Y%@/1<EZB7<!FH2@\>/2]>RUFU0`NA-^#/!
M3$9`@<1Y7E1]S=!W_"$]?DN+0\'KE$Y^[/S<:6GOF2V1(Z7-H*%]?R4XH=8/
MVGO/[(1Z^4@@&L!(9A832Q41KL&[XHD*#=/+W%`_M2P-HSI'-C`\$!8%F'AG
M721TGEI,?C%&$3"2F5A6E;5=)9<KF+0,4HYBKLX$I$0`_A6&!HT21DNTN>\8
M@3\)OU2IN;C?@?%4A96/G;N.9H)@"6\EQNT%SDB.&TP^4U4Z3(HA3'WT"/T!
MYD74["3]F+8@+`B\D(]B],'`QJGA+ASIB4D8XUTG#.'Q+48!5".Y22_[24<U
M"&?`B=]A3H.^*60.#68W&L>/B<PMW_!\=7`P$*03?-5'?NZVB-5219S0)[O1
MX<,"-W;T:D5>#00F=O51L5:N<!</(H^V\KGP(1O2`M7DOA5DZIPN?(N$`5,6
MWE%0?K5:@37">:\F+^N4\7HC(;V[O$CG'N@X!'`9XSC2+?8=2"+RI'F.I*-=
M0-9`,&5S,$XJ2^%4Z7PPH#QE=%/SE"2:@)X,ZL!+(QSJW'4]!R<^9C0C!$DA
M37#DH>^7GBV7\1&[H0*2X"8F1\IBDB0Y],16*(&%>ET&.L=\:>7%F?I'1\I=
M3E+3>=Z[Z?0VR6Q@FE`\BY4$O(T+(4+YESA4I08\!\_D/L84%?HH7_;VT,#@
MK@E,,=%-!2[#%72#:)[<B./XZH;"$C)!%JJM*7A8ZJ!HIL!<*XY?_6X+@YO>
M0L\Y9Y;Z`/=;S+;T;OOG#@1;V0,FO<&XP21AQH0$6GOQ`!<04&E),H22Z-@9
M>@#,D#&91#=,&`<MD.TUU^>)/E>N8$J%01M]2\6ZV+5*Q36(6(+3=A]CIJA`
M(^)(HS)L)>AH3JZ:)]4=0@A%V"!"8M(_?03T"-$$J),PJ/\>Q,GMP6"JY*B^
M.I;B>PW)Y:8EH4.`R&CA3`;-.IN)V`33-#<8,0."0>C-D99&;.5_H#X,+YPA
MA/=@)QEV3,@KA*ZL+RE(I4->XU5\4I/0M8%0Y5:?2%@B"L,F?U!,8!.K3"!Z
MWPYFI'+!@\BE6A7AI-:AUMM1DD[4R1F97B7.+*0M`"L:;G`1M5?81E$QI;FJ
ML)GO"0.;RX,3KA]@'1J^@VA"Z`4O';<)9N.@N1!5,2FS(C\`/MU"Z'*>.P>1
M!$XVXE)'NTM$O9AYX2SF@5@JR4NQTD<'AQ8JOQ#95NLJ1O(`)2)^5!LX$5?6
MK7@0B>"<6DB(EH;2BTPX6".X5#K)(,MU%FT+LE@S*08S.+Z@>?@6R]$>R^Q1
MGI.7\P`4AA(J3@(,8AG!Q&&VUN1W/9'_LB)Y(,R2QZ*D1\2-3-4PN,H26Z#4
M'H,3^M``XA'DB(X\HJ]L*&X%"8Q2.23`HZO&HSJX1_H#A+WX.IQT%,L-`N%+
M!]M')I4W6!+\1&A;VLKRA?(/B!&G851YI@0EN0L=[A:'U@3S4E40+K2I%%UX
MG!D(7!7BCDJX*(54O.`FFZ#8IN`&\GEV$3DVS&?!YN7`@E%+[B5R7&66BI6!
M(Y])7:+!^RX)KLL,@02?(HH_%@"H.)BS&2*5)#$G#GQF@C*@CIQ!$I"Z40H8
M',(]R,!B06V.C40SHQD%@\7B\$'616MLW@IC`Z0U1=5:^[$*O;"8,\661QD$
M9LFG;%X&`$R!TVRE&,]ZJ]WY45[E@,R"A8K0!+PEIR!,Z&HI@LSN)Q]DTM=5
M/B=EC.M-K4"95/3-->4(I"`VE2F\1!R9TLK%Z063\Z=(@"*>O2K6Q"DA&!AK
MAQ6S@:.>WT\$D1IN/>@PW?U7$60@Z?OVFV!V)S58VA^G<PMDI>0626O3#S/<
MV<6$"9,GI>=93RGSN\3RP%-@SD':([WSRO?2!IU4J:2'U\!U&C38P0CT*;*C
MK5KR6=(+`^=O/-&!XJY!+4NL")[SP-UT^7M%3#/\_<A,;_GJY*S[OR=AISNM
MKGL\^I^)*2-`>G4R<SW/M2,BXU%,),#05E7.>ZNG0RW]1SY)RQ>39Y8CUS\I
M\(+=]G@DNP^DUX.10'X-*@&%HQ/-<1\Y6;TZ4?]&HYRY'%*X<)`SBX!UP5`U
MN9Z1=E;%NOAE'&(H(1"Z+HQ8OZB(=9F*6'56K6NJ7(%PLH=%GKM*AC_XT5D\
M,\F4#*2;=!:]H[.HZ"PPA3UZA3UU[VA$?WLCZAZ-Z'"A]5F'S\.".Z`Q/UO@
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MSHYV=D`[TUNZ/FR-^D=+RZ06X0]\M:LP$N;^2GP5J^%;4),WK$ZC*V0NY'5`
M^"V02\Y=?N%RKNZ&$GM?GYH2W.Z)3,Y;DY_H:*^\-K77T?!S-?)=Y"OU_G+,
M/>V6NP[\WU!<WYK_U.)*/,+:K['N\!KI)V"QZN_*T7["BSK5-3[XIF>DNTFN
MWN&[^(2;0GOMPC^I&Y/>3N]>1S_QQB2V(92X^<>5O-0CV7YZ]__M?>N/VT:R
M[W<#_A\:P2RN`W"TDD;SBG<7<,9QCL^)8]^Q3Q;WTT&+;,UP0Y%:/F:L\]??
MJNKF2T-*&EN/IE0(DHQ>[.KJ7SVZNJOJOVL__SWJ$3FG_7.G6@6K*F*8@UIK
MER9TO[3*@Q;'R)]9':NY*E_Y72Q*B:6_RP1L?3.02F]H<G1:-CGA.JFV0I-/
M-#E%`BV5E:/D6TSMUI^6)3IJ7V@J-F=^4)W7QYOW-=XIGWZ'%88P"_<NR//.
MLRA+1%F1IX54*@004KG51)>846*<4>,)3/S6&>"%2D,YO(-5#;`4:5'L3Q<1
MHT(16"XEU-.7\`M/%VTIRB0"C:8:#=%$1?R`5DHNKS#8E)>82'=Y,9C%<D6U
M<E#X<!^[\)I2-KKPG_E^GN@,W,2!*XMCRAD4H[Q*?L1B#"9Q_IEKBH_'@:O5
M">NL@>&JZ,,OZ_QI8+R#C$".I7&$-5QI,3#)/W%H=K,,F.J6'*098VZ+/]7E
M?'2]J+QP55EL04[@2^(MJ%0JUP'^@RX-I8GS#.*)\["H=YF?UUT+`O`,3-HX
ME3Z<SJ1;K%=CK<@G9;?R$AQ/*V_M.3>\&[K[@YQ753=HXD+[`HY*33JJ:=(W
M)>(`[F_<>U\]Z`*$6$9,^K'X0P:9$A^H\(DJ2E"7/@Q(?B&X!%NJQDD%IO"+
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M8CN!!'V5XHG@Y)FJ+^0B?4[53`QRP;S+9X4H]6-=-A!(0S]OAN7C3.DG+)#G
M^K&;3;%\%[8VR`=;4,?ZN?"R/@<M%V7A5M"!=U@?/R\2C9-KDGH2KDQO+KR(
M!,OX[J7(@;A@:7C2K_#`*:"FJ3B>*%1J"]$+)*\B9QIY`.)U^8EZY]N6%>DH
M1Z6"Y+GJHZ=.P!*`ZL"BH*OU5[]>U=J+J%1O2N5[7'^&(Q!*TB8EEQBCJ!=3
M*[@FDU+6/M^LZJN1CES5ZKR)YUJM8X4KK0U\^FX6`\/_G<DX18.'>(@`#),X
MM^58`ZR.<M!W:,JJ=9C*49;KXK9PT[-"0@L]QYK;^.VL$T]3,2T+3LR6197.
M>B+GFZ[+G3-MOW:T`\7):FQ31;-*GW;DZ)-[6+//C1+M=YO*U;H$*1@U$-HH
MGI<_!'<LBT'MH?HE)];_BG\GCODUUB$#/74/^N51FN\DT23%%SU1Z\I>+U9)
MWE^2QA+Y<8ISU?Z?B!Z4#N[D)5RIV<XD"P161RW*$SY(</VR)"^6&J/-1Y];
METC#*D<IADT>5*AU[`*@5+6-)]7N+DH#%H7=?OH>L-DB3C8(3%=JNFWW=,2J
M&W$M:-EI"8$#*`&SO'C:5DNZ=`D1#%\[X4M]",19_^CQVW#Q;4V;L;_[(5S:
MCZN2<6D_+NW'0L1"9#'VOMVT6FT^+>(P^[,YOUX5[<M^/':/=M<(W@-@K2.<
MDWQ6S[=K&3WO&L/?F]0N-L-YI_`]Z5)6X&CD]/LME9T/2%DP?`\3OH/^4<#W
M6;9NC0(*+U\<MK6[R0]TR_/1ZHDNFSU+B=Z#`KFX/`H-PD`^="`/KH\"R+SM
M>PY/?VNX"\76SU*B]U"WFXT?X_@`<'Q^<10XWO0V\,!MGY*)NH\"#R_-Q]'#
M&LG[K#6.26L,CT)I,(P9Q@<`XWWL^PZJIM]G$_P4,!:8PSO,!=VD,=S?#=*-
M:!BN,+:E.2U_GE%A2_SW[:JTKL*UJW2SF.U3S)8<]A^5F&UU([W=:5EUWY-]
M_=WY^B]?'-L-/T;SX:+YV+#,QY;/X:FN/S]KK'3``5Q+B=Z]_CCK'\>Y#P/Y
MP($\'`R.`LC[.,`\J"#N;RI)?L(BV-G4%"#R*K6).)S+<28;XDROK@\_T-22
MF<GBQ>*U=?&Z.#]N\=KJ9IK#M^SGVTQU1UQ]QC)C^5"P;,&V==3I;6MSS5H'
MN]ML?\\ZZK)3#<0++\K&@=J15[V9]._UI[)W;WHX6'*!<J?>=&>`VE6Z]RU@
MY@C_Z$1L,++E?M^^H5KS)/(7S>U#F^S\L74!J!7>5U]G*DQT$Y*3(64[DS]Q
MHHN`%-T4==G\*3SO/A$JQ%8!6-^Z7*"S@>ZF1+_6?7EBE;=O"N8[;'*T[%79
ML^,YK3>J+3O*CS].L"(&<(\X>:OHZ.`F2M+D\[V,U<\R4=XG.:<$*>[BL=C%
M8]03Q*93XI/(&;4[F'14>JL-<^XEM3""Y[E*2)(ZZH8">X+W(19GQ(9""'"'
M/NU?-7^JNZ:)MS[VJ@%YK\):?R&:&)&605#V#\6\A[S_'365HMX[GDJE'^2=
MXYHZ!+W1#=IT:SYL]O$NBJ=BT#_]KT+=8%L.HV:H#GE%S_3SKFWOP[S[%+4`
M`R4&C`B3HIL4/BM)8:E.QP0QMSHM0QZVV1.O?&QE&YYB[]",TOH_X\_$1^J5
ME+R&+\`W;E62QKZ+QX/ZXS>/V$WP-7$/O@%?,>_/*OKU%N%`S1O;N*&FLR":
M*VR;XID52.B9(9!4?-C:<U'/609)5)MXX$^Q09+ITR3O[F)L1J5$F%'O*%C#
M!*7/-%F=2M._2V*S4]U1#?MNX??HS:1HE(I,^!,[H_JZR:MI*"6)&7MN9=<!
M\?V\`I!Y8[,)6&"G/QA5#/*EMLAHJ;%=SUT(C_96&6BQRBXWX:J5R*JW4*%!
M)J8Q3O)=;7$V!8"NM)39WW$EMP?X^P_#8;64[`57-E]SW_F%%,T'K6A^J2F:
MM?:B7/"<>XE8N#(K)L)M$+@-`O<282':DQ"M%^8]:B'Z=M-JM?FT]@2(.S'P
M51]&QKZ/N[2BV]Q%S97S[=HMF5]UB%C'N+VI'_K86!J#7YNTH39#>J<0[E2C
M@^L!ISHR?KN+W\&(.W6L<U7TY8OCLGF?9:#TB1T,^*=*8=O&QLY2HG>O-2ZY
M.Q7C^`!P?'44,-[';N^@LOMO5:)DC->50DSL?U!!M/&2-_L[G-O:%6Y./.;Z
MD3:M+8N9-5/JIIC9DI"T;[A^[V::C]+8W^?<Z'U/PF;:.L=0QK(M]H8WL&UU
M6ULS6<R=?-[.6N5G;R\=V4[WNDA680^;!8P%;`L"=KGDK/>HQ*OF4.0O]IKN
MOSW?0;,)__[)!R_`=U]_.X_IY=/;M=5<5_$K)7LN]26VP=.7+QJX:G4>Y\^H
M*DX_N_<1';4G23;5V<(B0P\MC80K`Y?*">M$8^G'*(I9)6DVR1-NA9?%(&#/
MR^,4CRI6G'K)J9<V7L9?/A%.O>34RP[EA["RX*RQ[BD+3KWLVEZ=A<A&(>+4
M2TZ]M"P2QPEV?/K*R-AWZ%$KNJV?97;WX/*7KUAF#*-A6$K.#ZFJW_+@XJ'(
M(=^"6(?J\][E^<'K#$;Q@:/XHL=9*-MHUM%=PW?K)W^>3C!6Z^.&6"6IB&6J
MV/392O0>4K=[UW\1IV+8&W98=_R%[9XU1&\'PB]?+*-[V&G+MQ2]O--[#BO_
MB`*9^H&?SMG$64KT]5KBME63U[_L#=#HX1]GAZHX&-8'8/:6PWATJ-CE7=YS
M6/G6QVX;H2?FO@H\-GR6$KU[#7&P3C$CEY';3>36+%O^@EL$+FLRIB^#8'>?
M!Q7+N\4K[)2/N*&+[-A[L-^['.E&1_#7^4*3(O&EI7E6G0J)W\?^9FLW1?(3
MOD'_[!OTHS[?W/DVVJ[X>@8?M3(P+)R$K;0Q,!@8#`P;)[%9VNCE=N[^KXN4
M`[C3_T^S9]ED,&Y/8-TB(%BM':U::XCPEW-K+Y//.S[&LY5X9F`P,!@85M#-
MP&#'GAW[`W/L&;V;8-<;?8+&X&6;S#9Y4_4#>$_*:+82S6RCNVBCW_JQ<M-H
ML_GI;*59KUF-%)N!P7J-]QZ=U6H,WDVPZU9-I1]NN'TQPY?ANR/=>W<7JSN9
M'KWVY0V^53+W\L4A2]WO47AZ[`)WN-@]9.3*D`^X./K`T0<;@,$:;1/L^N6K
MBEU_L]T)6:TQ>G?#KAMX.Y9NFLF``<P`[AZ`WP-^_3#QW6.'[[<'(`S=W/S'
M2EDUM'/;DGK;DE^FLR":J[:*L[M4`]W&'PL2"Q(+$@L2"])W"M*7*&W;1+$0
ML1"Q$*TC1)]BWVT)I;$0L1"Q$*TC1+_Y$R5>_3]L1?7CAF7IY0N6IJY.A*7I
MFZ3I#ZP'R2:)+T!9=1S,9_$'=1;/P&!@,#`8&`P,!H8UM#$P&!@,C-U/HF$K
M56S.OZ<S7_6VQ^$T*?J8I4DJ0]P<.^*#G`O3^6"3>W2;`6TA@)<3?;GSIB\#
MYV+0=_K]+C=_.72;PE!>#\I#YQ*P?#VZ8BQ;35OG&+H'+(^<LR%CF;%<(_JD
M2Q#N]ZX8O';3UCF&[A[%5[W1-W3\_::[`/:RW68<<\#%GH#+,[I"'V;`Y5?=
M"9/C*Y82O7O[T5*,Y(`T!$/XP"$\')US@)"!S$!F(#.0K0!ROW<]9!1;35OG
M&+I[%!_1+KJ[6.;PBCWAE:._SY(7%.,`BZU$<X"%C0=#F"',$&8(,X3MH:US
M##V<[>C+%]WC/L.9X<RJF:,K'0<&7UYY#D_?1?%$^7Q]Q5ZBV:]GX\$0?B;5
MK\Z[GM_64JF,\<OX9?PR?BW'[Q'M-QC+C&7&\KYIXZ"*/4$5OK+R=>;''%*Q
MEF@.J;#I8`@SA!G"#.%M0[B\"6`#SQG$G0?Q$>TZ&,N,9<;ROFGCT(H]H94-
MW5=9VCRE:]&6FWL9WBGAAT*9WIWP9)EF+1T\ORW^8FC=0U/HC1BAY4V,;!*'
MM4W4VE/:J@%;_KREVX[MJK2N(K6K=+.$L819O*PL8=9,B26,)<Q.NCLI0T^D
MI'/<9VFPDFZ6!I:&(Y>&-5LD=VI.W<785B]A;7=:!]IU^."LA;U4[S.:__+%
M41ST,)J/`LV,95N)9BPSEAG+^V8U8YFQS%BV:!*VTL87H^P)=VSG8M2HTQ>C
M:IW`_S,+YN)L"[W`FV.`(^MC@$N.8(%XX479.%"'<ZS</*>]GRNO:$6^T_AN
M9S#;5;I9UO8K:T/GNG_>WE^:A8V%S<(Y=5381L[Y@(7M2(2MD]*TZJ[(]KB_
MLS;Q7<535^EF.7C61*YZ@S.6@UW)P<L7&Z<\C6;[$X.3CJ/_XOS,N1@=I0#P
M52Z+E<YA&#%[J>[(^0-CF;',6+:!MLXQE+',6&8L[YO5C&7&,F/9HDG83%OG
M&,I8MB4^8]'=L]/KI9?/KG=W^>P/E:3*$S+TA/HZ4RZ^2"/Q`&\+F8AHPC?2
M^.#>RH-[OI'&LL:RMJL;:5>7U\[PJD7_L["QL%DXIXX*V\@971VTL&TX3[_C
MXM9)>>([:78M#<O!L<D!WTEC.6`YP-MI0^=LL)L6S)9!BF^GV281!R?&]E+=
MD1,*QC)CF;%L`VV=8RACF;',6-XWJQG+C&7&LD63L)FVSC&4L6Q+?(9OIS7P
M^9>O*G;]1(X#Q;?1^-#>XD-[Y_SLS#D[:SF2.:JP],IYO7S!TF;)G+HI;6?.
MU?FU,SSGNY]LV5C6MBMKY\[9]=`YOV++=@2RUDEAVNM=M`N6`Y:#8Y>#BU[;
MQH?E@.7@>.1@-`)/:7B4)J$6Z\Q?8-SN:6"N*1+9VI.AG-,X%G]=[V&:2__*
MDM2?S+?3\T%S"O_^R4]A//?UM[.97CXJ&G$<!9X9\E8E:>Q30N[G%$@5O\8R
M3).E,<\]LG9YS/@9K/U>O+X123:%L>88+D[OE9!NZC_XZ5S$*I`FOSDNF9L0
M<^^(N<)/,,X\B8(@>DQ^LH'7+CQ0Q=5S`8J&NRK`CC8NJ("__]#_@5X;E4"O
M<[58.2KXIOUAY?"B56M=C&R^+SJT^<P0.=?%WD3#;IS`[1H9+:I\IU!9JD8L
M:X#4PJ]_TCO*V]3YWA[1^EV(:#A`9FW,VM@F?+,V/GAM_.9!Q?).L3)F9;S=
M*OVLCBV;A$72Q^HXYQ>%@5@9LS)FS]AJ?+,J/GA5_%:F2KR3?LSJF-4Q"]UN
M^/4E2F5P[`+'V.TD=O^00:;$)\4&XYL-1O.-FN$.KC]\IS'9'>'[%-8E%YQA
MJB*)`M][?5`RO6(`_:7/]S)6+7<W=JD$NHT^%B,6H[CE((*EB+=C'!WKC/=H
M\V:'D=$59#0HNL)T?D\%S.I.HWV^:Y93L,#FZN?]'H4/IMT/U5+X(.=BPY44
M;!;&X3IK:AO1@V:JMY06:BKS#_I+.NL<D/I@+*]-]$E7($S/Z_>N#Q^]SS)^
MSR@O=)C&CZY-;/9*,2N'SAHZ>M[IP:L(QO"A8Y@W>[S9:^2I;NS*YLY2HO>@
M*LYY4\=`/@0@\^YN2[N[I>=:73.`[Z)XHOP-V\#]W3[9B%I9?IYL$_S75SIK
MSVGOI?1:]IO;U6%=A6I7Z>ZF$*VJF60_^[LI#EO=TVYW6@=ZF>/P1-E>LCOB
MBC.8&<P'`^8&BU/6X]_5SO*;VI)8L[-<O$>SE9XD[:[PODL]?M=NLY.5VU=M
M-VTMW;XDX+M3+[LSB.TJW=T4I7T6;M]1!-DR0-6,?_["NBJ]UI22_8+58^_N
M8G6'B?X3Z<<(B4RAT4\HHTL81\#+8EAF*C>;WL=*B2D\[SX1"F;DU1T$\0A>
MP\GH#'5S;ZFWL,<EV)BOI?F*?V^M4+*NCOPIB]U[F2CQ3QESH>2U"B4_=5X=
M0O!--)W)<"Z`G0!6S4T196F2RA"UF9A$,7UQEO,<GC-PKJXOG?[@.I<,>,^'
MW[G1%&1!4)5E1\@@P`\>[WWW7L#7A"H[_/5*'5;^]9%J.,,0.2$.C#2\N'`N
M+B[%HX(G^$F2@8SY(0P5ALI-?1CNT4_OB<0WL]@/M-Q-_%"&6#!9T*/NU!26
M0\"4B!#INK#O05G&V<',`U^._<!/?:5K0F<Q/"\6P'4W2Q(]XN\1Z(7SGAB<
MHS27S"+"S-3@FT`0L7E@V-PXT];E>#354(74A?B*!PN8FZM,F>L*B[2&Z?<N
MSVAVC<\`7J6Q=--,!C#3B:+?G/5&%V*N9)PL5TS+7OWMKUER>B?E[*>WP*D@
M2K)8?9P@I%282%R<6UV&^R9*TH02^GX&"'F?Y!S7(_D"HO(SBL4_7K[XFYN,
MXY]NE:?4%!%R0U@B>7\3>O3_7.R-U!>_I@G"BULU^?L/-_KO_SG[\,O_G`U.
M@<>GR-X?_F$DMR+$>U25&U>,.3I+!@K-05-0'L'1K#Q9=Z[0G1]#\4$"S\1P
MU*0Y*?&65$0:"2D^*Q?\`](D!:??@%NA-1#IJD2A8`:HAN"'>&P-/T;G(HJ3
M0M\F$I80GHA_EY^"_,NPXJ<,AGDSRHHJKE"G5<[5<'#Y.ED`!*C#4JD7V@55
MR;F8@?*CYSD"%61U1/S.M3/262-.H>`=<7*NWR/MD@`RD?IH,H$'`^&(/\^/
M066;:52(;%.1,QFG^JM^(D"#@4XAC5_GOPR2*#<,A5:$H8NYU1F6&Y2F,4L6
M/F%5V*")3W!K4?*J<1I?ZMI:?9T!$\`\/2BM?(6<`'QH0JA`T6)Y0*=CS&;D
M`IIB;5:T>1LM,2OHPR[''VI*Z8=@JE6,?\#$4O_4\X.,3.DL!C5"/"Z!6((/
MUS#_';#33V!-Z&<D@8D&-S!P!H_(H=O"4K->B_ANG-4[;8VG$<*QI.;1!__B
M'FP</8)(T-T>_ITABZL0H;=1+]8\&:_P5S2-]PHP.YZ+)`/&E^.\PM_D<C3L
MO_Z4I>+C#.==O#EX_2.QRY7)/?VQ($4BF\$P4L"PX(H@,\@D1P%*%PDZ;C*R
M,3I=J0]^TSQWG@@7#:(LP2M)F]F%("AIU&P"B$W!(TH-);I3QKT/>HA0@029
M=36.$V@G4)#(@1`X`TRIL-,I]1/\<'C^EPJA%7:6;(:?@_SD''7J.(G"8+X(
MEL=0/5T)4D7H^1E*(W+17#]VLRDRSM6^&_BNJ.;)94M7R8.U>S)KC!^BJ=!>
MR]WOM31/L7P+ZA367:6H?Q[\!-5/([3_&Y@3&P>X_*K&8Z.C7)(^E7,Q!M1[
MR&W<Q`/(X$,/,!=E@;>P%P*E,LE2\&8)YL7^IJ;"4,[#".>5^$"6UH3P'FTI
M%MXN-0$\#:P3Z`$:\1.\3VZQ^$14OT+3B:!'@<4&-9Z:K`WF'QG-ZZ"YNN.]
MTXEBP.8I&K<FH]8"=JV5"-GTC:KFRS=B]7<S!&\PST-'.3*7>`T%!6Z0><;,
M:>N6:^T%(S?QJ5M0@X4&!9G2K[251L,O4/_Z$Q_-,/`.,>I'GB8^*@PKDM'R
M($^Y@43?1$TFR![XP?)G-T[U?7T6@/DP`G]KK+U?M'U@'W*V+U)384=2]PK)
M[(T+AM&<9J`#R$3#]E0&)$7P*9@Z^&S0ZQ=VK/06"R'3XCF3OI<;P[K'KL"<
MBK/^J0=#&$8"'TSH`S9E%9K?JHG,@M1!8_4<\79`Q<%3VHU^/G6MZH!S"GV*
M?Y7.&"I'FOF\HCV%C[H-`YY!4BR\;%GTPBFL0_LI$LA8P].F@$1"(ZGH_-,0
ME2"Y/.Y]RT@]@5-*L?ZCD%.,UN`/9N">DH=46<+,&`5`3NU1,QUDJ`6`?(S&
M#FB7LGK5:D_S]*J9-7@M[J-'W,4YYE@8I^>9[1&1`J((DE['I!<IC>ZQ"M#W
MJJT)3@48-B;+-B;\4[C*=:,8`W$!^%VHLO#W`#SX@I_<8Y`GI'TDPABG])2E
M#7Q8$?)A2_'44M1#ANFFO**%V.-8FA!B@T>SZ"$!)!,W]L>(@7'TT+;]],L1
MYOFNDD0%<86_36N''?GFP&PZT%IEH<QTE`+F!ZND=TXAW;FF'GMC&:#[#=I`
M*=+#*+7P_LGUV07)&HQ!IR5H"O*]`FQVBQ?+??3V`*K>$9_UJV&9^LG-0K`4
M3&FLB,<GAC00N9/KRR$=T#0-]+8\[`%3$>->O>&<9XVA04>:H<&`G`PN+XOA
M+Z]'K<,C#,VN$3=GRP9`E(Z5"AW2&\;^.;30=R&@6]]@H4T3L`&MPROU%0.U
MZL=\V9N"1BM7_W/I$0!1'V?&YTVT!E]*,D:*7!FXF>[5:"SK!XS@BAL9!Y%(
M_"E^B!*%#]%_355Z#]Z$>`."-YWI:$66:!M?/&[UBE#@_J`Z0%[OH@/DY87-
MUXT'G2J'W#^><LBYOMS4G;EGM$_N$B(8OG;"MW`UCAV_#7>*U[092Y*]3"TR
M:RW*[O+4]BFN:R59'I14KQA`?ZG]IO<NE4#'L<="Q$+$0K0]XVJU^=PN<3MP
M8*TCO!OY9XP,1L9N<^&K&XW#J>_VRU>\*H,!3KH6$.JK8YNTGS;#V4+X+B?Z
M>N<YS:/>Y<&K#`;Q@8/XO/<=>7H=`?&S[-XS\O$/T^[=^LF?IQ-,L?/IDGV2
MBEBF;;W5V/+MG>C=*XU!;]1AI?$7-GC6$+U[[`X[;?"68I?W=\]AY1\1WG'!
M&UILV2PE>@^6K7]VJ-J!L7NXV"W:B@T/%;V\AWL.*]_Z#SY0Y(FYKX*-U>=F
M'=%E'4'/.UC?EY'+R.TF<FN6+7_!)</6R1&B?`O,<?;#C#(7=:9Q-5.HS,/1
MQ0(HK2-9R.O(X`F!3O^1<>"K.,^1*;*!%C*;'<RNT6D]E%^#GY4#E6F0;B"3
MQ*1D1H)*--U'@:?BY/]@%B1E!V%*'!:H,+G,]8$X9VREJY,5%5LJ!1@6TK2>
MEMVJI98U)0$U5<[(LQ[72#!+U706Q3*>%^M<R0*;!/IDN7R>*S7=E9(7E:)"
MU1)?E?H7C8EC-T7"T$TU8>AGDR[VF=+%6M.>:KF?,H"%I5\7J:SU%%0J@W7E
M#,ZOE^12P8S-@W""?B7]-RT&G,61JY27+!:Z,8G[JHVB2O6T227S#1Q?&C6)
M`#V4PZJKX.A/,!T-ETFB[DA2JNL1N3X]=LT,0ASMK'^^NL+@LE=_^^NW5]_"
MVEUY&3!3[NN3C-/YE[)@3U*6!]MDT:[F/]?4&A9LD.AE2RFO"RSEI=/BB)NB
MRLZ=:^+OXK0U^CEGZ(P86BDH5:FQ4'USK-)'I6JID;4:2*8J"&D@8TL=`:/+
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MFJ[6E>-CHEKVYQN:21XQF*KI6,5%/=&?(ZQ`"B_>%M,[&5Q42.\WD4Z'!R7M
MB<&VR,+8!#AT1-*/A9?E+0W&-)09?V4)03\T9:=/J#25H'JM5"NJK`N]DA\3
M0`B6@BSK&E>/'1;+5R[,BE9$G`R+BN(S.<^+0E*!O>JC&EJS876HM0OS810>
M^Q4D^G@$OQ:-0<PH(M(3OT>ZK%[!`A.:,3Q:DR'<`&83*OY6/:@P4[:RLHLJ
MN"X+E7IQ)\-^+OVQ9GNBA5J?\:!F>;S',GXUY6+JJN&)1T7=M967>ZH"J6X<
M%7HU0V)Y9.!T$"!MRG_0M3&727<ILL5#MB&RW_JJ;)ORC/.2ZC$+GL[X5'PX
M>1-Z-W3J?*="%U9D@R<MZ\G/2GPW2,PN#U(N>Z+"+K*K-8;M5Y/L@*T[4,JF
MZ"/HF]^PQ*4=//T&5;P#J.KGK6S'%1`?3?L4`FT@QQ$P.8KG`BM!*G-B+T48
MA:<N'J@'I!BC8BWH&:B\?\;RPKI]Q@<9SP-X7'X8I/N1T"64HGO6R,G'?>Y`
MM[*BVV4(_SCB?1)+%32,1[.'X8:Z8&EM2/CX/Z3[)W:1PDYBOP,W_Q,,B9HW
M$--(3<-X.+/>.@NY]B6U6SSD,TYA3AA8*<T.F9_0Z[L)<C:+HZ_^%-0]3!NK
MSUX67O[(&9J"U,_<9U3W!7OV+@]#D=V"XT&MGI#';\%W"*(9'>5^@'6+80?3
M=`7#"L;;K.W>A^*=&L<97D%ZND%>Z)\55Y?`JRS!M%B"LK-3O:^61!F"-0T%
M>*4SQ$@A5-+]=^8G?GZO[4L&ZO`NEI.6^T=%HY%RB#K14_DGS)N$-)CG)=:3
M_"K0$S*P;=>"`K@LJM`/KHRT.W2G2>F^A;KE6.Z'-A'Y3G<H*0;W,E6YQE7R
M1M]K`C4SRHMQ/]4GZ&/C[W5OTW(,W7,"J_A7MNP3\#'AB5B$!!444ENKQ#UD
M7;0!7?2;N@,F@^(!V+-']9R[N'Z27_&)BLA;0-R<:FX"W'UJM6:NUU"'!=1.
MY04;#,^-,_B22E:'RS!^I'1]<E1D\-.R407X![0=*R\NUDC1S@\^`'9I=`<)
M`U#Z!D^L]+8UQ/9E,HE"\'1`V41)XI/+$Y>M(FH-3)L$O%XJ?W4`T+1A>43%
M0$T'YZ9V?,Y"(O*1>B>9EB&Y@A8^/(,Z>[7N^LLN8S`;/^^<!*H_"_0%RO)^
MTR'HDB7W^7?BU%2Z@9C6J^)-I1N(%1SNBG(A6:^Z+$U-HRK.?T-;$(D=/1XP
M;`54N<4U7KI+6-SUS7<PU"BC:#I>:7%LKA9[18]BW.&)28;=`\MVQ:T7H9>2
M7?:)K/0;(8F?4@^EH/2L*NVG9M1&)V]F4^GU5FO2MR9)3>U[8/(``E@VH4\Z
M"H>K2<?D*1!Y7ZS6GD9%TRJZV8C=(^)JURIG14ND96VPFI^8]]A:WAQ)NUZM
M79C:'KY2M3_I0N137Z3"E-`R%WVB<N<R3R292D\5:[\<0R4R*?%!4-BAL9\1
M-3`R85D*VS;U>6HZY'E&>+8,NCXO>EJTIO[-=V&C#U\MA=LKOHZJB+36)N^W
M'\9-]JN>*%A7;IKW;'2Z<X)C-EM/0X0452H=W;RIM.>#(HD5I9OE7"\1Z^2-
M94V3,]SV%?E)>$`=T3N@E8+<.6[2K6_"$!-G;M4LBLG1>Q?%4S'HG_Y7H1OR
MW:$ROF>IC)8ZH6\7[5Q]TD4C6Z_2(1=]ZH:YEADTZJNK9M6<MM]\\#NQ!9+)
MT:HTV2LNR9=\F>@&Q*@PH\?F=E1X.*7U7^4,GBBD7S:2ISUH=/`KLWIJY^D;
MH&&R."R3C2K-),O#.#0KL%?0-_O-D5<M*(!;&Z*G0H5LZ*2UEL_=8=&JZXKG
MA*?P'@3LTA*T\I'&SI,@U(T,I>?+,&_<3")A8)7J^R"X4B9PC'<L]#&K5Q[9
M-N^9<D70)^%J-?1/Z,J[G-8$28N%F4JE>_:##[Q[#Y1$LWM4!C<.1MLEO"1W
M`QP$+\XTZK#.A5/&K6&/FN:^[`.X:5%&ET6F!#"*U<>.2;3!>4Y!4$)8(P==
M#_)M'#'&?:Y.G`DRQ#;]"D/B479W7Y&*59=U#`^03PO7<51,MX>\@L2TB`6"
M'"9TA&!VKK59YQ/N"<"+#LX]54]YDJX.`A@B@*U:_M43O@9:#^E`9='I#-A%
M7TP5S+\GRF`DZHG"-UR(3#9U"5_,&38$Z7VV5OBYLO#*W-4G^,44PRNZ145O
MQ33!^B,7>A7J9KK^=(SA%!.$;'XVHF>&:SZ3J=YX)&G2V*<P(7[E7GV#-[AN
MG&-C%X.61XYKBY4#H"6<W-:M-IM1A\`S;,8>4,YJ6(^)%SW:FXG!9N\44XXQ
MV.+_+]&],#2%<.BZQ@(!&.,&+3JO;P20R;HI=C&X:5M)K>7S"Q>-]-13FDV@
MN[#2L/>-,!0=AJ"2X@35\2+4Q:M"\LY^;&:A69^2AQ((#?UI-L4GH]>23PEA
MK6_8B5<Y+E?TT-ZBE[I&>NXS=R#%SN5&S>YE$(6%E\-70VAG<MT3.6OX-&]M
MY^FC,7^E,`\NFJXP+#I."WY2SGD'[*G;<\2K2KV!_+-*@0&0]AD8DTQJ6V(*
M7C04X/`R%[8^T6/EC`]F#BX'7J<(T=<`"P$;'(SVWZNI[U)>K;;M)MSEZ5ZD
M!39@/-@2D8^NS&EBZC^@%=)!:]![VL;*XDFHJ,L@A@N<IH%@>7TW;X_Z/JQM
M<XKAC(<(7_;AUV1>)TII=>6<7??SQK&UV3^MZ&""4)Z"[2"N@]',95A^C>(,
MZYI940TPX5U?UY_I^)PYRBB6(%?3U-A=5>@<#/,[#V7!$[S776[:Y*J.P-/(
M4P%M<:/<KA3V+*:M*GY(&]P`38SR-&*?L*A2-26_"QE1.`_``T\!FM!Q`*OG
M4YA3Q[2(;84Q:_+@\\>;Q^HP)W`>(T]T9;$87R;5L<U&?&G_88JD&0Z8G5\^
MR?KJ*.HEH7/`\Z_KZ8(^@?^B22Y^F@]M3'-.`1[09/$:Y\`EJ'$,Q^Q$B[`P
M/).X0&N6:'-=177NHN=.*GD8TKWW89>"NX/\5GWI!8E/A="5[DGANY2GXV\6
M3\>'ER64C+-%$HH-H[33U$Y[;9)/)J'=#:-^\(VJ0X;5".((=5:2.W:U8BQE
M%^S=V:5&WZ/=ARC<C%]QF_F>6DNS@T$.!FI&XHK0;&'?8K5O\=%-HS&@?WCM
M-$1C'O6)@:ECA<;%3W4D]%'2-E&+LRN3>QWV2!KNW@QZY\6&JA2U_PM[`Y@9
M*A;0E[&<*;`^KL`C@0B4X5Q\BJ-_8>4>>!8\&K83'FXL$NWEZ.<DYIAO=/4V
MMUKOT0T**5BJE?L-*%VG$H)=I*U?T%8))?Z[)*[(0JEO5%&1@%H$=1E4\G>\
MQ2"RN7/8K[!@Q3!/72U5M".*]$A/AVG>>;_'8\D'2@IH6%M]NQ^W^NTLR0-G
MKKYL97[2.A]\//DL-!M0V!E>!ETOT-8>8XLH<*")KXV<GV>-L6I,/IW5FKM9
MA(WB;=*JM5P`@/H[\'<_9S-PJ'0QJ?(8*]GR>92-=6>7:N1^3U0Y)9!]`OD'
M@HHQ..UO;U=1?T,X_0F?K8FE?]'WE+3_27J7]B\8URN:MM#?B&"1RJ]U`5S[
MMO.F4G$JY\!K2LX_<,7^]M>OXSCP?\+_PAO_'U!+`P04````"``I<2T_)=RW
M;\,&``!#5P``%0`<`&-S8G(M,C`Q,3`W,S%?8V%L+GAM;%54"0`#3IQO3DZ<
M;TYU>`L``00E#@``!#D!``#M7&UOVS80_CY@_\%P/SN*VV%K@F:%ZR2%@30Q
MG'3;MX*6SC91BE1)R2_[]2-E*8DMB:)?)E%)/R5Q[LB[YSD>CR?*'SXN?=*:
M`Q>8T8MV]^2TW0+J,@_3Z47[Z\-UYWW[XY^__O*!8/I]C`2TI#P5%^U9&`;G
MCK-8+$Z68TY.&)\Z;T]/WSFI8'LM>;X4>$-Z\2Z5[3K_?+FY=V?@HPZF(D34
M?=)2P^3I=<_.SISXOU)4X',1Z]\P%X6Q!Z5VM0HEU%^=5*RC/NITWW;>=4^6
MPFLK##@C,())*Y[^/%P%<-$6V`^(,CO^;,9A<M%VQ9A+_6[W](^U]IO[$(7@
M`PWO)M>82D<Q(D,FL+*Y3Y`0>(+!:[?4#%]'@T<WW!GR`RDCF.2$L.GJQ&6^
MHZ0<PR$=9;B+B!N1&*$;:>:&`[`,@7IJ\O6G:O`CSA_'#G,WIB2*+<8W04MF
MC"F9(#&.>8E$9XI0X"@P'2"A2#^)X>V<=A-ZWB0??^L)`:%(1R9H#"2>[]N6
M@%.+7?V(<XE8J7FIW#9Y/;YI,.)N.I;\=8.Y;'@G$HZ(?#\>K8,E@:G^A#,_
M%ZET0J8SM,6X!_RB_5:FCTA(*UB@9D"DW5H`GLY"F5HJQWS(60`\7`T)HF&/
M>E<_(ARHB+T%'05:-8L9T;N;$/2;301]9LQ;8$(T9#R*6`S\DQL)R+^7@NQL
M9>37E:1O,!IC(HT`@XR8(UQY\G9=%M%0#-$*C0D89/%\A5ICN!CT3&HO<-?&
M'"]MY1%X.T54L4YS""IRVL8T?PD3D.9Y(Y@#C0R63X%"0]@I<O?GYK#KYF"V
M*U0>ST?9OBR(XZ(`UN05JW+_)7`\ES[/X9G%MS+.#1*,7M-VADH]-]X&7G>N
MN0^9^WW&B`1+J.-2N-($38YP]2?:9&^);?D+D0@T!N=)UQK9Q7!GS[(YCMJ8
M@_K,]QDUHB,CVA`NLB[:6&0^<$`BXBLC*G*$&T)&GIOEA66GAH.9Y^&U&4.$
MO0'MHP"'2-?J*=)H"#.%#B?TO+=IM8P@1)B"=X4XQ70JY(DR\A6^X,GC"W:Q
MKGHR4&X(9R8P)/1U3VWB[YFA=^$,N,S1`8<94"%KPH&LOGRX84+<@JRW'M!2
MWPS9::2&,+LS0"G-Y=7%ZRZ9GQTX>M3;J8`N5:WQ(+]+J\&"@Z$6>LUYWLXB
M>@0>@*]ZS>H,RV@H89&33`<T!`XB7+NWKD/[B/.5_%_/5SUJ[2ZU]Z"-9/D0
M$&TLZ(]R-F\:B7F2!_6-CW)E9;U?]H@,)!IWG?:]J)(=J(KK*=E9JPYE1$`D
MCP/N@<^Q"T)_!Z%(PWP19@E5GWP;RL!2P8/_E851`MH](Y'"/F\3-%"JMR+4
M0YNN+Q/?C[LS%N#_P!$5:YP0,2:@1*LQ#)1Y;W/;NO8L<A<`EQ/3Z=4RD.<8
M;<V:E3TX<OM,2!3VRA\FJK7&<"&T&]%KA$`E661MR7ZYQ$BW,6P<+:-4>MP1
M(#&9R<KP4N9-PN);>HFSVA.-3L]NR@Q]-ZYUJZS>(#Y'28N_(/X=GGFI*^"*
ME9I!E,YK&SO:GX%*SXBTM^?YF&(1\GB7+J>J3+,9?)7Z;]['?HW%U2VC+(5Z
M;4QYX!3K5![\"%/5SKZC3S=#!E2&0*3@5>7XD$.H?0Y@/$2MRZ&4ILRR,$;&
MQL9H_.@BZ[.N\"_0:!9KA7[_/"#J<AB$3T^V='EK0Z[RF-[DM,36/.EZ8SD/
MY$S\YOEH8X+Y'[8]JXG1^'M0:CE*F[V/Q.R:L(484`]S<,-]V^S9@:IHLV=G
MK3[_*1N&G,VQ=.73ZJL`;T`?%V//E5FY[&GO#H-4OECWS^\U+LH=*<FLV$VG
M;4RB]S/$X1.2GJE;)C*;Q,CHF@/Y"@UGJ@@&&UMPEQ#(#(7+B-H0:S@]FR[;
MV&B3ZUS=;H5+6/\<T*TW$35,E>LVG#X#<&QLR^6:O?7RXJZT;JN_1&8S$%EY
M#35K^M;+CSM1NZW[XGC-@&-^Z?20IX590X8<`H2]U)ZTM]RCZ\NRA5^B<M!P
M#:7S,`A3AC75STXO9Y10?,>?+/S,$0U'X`*>%VR>QJHO@3HM-"E-QWJ'QG@E
M)INX.4TZU9=`DQ::E"9-B5/#JTZOY^G+P7OB'H]CRJFNH==O:Z]K0.<@#NUU
MY0U2^9O.:!5'Q`/KN3\B"7'AMUMI_-MA$!O7E8;,S/O2.\!5WD+[N;`R7"1O
M8!VVL/(&J>%+\5P`3US+*/P;<54(72V!NUA_H52K9N/BT1"6\\5Y&DAL[#BG
MR_V:\1$$$9=K2Q:XDV=OZAMD18URTPDU@*>\*ZW+@H_?)BO_^`]02P,$%```
M``@`*7$M/[Z*WPGO#0``D<P``!4`'`!C<V)R+3(P,3$P-S,Q7V1E9BYX;6Q5
M5`D``TZ<;TY.G&].=7@+``$$)0X```0Y`0``[5UM<^(X$OY^5?<?4IG/&0*S
ML_-2F]MB\C)%W6R@DLSMW2>78@O0C9%8R29PO_Y:-B9@;%DV`HDI/DTF4<O/
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M>XGYC>RMM0,:^!E3^6)<!'B(XC`RB&V[;T-(V001NA^@:=<[X4RZN)C@R3/F
M)D%N]+L+PC&`X7[\C"]6Q`WB+.I]%[2415VC0V;988(I`U35N2^>.?30;E]^
M2)W%FQOFQT`OZM+@ED8D6O3HD/%)XJ+.S_+L_#&:3.$O@H'C#=EH\=9GDU;"
M3]G1CB`?(Q1AV7E_>$<H.%^"P@$31/9]'2(AR)#@H!9<S2YW!'[-:`#O#@ZN
M)8B0!/#0X`L*Y?SQ.,8X$@/$`<081\1'82T&=?LV9X,>8)G@;AAA3L&^,]Q4
M\]L=F0/9!^+\FDVF'(_E\)WA]&E-L9;V9P[R-1+CNY"]B!X-",=^U!3K=D<)
M2)B^"$W>\&^`:`,KGD<87J<@0RM[W'G4)\$8\S<>%,KPA_%"GY?XNR$2SXG3
MB\7%"*%I2VJKA<-(9+])]'=QV5[&.V^6O_96"@!VN`<_BNPI(7K&8?)LK[RQ
M=YEJR0;B)_3\^J:HT"8-O7;>GEV^B1DFG:RWY?Q3*Z`;<C;14%?V2%8!]HSQ
M`/.K<Y"(!2!A4XE9NKMT3OOL,QK!&W@;)F(P<O!(_O#Z]Y"!G[LZCWB,[1GI
MT<<4<<*Z<Z+U9JVW]SK[,)DB`E*8<&66"O/E\)=:\>`&6>+Z3L44^\D\?;,1
M2A<9I4S&>[</PY0%^0JKY+5=8AP%CY_50-[-^K)K;X;:7#?NTU(K0H8M)K#_
M=L1FK0"3U%CP0]Y&\"LOG:D?\(B(B",:W:-)T>13UM3[92^6*%IO-IN(%,`S
MC;>MJ/P:<',40E2&Y__$"Z7.<VV]]T>C]&WDF=8[!];Z=<SE"NB."%@`_0<C
M?DN#&Z!2HOBRYMZO1Z![!?A,_>^LO/1W)(2%$R`9,:Y^Y3=:>A^.0.G%N#-]
M_W)@?3]Q))/ACXO),PM+-+W1QOMX!#K.(\ZT^]Z."V>3":./$?-_/(X1QZ(?
M1W(_0$)4^W.%H/?I".R@12,SSJ\'-DZ6AWB";DO,L-[$:U\>@<;SB#/E?CBP
M<KL`(I!`[D)4]I)OM/':>\E0&%;O%N1,OQ\MO;P##.N%0!VC%+;UVGM)+^SI
M==Z"GNG]DR6]IS%3"NL.?E>4W5&V]]K[R2+L1_^%\%\71E:-(`-7?1.L6GOM
M8UB3*L"OU%^R,&UMYN[WE,W7W!0[Y?5/>?WCS^MWA<"1Z#[+_)`?*8RTV7`_
MF7R#GJ84MNG<5W/5R_W)+@WD/[=_Q62&0J`DNM$UXGP!"XE_H3!6#1LM^3UE
M]O4,M:W\8B/I,G$FM]_U?18#Q`?L8X`+CN`>1\O<DVH,*<2LYI-U#55!P)VQ
M]55FN]=@5MNF1,)JQEG7+.783>><FUND1V<`B?$%O#$*,ZPWLYIQUM5]#K#I
M+'-SA0\XGB(2W,ZG\GP4N-?D[$Y*JWHX:$A;S4WKFD>/A^E<]:[QF,94LL'`
M9@9;>^[((3:=P=YEI+`IYM%B$*+T#!?$(%,97ZI=E4K,:BY;?VPH"9C.8N\P
MFS,6O)"P:#<GW\1N3EM[PEY#:SJ?O:OOJ70Z=O/:]=S-/A+:S17\C:!G$H+&
ML(#AEFP?C5D(X(0<>M%"8QFNVX7[R?`FC-P)9[.5T``M]-87Q0)V<^:U5*]>
M$6[3<FFQSF,<K)'5LE:QC-T<NQF#E3-S9P%_@X<88`4/&)97L<;X*A;PVC;7
M[P;,54[+'5]8:V05O7@VU_D&;%1,R9U,P`WF9);<+%I#>L^HKS&HE))>VV8*
MP,CHJN3G3FI@#:+>^/+:-O,"9@>6Y.).QD">_R+1)-FEH/+J843H"%-?;1J%
ME->VF3`P8*H*;N[D$AYP@/$DV;J06_\T`D7!0T8]&F&.190R3@_X9?M/W8F,
M<166;=ZIU[&9KS!@^-VHNY/\:+0:5VBL8S-)8L"N:FKNY%0&?!DA)X"K]LP+
M6GL=NYD2I9I+-S6*6#BSXEX['EUYB"'7U.O8/438P!I%%-Q92#]QC$3,%UK6
MV&[L=>R>*6Q@CV(2[BR7NT%`TD</$`EZ,"M.2814FQLE$E['[G6X!K91,'%G
MO?R`(U``#FX1IQ"MB*[OQY,XE)5%;D#3/E&'@E7"7L?N3;H&9M,CY<Y2>0U?
M6<62;TR(>QSUAT]HKDX$U^G)Z]B]L-=D2-9GZ,Y"?)MQK6C=Z]B]^]?`7,4D
MW%E?5RT]=MC;]#I'GB31(5AQ#>@P5R#J5M4ZW87017RZ"^'N78A3C:-3C:/:
MD\>IQM&IQM'!:QSMD`["DRGCB"_2B`.F\3Y/^`9)IF2`>5+00)4CTNO!^?I(
M]?DXE-3;Q*Q3@T-7U/D22S6(N)/SV\S8-QAU>ATX7Z.I-AUWLH*;D-/7K1M'
M8\;)_UY76)6FRPLZ7^%)FX8[Z;\BJ#TAXMIF2H6<+Q"E1<&=I%T13+W)JT+2
M^0I2^CS<2>BM;6\VF+<TI-TO0U63C#N'6K;JE&E-6`HI]VM::9)PYP#+%M#*
MF:I$XGBN_"@(F*Z"9=`N>E.4LC2@\Q6R=%D8+Y1EZ(!+"E;WA$O:VOVR617@
MG2N;M?U%D],&T6F#Z/@WB/I3S%&4'&[.CD5H'!)62!U-&2TU!Q.)T>UO`LG?
M>!!7"]F3C-OZ2Y_SR,)8]E\TJ*N%K%;$JM#CIO*UN!C862A1_1-'5(0H[4Y;
M]VHIJ[L"]95?2<:=+8%'%&*QO"7ZB/F,^%BHZY>42%C=`*AEHFHB[FP`K(@M
M*Q'5FCCR,E;3_(U,I*)B(L5?XL*NF8!PM-$<HB%J-76OU&B!*]/CL[_9)'U^
MLSE%1]9JDKZ9,2H)N3.[/&"!02>R2N<-.-J0)76BEFP5+DPI9S5=7\-DNF3<
MF6T><7('$X#^@?@/O$93%0^4"MG-T#>PE)J*.WO*7S$%;B'@[`83T*SD)?,E
MU<:JD+2;IV]@,0T^[NPO;_&K$\393=,W,$TA`W=VDPOBT7K)&+M9^=W"Z4T6
M[HR0>T;9)L:L`FOULJ=2]G@2]EI43(0-)4%W4A@Z^^)W<6R]UL1NL2P]714$
MTSD&SARU_0JLY<CLT]<R0ST*7)+/G\@,Q8#C2'G[4+<+NR6TFEBN"4-WED/)
M1<EMVJIYIUC";@6M70RG(.3..JB48)/IQVXYK5ULI:3DSFKH-9BY`_II#:D8
M("^C'4;%%SQD?'DI^0G-L;B=`W<@0"CBBV0R+JY"I+#W'I]JMZK7+F_,GI7B
M3J"Z(K#4S1=8APZ5!1Y*).P6\MK=UH6$W%GE02"@M;[;:&>W"-=.'CM/PYWS
MP%D-D.S$ZQ<DB"]3HB2,(^6YQ0I)NX6X=K&6!C$39X)+%GE_8C(:PV.Z,\Q'
M:(3O8\FT/TP/B%6;IWXG=HMT-5XHUN98<4CXX.?JRNJSG([7G8[7_03'ZQK.
M\<>2"\RA=BR;4>!6[B#`)R.:UC3W%\EV-;A7J6(:K&U>=X/_QB):?C@H*1*5
M?E89>I$'EO$-3O^M2H\<`(+5PW^U#EP>3B'NI&L*^&J4:%-('4T1`C6'BA3-
MP>,0^:'6NY"]B!X-",=^=`I`3@'(SQ&`R%=[P-F,P`CYLO@.6'ITM=O:!4<[
M2\NW:6QCUN[LF$*9^M3<B7>:Q9E6E[R-%*X3ASI43.HU9!%/[`&#I_!)\H'I
M5[A/S-SXW,?CK,8;)E^2/2G''1^0Y>EDB<N)S!XE4;-J7BX4L/MY\#T9J62N
M+U.`,P[D!D,,[9,J2ZXWL_N)\8/:+T?;G:%XR',R5C]9?E!SUU").PF`?'9B
MC?MZ[>3JR;U>1W:_GW[0UZ*V8O9X.VL;R_)KLJ`%#*]L\4)95]3J[9+Z:B[8
MK](CN;\K6]GS^_P507+84M\^"E&[ETJ,&JB"Y1ZOQV_3`*\^123(OAN[.N9/
MTZ\[E'[C?9?N+'\1_B`.=%?].'7DJ=BM9!_QKC6OYF3MWFZQ/9<6*,.=(U2%
M<'/?`J]K^IRXW:LT#EB_0!_NG-S:1IS[NG@MZ^=D[5[*L6WZ`F6X4P52/S%H
M9#O#\C4BLZGR&IS=64:7X.[1&1:F]K$4G=F]C61@(ZN"FSN&ACACZ?.Z_E\Q
MX1B8P,L9+08AK$(@")6U\:?+#=8R`^MW8OFV4C-C%5N^'FEG4MSZ.C`RHBU?
M>3)I\'JDW<F.E^"^(Q1!C&/&ERLZLWN%R8`OK^#FSNVWS"/=,?Z`IS'WQS*S
M-%RKQ*OAP\N%+=]/:F8<M>]6DW7&9P-I'^,@N4GW)^(R/W@[Q]PGZL(A*C'+
M%YN,&K."YC%Z8B,>V/)U*),VKD?:G?#Z=CC$?M0?WL[!Q=`1?H#9J$\E%0@0
MY3\R2)RA4#HCA<WK=&/W:E6=^;8N*W<2X,48:]]9J-.-USF:D^@U6;F3WRY&
MW@77P_D"O$SRG9;:]LS)>YUC^3Z>-IV*!'7![8*6?.`SO`#PG_\#4$L#!!0`
M```(`"EQ+3\XY/":1R$``)CM`0`5`!P`8W-B<BTR,#$Q,#<S,5]L86(N>&UL
M550)``-.G&].3IQO3G5X"P`!!"4.```$.0$``.U=ZV\DMY'_?L#]#\1>@.P"
MHY7DA>VL$SN8U<.GRUJCD^3+!49@M'HXH[[T=$_8/5HI?_WQT>\''_TH4KG[
ML-C1#(M=Q?Y5L8HL%O_PQ^==B)XP28(X^O[-Z?N3-PA'?KP.HNWW;WZ^OSSZ
MW9L__O"O__*',(C^]N`E&-'V4?+]F\<TW7]W?/SERY?WSP\D?!^3[?%7)R<?
MCO.&;T3+[YZ3H-;ZRX>\[>GQ?__T^<Y_Q#OO*(B2U(O\DHIUTT5W^O'CQV/^
M*VV:!-\EG/YS['LIET#)%^IMP?XZRIL=L:^.3K\Z^G#Z_CE9OV%C0.(0W^(-
MXH__+GW9X^_?),%N'S*V^7>/!&^Z>0@).6;TQQ'>>BE>L_Y_=T0?(?K_M^SK
M-X@U^OGVJNB%]W!(C@_)T=;S]J*3T'O`8=[5F^,?T`S<?632GWY3Y>XS>VR;
MQ>90?JSU)8@HCQ`<WF`2Q.N+:!BK#6I0GN]2CZ0CN*[0`_%]'Z=>.(CC"B40
MK]=XV-@6=%!C2BTQ'C:F)>6$O*9M/HT'LAQ!-H^PSY_I\VN<X><41VMF_L2W
MC%)BRX4-9',`GYIBO]99R":#F-3E]),'0F4Y/3WY-K.X[)M?SV/_L,-1NHRH
MVJ=!^G(5;6*RXY/)\B%)B>>G>4><==[]K_JTQS_D0M=X)#B)#\3'1@*+<:\S
MXST8,,,F5TK)IG8<'?U\]^:'G`QYT1H)0E2A1+_DM'_]@WC^=.)0I^,A+L#N
MB%1+4L>21_R<-_I1(5;6XMB/J2>S3X]J+VQ#XITI>')68M,A.=;6BZJ7L?&2
M!RY-[FLP?3G&85IX'UR#CDY.<Z\E^_I7.OFDF'%U[SV4%J:B,#T-`;2CE\4F
M:(H&Z!?>!!SQTW$*@6+YJ\\A*WWO%O!)9QY\13\F.A@M&]O`:955"0)8,\3;
MV0?L>):M(+<%BE[T-A%ABN`$^^^W\=/Q&@<"O/1#$[/TJU^%9;_%VX`9]"B]
M]G9=5K6W*0!>)6PV7WTV`Y?M$&L(C=;)&8;`J@H,.5(52)@7IV=4,X@77E$/
M_OE/^$4*U&9;4*2V&>UY\UE#Q%LBVM0>6*?C&1:O/:!H`[8;$7,A]NQ`"'W@
M99#X7O@7[)&+:'U.K7L/:'N;`^%6PFX3!EE3)-HBUIC&/FO$FMN`[TRL0Z%8
M!90JD!4HF=?Z7@8A)F?T:=N8R&UOO26HY6TRV6/#>#.4M[-G="=A%];>=L*@
M;6V[,#`7/N^)Q_:1[EYV#W%KO#/FZVV`,-EDK/EZL]^1:&`#AN,XA$)>YPNN
M8J[K[<[LB\:[71S=I;'_M[M'C[Z=U2%E6XN,#;EC*B.$]5+E(O2Y?YP*<;(%
M$H2H0FG1@P61!]B[U8!9AZNKQMA<VI$O&]_3;GOTH-8$"/$-MGH7\MGO-A`\
MAC\H1':]VBKV.M[K7"A;TN>LV;,N0Z_/W-;;`.&LR5CS11:_(];`!M+&<0B%
MM<X77`5;U]N=VZ85:1N20+Z[+;"5:S+::TY$0ZOA^]0\0UO#3E!TF<4N1,R-
M6+%2()Y\2;_KVHZ2MP=&;A?#O4C(EG$R0/#F-A$\->_02.X%2Q>:^Y`"@VBV
M]J6/Y[*U%317F57A@2]).H+D:?BV@^(60/HQW$2'A6R!U>8RB+S(#ZA&Q4F@
M2`HS(K>142`7IW_#?K5!!2'**2VFADTF6&PHF)7L!`T0]N8KJ!$(IU7+),%I
MHJ$_C8:`FM)BL16$\08.0%_-Z=W=Q?V=30!WO^\F5#M?-APHS[SD<1FMV7\7
M?S\$3UY(M299IF<>(2]!M/TO+SS(\AGUZ`$AK"M0:PN6$O!T6?ZA0KI`RQ3E
MU(B3VP+]:-E\]@&7I),+DE:.1+QB,?:M$REPPBS0`]X&4<301N=GP<I,$I;G
MA"#EP_3;7LD@+;21\6L:;A/+!^AD^'Y\H'S<8A]3GAY"?(W3+#U#YG+(R"`=
M$#G[K4D^:X[*]@M$*18HH['FG@R4@Q3M[9CFZ?D&];@TP-_RO]3(A]/>'UG:
M:H45M>+V40#J;#_33;B(EC5EM:RGAKP[@G,%3)H0EV,$#MTW!.^]8'WQO,=1
M@NG<N4H?,1$!D!KI.M2`J-<3IHFBC`IE9-Q!XH1(4%I7B'%B84&6<+EB+I>?
MI;9ZO`L[LQJP4)"FP$"GFF9!7Z&@U\@T_%5;:J\"C2-JK&*3%R!P0C>GX!1^
M54_E5%I5HAL2T]@Z?;FA`\F/2=/P=,]6PZEG*YU@)62@,ZN4_;:9%LT7B!.(
M(^\Y"8\&[<VE@P3A$N!2@F@&"32G36?Y-UB@FQQ."_2I6*#[Y(6L:I.]Y;D9
MI+O@Z;A]HL$Z-VI#UO9JE%8,,)Z/X_67(.PZ^]%J`AFQEVRUPMSL)VL!N076
MM(RA#<8,K)P&>T[9+2U^W;%$345N+;'4M1@Z8%)&2O`A4F]L9#<DZHTP[,=`
MAJS!!SWR:`<<^I\#[R$(@S3`"9WG^:&BQSA<8Y*P.3]]T<BTT>X"4'T,Q&K"
MI4):>';4'[>?K3-&IJOEIZO/5_=7%W<+=+;ZZ:>K^Y\NKN_OT/+ZG/Y]?7]U
M_>/%]1G_^?;B_.+BI^6GSQ>\Y>H:W=VOSO[$F_)/_[[Z?'YQ>_=;=/&?/U_=
M_P6]/;^XO#J[NG]G4[E,<=Q4/T,0P^]%WW@O>IM9/006]I];+/?N?&8M[:_X
M&7.^%RWM;C0/'^@%XK.C"_O-W0#OVVGN1#>H5I(#7E>LAI9B]M#`ZF8OXQVH
M86U1I;$+&FK,?U@VMJ:GDPRZ&]HJ!WZ'PDI1#Z>SYWB#Z9/7M_@)1P>-F;2'
M`%!;>UENG=C)&J*LI74]->><B)9V-'0R=B%U40[HIB)*T6PEX%1KH-VY4LM>
MNS0Y:C%<WPNV/C=.R[.ED%.A>DY,?B1X\M+@"5>8N::":LR"<DK0Z5`E1-M<
MYQ1UAZHDLC=!FLKR9X_P],D<_M-7MM.<*B=G'';2U%*$]NRIHP56IE&]^=/2
MQ"F?,1V8*'MG&Y=FQB%,6IH*->9`^/.9\6X7I#M^M"A:G\51&D1;'/ERY9%1
M09[%E#+?.C%6MA8',:OMK1VY'"6"+Q,!]*2;&D:M\VU*#,%IP2U>8[SCAW.H
MO)05*CM]R/8J2C%]^:G8Z!#5!?/S=\L=6VV5*,F(3@%U:)3H37R6G:%Z;RCO
M;I%M&BZR^I.+\NBSZ-66(LXU#KXHLYFP;;/?H]^<O#\Y.45[CZ`G=G[S]^CT
MJ\77'SXL/GSX4&IS&KZ@_2%-:QV(`IUQ6=`2>0D[YOH?!]KZP^D",6QSJ[#<
MDR!$'T[$5W9FZ/\SPPEI9<>;J:81'FVC((L&#4C`<"/EPB@AH=HXS[!8IBD)
M'@X"P?<QNO'X:H_]Q(O!DOV69W!3T=ZN\2;P@_3==W:+`9EF13B4!W%#LO5K
MSI.JHDI7:]ASC1W,=IR-RS83LOK4O.$"727)`4]?K4+_\*(1[XG@_3>G)]4I
MZNMO%B???IW/0-XA?8Q)\`^\_CV*XOS;@,LI3@2^DAE_BA?;LXL[6@"CXQQ3
MB.%0)O0T`KF3*BVQ=ATG4'M,'>P"2U:27EGKJMD4>"FEP6;7XD-Y88`3!EF?
MZ]P4M^.%KQ<G)R?L7]LB+U`0^>&!(Y]TQR`+].&;Q<=O3Q???/,M-\7L3VKA
MV9]M6TXCDX_42I^>?,C__-VWM6>;&_L%Y2S98Y^MOX>6]CW&@<<!HS]6`(?,
M_5A1W#'T?9:S:R&QPVS"F?A[@KWD0%ZTC'Q'8T`SW\EJ^^XCT:B&$%LFWHSC
MS"9[*372;+'QP^(K:I"9@:VO^UARI`U,TO`WY90Y&B.&W!0-E^&CD"'"6R_%
M$TLP+P`AS6^_56L:X%Z3!IATOE[SXLM>>.,%ZZOHS-L'U*>0V.$^"LB$\UZF
M6YG/14O$FJ*K"&6-K26;#^&=E0,Z"B+DS\2[7L:YBYP;3`S#41,4J'%JBIA&
M('?\5H4M:IT"D!HBR#WPU`LBO+[P",-%LO3]P^X0LBGR7"S12_>ZE<2@>]H:
MHK0W&041RJG0VPH=R@A;)SGA]J<'R%05(-MGL;4=["CW!H9W3E0Y99#G%=0=
M0ZUO\=K;YIKF#O389<X"K[-X%N_V!#_B*`F>\%5$HP_\.4Z2:YRN-O?>L\PS
M-NP)]HBFH9`RFR(*H];Z0*(3])9U\XX7K&*W\]"^+)[JG%#DK+QH3>20DEL[
M_/D:93-QUFT`-N:`=6I*L3H.[LPX`XUTQ\'A`1;:9JJ69+KI:&PU-4N1N"1/
MR7(G#ZMKD9*?BT@ZLK#LF'_7F#:PZ\:P^6TG;M(<-TX9Z^F%<\<"]YLF=8*?
M<Q7()%952>I0Q;$.='57&G/@3)RN`*TS:(N^#!(NGSM&V8ZL91JP(V?UI/IF
M6B'-P'#XR0/AYN#DV\P8L&]^S2SGW2/&J3"JCS@-?"^4Y,!K$@(8`FT1FLC*
M:!`G0K_4R/YJ,?T=7"`(+3`#6JX#1B@#S,G!NWU,//(B-)`RM2+\UMXUWZ"^
MP>2.;<3+$G4T>X#,WM$6JF6B<\KB^!TE1BN"!+G(N$"T`\1[L);L,UC`GB-B
MBS+7$[T-(K2.P]"C01SUA44FAM7YQA"DK;P+(X1:TSW.1+(J,UOUE:Y-:D_;
MNL10JYF@0A4R1W1+1YQ>I6IG*SND1KUX4^A/']AL'>0:,&=I=F#MN)>!06\=
M2'%RPII`O%<P3YGA4GX*QYE9JLZ64/YE<?1#6\E:A-:4JT,$I5)ETU-)Y(8B
M&8E2GY.\7E'L:4P?N.2:TH,LNQHBCHD8:D=&9%DS"M9UM<*EP\;:(M2U(9A'
MA`$'@D>]`P>J.ZN504>;:YI@5Y/U`C(5I66=EL<O?:!R(!H;(XQV$`:Y(SK+
MVW%J6W0F"=W9&]6T$CIVSF8473D/.B"$UJ&V<R[?(+JLG_!U,G(>)=@KB)D-
M4"@YT.Q,M%SAR2!4EE'942*-R+*N/,Y$R(.$<#$VUH"21".L1\4M7I0A<1^%
M30WH#<2ZT.]0F1<][MT)@J<9>`?B7P7LE1IK*?)M\:$7]DK);.JM/.#HQI`#
MX>XP.9P,=*=^)4[%N-,+YTYXJV,*E&;,9F!;J[,AV)&E4G2TME5IJ&!65?E%
M-'2BUI":YYIY<J96D.%8.V5^Q@GBCJF1:*JT>$Y-3>$,BS@RQI<9V'T,&G6U
M^R@`#4P_TTV\9$<#BZ8.U,V>A7E(A"L@TT2Y'"]P2%]14^2EO,!]?DI2`^TR
M*D#$RYEO`J=H73\:ZP#XA\J1W2MJM5"\!H":V%>C9\3!D!M,$E8[B"V%K6C_
M8;Q]N8O#`ZLHU.4=:A!!'0A1L=[:3:NT1SD!*BBLG`$9)4.<RY#,)L,Z]@_,
MX'JL^ZF$6&ZWA-=.S#42K0^$*6CZB)'P]1#3'/99)NU[:Z=<M+2F=L)%1V5&
MJ/$]\:(D]$0=,&T]5E!!*;*2^;8#7R%P195'2@&@S-(%YU<B@Y9!,A9#VR*E
M"GGMF20]"U"S25KJ#UCUPPMQDEVA?H?)4^!C5H)$XE?W44#6_^AENE7P@+5$
M6=,%RAOS4C/6RGYH<R_.:,=-7]I2X8^IV0:M("&'>:N,A!3C%B+?B^<]CA)L
M%/>V:&Q$O1V,]\>*>6.7PET-`<[B)+O:M<0\SLC<B'O[X-,;]?9@9X2SS`9I
MM1D4^>J00KG->F)T(825)'0Q&AXA4;Q118MV7-%A(HEIR^?*3+`H6I?&*@FK
M3BO!^YAP]1?NJSW'U$#;:MZIOJJ--@7#HF<M6EAC8!SXY-;`R8AZC$S4'JAB
M-9L&P3S0[K8(*AE=-@D#(E8#E8,L?)]@*OWC,EJ?4S\]C/<,!)G;(O&.Y72@
MY>[E`K3+.HCVW,^L4.1.L[T2]R/D6)<4MDK<S\,];$5T#55H%T-7ZP'@*A3F
M%YA39G[RR-]P)0*1+43U$T&N1<E8;RU'B<8</45SVQIL)@%?4&/\[_+&EI:C
M)N8:=#5*"??6@I0*ZW"Z^B..,/%"RLIRO0NB@"T0L'M,U0JKH@346K4030AE
M%.*^MQJ-;?T=)XM7H[&CRW-*`*G7FJK15&X]O;"XZFRRVFQUE5EK==F9)65%
MQ-F]H&Q'0^?AW>I:N/8:N`OYCCH:6&EM-[]1JH6UO$;KJBAEFGTM,A`R*(/G
MATS/K^6T2Z72M4`,IW;7<137V<@L@,:FJYH64"5U!&EBITI3Z&A&YD+Z\1"9
MQ(U#029,-@F]L[HCJXVQIH+H`@PP#O2"B.GI*CK')'CB'NM51)GAR_$L7>*&
MX%1Z:9UV%Y"1H;Y8K:"$DN8)^ZL(E?2HT@%//5H@T8FUD'&XD&>/]"_,;O'=
M>$%>R27>H"\>(5Z4%C=*6+H)XW5)9G:IO0W90,-G0XO2BJ/-S`F@0\\FHK8%
MESGU/120CGTOT]WS;(<'8<V]-V0]F(=;/==^$EY!W7HYFENNO13*#KCW0]QZ
M)]QY4S?>.=^]=Q$IMJZ6T_+L1(AA'%I8.M+.IO!+*M99'%&6#I2K5;&<\0EO
M8I+=EGKO/>/DXIE&/S%9!Y%'7JY2O$NN64).E-(A"[E`*:8@41^+G^>IX$?K
MYQJ\GA/N6;3#GHC*1Z+RF4@\-+=%_+$+5'LPXD]>H/JS4?YPNZ?]H<:3K]T]
MB+':D_@I2.@3$/TS7[](V0/LV,+7,!+P911F-5/=I1CFM%'05I[RF$TSGW"$
M-X':0K<IP*UK%],]EI$VS7<<T=NLM34/3)_[&R=MS[2<P]N*7K!WZWD?T@&#
M)9QJ;3[6VT$&10T&6X$03ALE5-RZ^UV'_Y#^9"GZ&<@=:)S3!=%6;-.!3S@M
MNO`(*]&6Y`7`/WE)X+.,VR`\I-+JPRI*0$U3"]%$1TY1UJM?($XE<M<%G2W%
M,Q<G!SNO49]?J<A(J\5-%VS&"0]K<=ZYYP;&AV(0UC,-@I9V.S4$#MX"H*FV
M35NCI[,CSLW]&0?;1]K3DD)]ZVWQ]6'W@,EJ(PH0JHW+@$Z@3M*9BM8$:$Z/
M\@Z0Z($=L\LN`[!N@:85U*,=,#FKVIB\-HOT*H:$6RC1V?0!G-;QQ;$C=/^(
MB\&)A%[$FV)\"#I$09I7W!>IF^68H?312Q$S]8>$_DJ'PO="_Q"*+8;V8%W<
MW-D[XSC(0M8..PXQCX#GI/):G*N-<&LI+V?Q;D_P(XT6^78W_U:=L&;:$^2)
M*F,A6\=]BKJKU/QG42##:*V7_`?[N6U3"AR/$1CT#-0P*+<.1@W",7#J1P=#
MES&AEB8Z.Q""(_^%GZZF_-%)@`I0.6N]7/_/(4F9@-0'7VWNO><;?HZ<]L)J
M4.-S+/Y7Y9)`L`"=G`(SK-UI&)V:)5::%BCC`N5LH`H?7"\KG*"2%9X:R`M#
MV,L,M#BP^:CY^:A5ZBP@K^C78IK.JQH7\)0@0"O7F6,$9^)`;T)JRI1S*+'X
M,BK8>Y`DS'=<2]-O44O#N'!L(7^,D/86^*?F&OA*()5.=-P(I%`(*S'<F9<\
M7H;Q%YVRCE(R.]%9%_O24(P1($[A5M1E)DBL*8BE:*H75)+0J0]1H!O.C`F^
MB;_&ZT\O/R>83K_%N<`EG;6?@C30*H$ZH#/8K6MS4;MV9#@*\V[0IQ?TEO5$
MI\YWJ.@,E;TYH'.3B%[*YA7-[1[J&XS=CNWJ8<"%4]3254[NXUO,AB@(<6V?
M_3Z>3I5G>1R@LL\T7*U:^N5CF$M</`BU\V#HSZ_/<%@8QC1&I!C&*-\`I]^R
MSSX;P7Q#)';-(,VIHTV3-:."`OKDV7X]YFO'-$SHW(ZK^EO=!)!^>!_++<>5
M-3SB+5&UJ36_6YMQMA][],`9]RM-\W(RENK.S<4^:+@@Q7LK4)"!'4Y)SS&-
MX?U`I9JU9H`*V6"O"8?JS[94SX!%NTHV`:.0ZM2%S*82=<`2],A%;1V[,OM^
MSD[^Z[GCAAW!'M`P$['CW`8G1&_S+MY1C[CB$%>Z<<`C'BVO*`F1-!S8),%9
M^;:P[,6J,SL,NQT'*\R!.R)7L_V\I>_'ARBE+C(.GMC>15^&I@XI5%ZFGAB:
MJI21LONX<F(K.9C#A"JX)S-PKU<(QB+WP[C0?FW--,BN#,:W092#:9T]57;3
M`C-LWHZQ1%MA]"5('YFIBS!ZP1Y!;V/"_W@X)$&$:63OO_@A[9K7S_-I2$N#
M5Y+PLV2L=_J\=9"BQ`MYW9QM'*^%F4RRZ\'L)3T:O(I:JJ.^G9G`#JY(^9@?
M6<DA?3LH(X6V@W(Q>NW@BJ"<CAE"3NF*%3032;`^APDT28@>QGN?$:D;"H5)
M^3&F@QMQ#L,%#>P);4)M]H+E46]H)VL1E6P9-VVC`#I#3/MFP>V9ALGHM&=J
M>S&I7W=#4>(%ZW.\P81.$L7->=&:9R4MN4>M[^OI=6?/_],55],GS+HKCLJS
M*55D6(J>''$0ATJ=BY=7P%Y0J[./DR`OD<V(+1RY>:T"CG*3G1%Q.E9M^]?L
M^Z*6Y+XQ3N7HY,L*44P]:-J(39CA"UH'B1_&V28:ZRJIYMCP+;8-2TI9<"\<
M/WN[?8C9Z(M1J;R0@$H6;0.6$"@>M6B4@'#).S=ZN0J/W62VL+G<F(>?-]Y+
MC\NO3VMU4;$MB.GB1T;ISKJA6J2"]_U,O.N6@IF<<[L+F3U:H5Z[[%8)RPI.
M#G1*+M=2376\26Y;S=OBZ&LZHZWN%SBE[&K!<@G"&248KO*3\&]=\7NT14OW
MNU7%IOKG#L@M?L+1P6Q^;]):5?RV()I:GQ.BC-(=E5>+5/!.9N)]H+*/Y]RN
MFO=HA5K'NU7"Q6Q\B:8;=.)D]GT'W`9DW;N?:M\CIS+%U5II.F"YW#Q*T&=,
MC+7.NE6YBIYP,M49'UEG]JV,7%1#:U-TYE:J_B2BE[(YDE(_'+N:"JH&+IRB
MWG@O64+_TO_[(2"8,DOM1_IR0U]2NHS6%_1;?F&\1$$-.@%43"/16CL!&3$[
M0Y.1HYQ^@7@/"[[J771B2PG'B4F9>F01#E_4%W1<+#R;6%I3_ZL1RNQ:KU<J
MUKV#KPQR1C`WDLV9P-A"NNBJ3>*BN>F:3>.2N>^'Z01*08=#YE0`.*-<;OJ9
MX_U+5ZS*91!YD3]1`"CKS+Z5D8MJ:&V*SEY%`&@F>BF;VP&@!G8U%50-7/@`
M\#(FMWB?N6&KS1DOE,P/MFH$?A)B"P&?5)3>0(]2H9*,US`2Q:(YI>WHSDRF
MBC>=LGV&`WD1-:]M!SXSB6$C&%`K3%\0H-060.TGL8_QFE\U]F=Q0?3%,R9^
MD$C=?2D9I,;+V>^X-XHW%Y<89@2HH+"FXP.EX.>7<-:2*4F\%Q<QLL`YN^[;
MDN<.*A*H]FLH3$OOU=KBHF,^B4/NIB,^C0/NOM<M"XOWN9P/5,XL1GZ'-AW.
MN%/!/YB4;D8<XR,-^*O1-AOLIZO-Q;//ZQ#<4H=Q%3%N60%_^A];^WSR0N8:
M26R.43>0EZ:9B=>Z08V3LW`C[P"Q'M`J$N:(W^W`/E2ZL7:AVDA1<P'9H1"$
MA>!Q)!25R<D_X!GEU+LSS;*4H/>?#=#-UF5HYHH)6%6]DPWCBS6,NH&LNVXF
M7JLP3)^%62#1!^I(@;56?GV<K,6I_,`YBV-#,M`R[@.4L%77W5P#`2OEBD,Z
MU,^ZB</`UZQWVT\$6;56QGK/&2OF..>M'=B%F%$$T%*N2A"U"K*J$`1X^179
M>E'P#W[H^"R.$LJ/*(]!=?:&OOO\0/)JDX4D7E@4I4_.Q>G@`\'W^#G]%,HW
M'29_%.1E5M,/4ZMF>N41"U1[")\8JH]A84?Q(%0^"96/0K^PAR'^-&L:[MJP
MQ>.&#?2^IID4LW4OTSQ::6,.S\HELJPL0F)R%A."^4U29K.Z1C=6YGDM\233
M9EY-DF>_LAY0I0NGW`%;DMKQ&O1AV^]':&/6+;W4<1O,^G%,,V4SESY@'9C)
MG1#6-?U43JY#L`N:1-"=RZPQ7:II8=,)E()T;%U7#X74SX0X,!M"R@2\$:\'
MNH[=>"W$.:`_9G&Q43<N:)5>8"8'HV.!J@NR.J&%!I'C`-P"WD12\,`3]8HK
M46YQR/(>S^(D3?BE*?SVESS#3V/B&]DQY&TG8X>@M5]1XEADV987YF1](M[I
M`E4O-"H2=>W/J7..2*PS(@^Z(P)Z-<HDJM*Z3&4*/7'07GRJLJLSO8_MV46+
MT3L(4YL,!UR#60=ED-5PQ(>82&4&&PZIOHRH'WZ+UQCO6-'&2H8_]6_X__G9
MABP?6.(P#.\+JG+X0$&;<"Z[J9V\X4ZP^%0<",E3]^VY`O^\@FO=RC"1Y,S5
M3U^Z;D[<TW9B:<_[XI$U8O+PZL]^>%BSU;_=(4R#/1TR7.UC+]08\2=OQ>:2
MO8+08RQ`K1KT"/4',F`R#V9$9RZ:,-F4/$25+?HF_]2R3V[(9,+_OR7K-P6#
M39F]99_,2;SQ2/IR3UE)/.T$`"4I8""F(49;BT7DP&E0E<B!A1<H>2##'UVH
M->,;39S9UQFS70R37AS0)+UU?0D('=O`L"VG"YIGL'=ACE;`HR]T?@U2L1P:
MK<]BGC^`(Y8F7+*G,:&9]0-Y^,50P-;IEY)>'(*I]E`#K/6)SP%100^,#(%N
MZ\3(`-PZIITZ$Z9A1Z[IIVPZT4>M`S.G&](ZIZ7**700?D>L:GT.?!J;LR/Q
M6X*Q:KM>20*U0B5GNXFEHC4JF]M>+7=;`JW5(C,1V$V+M`DK'9UI%"*9@YS&
M*,%TT+P0K8/-!A.VU!,6(GM%]]96?#34I+:NH]:1*72V')AU81M2:AL>F&U0
MKD&;=@.NV]KB]6J+M`?[:\T32EJU"U"N@)F1&"SC/X?A,-/5;F-BI*@C#,P9
MWC]Z81P5F%*Y!/T$4$9#QG++M<S:ECICVQF8C7LPG"LA4T.T"B]38E<Y#THH
MK*%7&AEU`,#V3.:T`%KSE)$$\BFI+9\[:BF?:92J`+<B='?8[T/.@Q>R,B>7
M8?SE(E1&J$;D@*L_FN(T@58E$V6)&"'**1U8BP47#')-QP2$S94<`P3"%@!C
MC%29*\,%K<QK[2Z`"W]IBM59](O1+E`-DQ5R-Q94[8D(71S+!*!=A;$,T#G"
MT?R1Y>1<17Z\DVT;]C:%<BV[V6Q"A+="HIGM8&A2CL$\+0D<:BY6/Q:FP:(R
MW.EL:P&-,HM5?[FV@QOGF-8*:#2YEH<RVXI,+JB6/'R10!LP<,GK.-WY./)(
M$"^?`UDEY^[VD*%)#\,MESUO1]V(K"4UO+2M71==-MPMGUPRUH`(R1[^<Y3L
ML1]L`KP^CW=>T%+EJIB]-)!(D3#>0DO6=H$JK=$OHKU=Q*B&OX4:Q=C#(8?=
M91?1OE^NL6SQH]8,$!\-]KKNMN8_+Q!M8"N0TF723O'CH=Q!*E`7"ILZTP'!
M:?Q;#;?6AC>K\`=M^ZV][`7SL&?JH?8XIMYV2_B5:LC;L9)?_`ZD]!&3C._L
MZV1!?=:$'1R*MN+2I&U%.'OGA#I@V^>O"LP*1C_3AC_0S_0_=OJ)_O"_4$L#
M!!0````(`"EQ+3^B.M7-&A(``*L9`0`5`!P`8W-B<BTR,#$Q,#<S,5]P<F4N
M>&UL550)``-.G&].3IQO3G5X"P`!!"4.```$.0$``.U=W7/;-A)_OYG['SSN
MLZ-(Z5<R33N*/S*><R.-[5SOGC@P"4FX4J0*4+;5O_X6I"A1$@`")*V5&#_%
M=;'KW?WA8[&+7?[RV_,T/'FD7+`X^GC:??/V](1&?ARP:/SQ].O]U=G/I[_]
M^L]__!*RZ,\'(N@)C(_$Q]-)DLP^=#I/3T]OGA]X^";FXT[O[=MWG7S@:3;R
MP[-@&Z.?WN5CNYW__'YSYT_HE)RQ2"0D\M=4DHV*KOO^_?M.^G]AJ&`?1$I_
M$_LD234HE>M$.T+^UUD^[$S^ZJS;.WO7??,L@E-I`QZ']):.3M(__R%9S.C'
M4\&FLU"*G?YNPNGHXZDO'CC0=[MO?\JHO[N(_?F41DD_"BZCA"6+ZV@4\VDJ
M\^F)Y/OU]GHEO#\ATQG\'Q$#$F$\7KSQXVE'CNH8&77J"7F7D(1*YH/1%8L`
M#4;"82R8Y'T>$B'8B-'`25Q+EC4%/X^C@$:"!N=2B)`%\$>#3R24$^IN0FDB
MAH2#$!.:,)^$3AJX\FX.@VN094K[84)Y!/@^TJJ6WV74G)`#4)R?Q],9IQ,P
M$S#/_EI56;7\FA/YG(C)51@_B>LH8)SZ2559=QG5%'+`QR1B?Z>+^:N@@]&E
M2!BL;2I@N7\B@HG!:,BI@+_NOG,X,Z^IS"WU@56XN!9B3H.^[\=SV+"B\9#'
M$?SHIT843BI8LJPI.'";49XLY!;[UYS-)%,G,94,ZL[?">PR@!(-AF3A;CD%
M>6UX`PH'[T-(8;5.X^@NB?T_0>/TW^&<@S""_D$X)X[6<V)<6XE0;N>P@R>+
M>V`HB"^GONNLU#"I?:I-IRQ)P2)1X,?I5`??C%$W^4Q\:HIXPWRY24?C_IC3
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M4A/NY_S@QPT`=T,_RQ&=67J7/_,G+%QA/^+QU-V2N2QQB1XG,0\H_W@*%',!
M(L8SR4@&*4"Y$>5\>6X9A$\E#Y=3&PF_.W#D".S^_6<F;&`LCO=Z*&CJ(2F!
M;DOV(T=PJ<S72,RHGX;C+N(I89$)11V-]^XPD-Q&2`.H08TC!S4W!!QL]!I^
MM%J3J\'>]X<!H^V"+`J>`]?%1$Y0_\TX?NP$E&6@P0_;6,&OO.P`N:5C)L^-
M*/E"IJI#4#?4^^$P<-JP_R96!M&U2VP?-C\'L3D)K\')>_X771B-OC76^_&(
MK+XKNWZ!O*S=S^=<JG?%A$_"_U+"X79[`:IH3*\;[OUT%-8WB)\#T$.9^%<L
MI/P<)!G'W#SM-T9Z/Q^%V=62YQ9_MV>+WW,B\^AWB^E#'&ILO3'&>W\45MZ6
M.;?O]SA;^3I-D*8YQ&">R,<$4D3SOFX@]+IOCP(*.TUR@'[8,T#Y7?D>V&J@
M*`[QNCCW>E>C;\N<F_?'/9NW#T($4I"KD.BF^L88KWL@5^T2`^\(G5OX)Z0)
MO(K'&SP6Y5BO>R!78LLIO2-\;OF?D2R?>5"96%?P.]5-UCC>ZQ[(;=82`:4"
M.0KO45&0?JP]!JO17O<X[JD&\=>7)C4`G>ULPK:ZC648+%_4806<%%(94A,N
MY*_9"=?I;C;F-Y:@J!@)/1!_R3T2>NQYB;X0-!$6>\?FP$/)0&P`H09M1_"F
M`'ND_"%>I^#WBYM\F-2/`OF/?/SX2$+YJJN?G!/.%W`=_3<)YZ:MU(H>.4&Q
MBYP:85M=6@'\\CFND(]T0578K[[09!D&-2U?`QER?L,6YA(5&LM(H<*;OO(K
MJ%B.K(8".7UB"ZI>>GW\_ICPO(X>09V8+V"N&D`L#D-.O=@BMR6R/OA_3'`-
M.9T1%EP^SV0Q$APJ::%,9I+RI6A!C9S@L0773A-]0L(1\Z3X/A3#`;8X0#=T
MQTT@69^86S+K\Q/'M4:SNI]A2++G@7GQCWF+-9%AIZ'LEZ59!WV&Y)@`_AS'
MP1,+5:G<[2'8J2QK-Z<@KS[)<FR[9NEVB9T(<]LHBQFPW3S,\8!SP\@#"UG"
MTIK3-%T]B4-02\C](EE81'ML61Q@WDT;"'+1J1V7R?S&/"0+N[NDF@`[M><$
MG#EVL*M86X)"?`Z"K@UEA;6:!CN/V`S<>MW:L;8OEI+>4KB&SRW6MIK`Z^+&
MB1H`6Z]88R&DPSC,RS%637C<:%(#^*J5:D>\Z8)R]I@VBREH^26.?(OE;*3T
MNKB!ID;6=:F&;0A`%92S6]E>%S?ZU.R2EMHT%I="A+'0_D/F(C?;B.C3L'HJ
MKX<;DVH`YA+MVA&M6C?2D7L3Z`@BP1\97T<)!>22S%K9T_$\(]V?RMN(85Y4
M9^KU<"-B#4R;>LJW(;Q6*69CL'4/-PS7P)PP*]=8U`X[^9B)FBI;]H)',=KK
M84?CC"!I4XTJ/5H1ERD4#)4^R-H:ZO6PW]-7P%*E1#O"+?><$C'G"RLL=P=[
M/>RW^1705*M1/ZBB;A>VYXAI$+!,["%AP37X$3.6$%/*44/A];#KU"L@:]"E
M'7&56YH0%M'@DO`(O$/1]_WY=)XVD+R@(^8SL_-=1NSUL,OC*X!NIU9C(17L
MA$BNFZ[5\4TLQ!>:#$;WY-F<)G'AY/6P*_BK;`?N.K8A9+-K*Z?;E=?#;B-0
M`6JU&HU%8@XCCJJ\9-9X[>"]._I0G(V*^NK7FK-@?V6;KI\1J-LKLLAZ@W-9
MH\A2PM<Z3)LND39FU.Z$[:S`?&T1>:P(OK:(?&T1^=HB\E"0NZ?36<P)7V0.
M$IPN`Y[J&:2AL"'E:0\H4QC0CL,1M)=TUZ@5X?LM=6W:GMF2'D%W2P=5VA'C
MW\Q$55CP=@R.H+6FLT+M*-;=5#>;Z/UY,HDY^WM]%RT%?IOP")IZ6BO2CO2`
M2LWL:V>.(&=$1]!/U$J)=L3^52K:'=HEE-A5HG5QMNY6>DQH%YX<5#BQ+:BQ
M2TQ=4+=4IQT/+W>Z\5H=U08J[&K5BDBKU&CL$>1A(5QZ1FLH#K!,U1[9M0KM
M>.;HV$C<A@R[0K46OEMZ-):%.YSW<IF>M@_FLM'85:A.$1*U^(9NMK6A1.F$
MN_N%\[UWTY("K"2R>!2OH7C-KEHN`[W]OK&T:L7\S8%XE-]>8]O!C'*2I%5#
M^?LUB^W"0'4H&=6;\DXG9BV04S.:ES1P/Q52"GF#&2P/H;LXG$O95&NNG`@Y
M=UH"PB9R5MH<)G#WG$0B))DHULB9J9!3HN[0E:K36(8,\[TL":E8=MFXH_R1
M^528>^YI*)"3GT[PEJO2ABXC*Y,L.WXZG97;-,@)SDKPFI3!SGEI-M[S6,"=
MK-*Y:4&*G+0TXJ'8@.TT.LP3-).]VCEJ0XN<GJP&9:E*[7AS<@N0@#GE]PLN
MX'`)X[2=Z])2ALW72(>=J'1`W%J?=KPPN:-I)PO0\G?"_Z0%&YF\*"T1=FZR
M`M!F9;"/VF90_DPCL$L(.O:#*8O2[W'+<&DYU"64V!G*"GA;:-2&+EX[EG%Q
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MP7R9*6#A/#'6`Y108C?,K8.TA6JXK;`U5_D_*!M/0,`^;/YC,J9?YM,'R@>C
M[-UT.;3N3+!;Z58.!SAK^6)?KT-Y;J[K1;CO5^>[+^#EQPQVQ+)JT>[$Z?65
MNFL8U-JNNNSDZ^OUU]?K!P!<-;_U>%ZH;\O=BDBW[KRZ@ILV&T?9Q\O\1?JR
M"78AB4X4%-XY]8/_S46R_)QSVFD7?#L6!\!%%IC1"YK]6Q8AW8,(A]*7S&*J
M[=$D;7CDK;"419=L`]7AM3<S?;["H,6+Q>-1G.MS(B978?PDKJ.`<0IN*YY7
MO9+%S87>(7OUE]W]99417YWC5^?X@(&#/5G.VB&/'QEL@I\67P6%XWCUAJD/
MI_ACUNK<XHF/,[/C<K/=E6N%+U[M`H4<)ZR$ELT%"[UVM!E0UZZXN(]OJ0\.
M#@OIAJKW<7-;PTO\.61ON,DI]D+F:<?CICPE0],X)-PH4J1-#H:2`+E2]J4@
MUK@J.A.T8O.ZH""LS\KF07$8<B'M?M'?4KP=V\`^'[_B/H+<[V1Q,$H[OE>Y
M'6TLV*WX:2>KAE@.C)!+A_<[J9Q-@UVMJ'EAL:M'W_?EY]'!@A06BSI094N*
M75SLCI+B986EGK4=CWI;1PF^`[X6/ZT<L<?70(I=4]PHOB5ZUG<R7A3@M>QP
MFLT(D]]I365:U6E&V0<[^T+01-LCHB([[&+C_6S^=2U4_RWT8;H7R_U0#,FB
M)+-12HM=WHSM12C,T8[>^TI5^1Q$7V_4KA-GBQR[FOH`YH["(NUHX+^K;;[=
M+ONL.<V=+5KLRFSLB:,P!^YS\'WG_AK)^:%7DC>;$G+0NA75IVJ-KZ-'*II*
M%!N889>C-Y`I+M&N'4%:\,N6^W3?_VO..`4KP*)(%L,0;HS@\LL/'Z;]R`S3
MPYX)>KEZ-:C5\\9-[8;C*??'L+4TLJ6@E[XW.6?<U&[#HUJ-QE<L(N`6-G,0
M&9AAE[(W<!"5:->.[I#Y9GH5\ULZFW-_(D.8H\(7@RP.(#TQ>IUZ-6C-!X]9
M7>0`?D/3@L<^I4':R^$/PF48^_*9<I^9VPR:R-!+W!N="B6*?ELG2",G!WIA
M?)/SPTWM-EQ\+T<CZB>#T>4S;(O1F-["YC6(I!%D82S\([WR1Q+*#=0P7US8
M8!?9N_@8KGJUH3^36COG`D,7-E[OB$J_'/5J1PLDM=9]V"XY7\#.F'XYV'DV
M;-%[/=P8:OUIH%"HL03>+)UB("-/6CT'CB<4:JU08UFX;`Y<1L7[Q?Z*0@=\
M3"+V=\KTJ[Q#78J$3<%>\K6#;#(C!J-AX0_ONU!TF3X'RP_CD/F6M1M:(H0B
MT:*%SR4&(0O(LM*\:-G!:.F3DG`U8<4%$WX8BSFG]X#PI]`<!6CZ3R$7JAIA
MU*S?%S#!RQ4@[&^9RY=O41(NLL^)%PS+XPA^]#/]\1;W>>J*RSWGDO.8G\=<
M5J5+79R6>SD;A`W`1CR;U>W$YV"6KA4DFL7LJG$;5FJ>0MO(/.X_YJA.XUDL
MQE):A!6HE<GM>'5A@[S^;%#0!U1=M&S#FEO7'N:)A7VON+5MTRS&JO[QEH8R
M]2"_BB=2*1^*4EHLQWJ,$=:JM<`;>-DLWYJ<D5=T;2`UR[V^5=JP`]S2@-*I
M?*!=R"'"YI?^.UPF&)?I)?N]05/AX?+'#$N\,B^G5=V`#J;%69T9TGJL8_6M
M)5A+]W:LNG2/&1)P-PHM^/9^^NKDL#A?RT@13E"=2&[.K@,7Y)/1`@+-V>>F
M8QM6G-QC6%:80*+`3[\-,J:1C*WM>]$51$D;-A=$6=O?8@4Z\4%8CE;RV:Q(
M-T;(B](5%5TZQE7G-BS2&^;++J31N#_FU#4RJ_'7%#S+7$L#21,>Y(H]6;$/
M5I`F8+L'"6FI[^C(!M-K-!M4Y1RZ*]>&^7].9Q,2`BZYTK5G_P['LKFO)6AB
MYN\P+YWD>@K,^6PRDFHV&[5HP\2]F\]F8:H9"?/6NM?1*.93E-RY2IS+L'3S
M=R''\*>6HA3%6_L"5I%`6Q;8C9KM`#"\9+%4L@UKK_B1Z+H;=(%7V4&A&-K$
M$5%@6WHXJ,9B'@MJDZ@.!(WD>YZ.'2F8C)K#?_P?4$L#!!0````(`"EQ+3^&
M2YMP!0@``'0\```1`!P`8W-B<BTR,#$Q,#<S,2YX<V155`D``TZ<;TY.G&].
M=7@+``$$)0X```0Y`0``Y5M=;]LX%GU?8/\#X:<=8!W%S;2=!$T'KNU,#:26
M$3O;+A:#@I9HFQB*TI!4$L^OGTM*E!6+EN4ZBW''+PTMWG._#DF1XNV[GY\B
MAAZ(D#3FUZW.V7D+$1[$(>6+Z];]]*;]4^OG]__\QSL9+$F$D<)B0=0(1T0F
M."#7K:52R97G!4L<):!"Q@!F\6)U%L21]^J\TVF?OVU?=$`K(Q'AZB8649_,
M<<K4=>OW%#,ZIR1L(7"#RZM`SL0>.@VHD']\?#Q[O#B+Q0*$SCO>ET^W$^.U
MU<XH_^V9]--,,"M_X>GN&9;$BNO>4!6`LO!K+^LL1%F-WB^WH+BLE-8(4RX5
MYL':B8K3>8B=R\M+S_1:44X66)%PJ_)+3\2,>+F81:6RO<`X*5!S+&<&D7?D
M">^L$VXA;:S4=AAT"CI+%9$%N7'*E5@]3Z@DP=DB?O#R3H>U(!4"AN0V7-[K
M`(:$NC'0X1`G3\'2+:]['`#*'XA4;DC6YP!Q3`/IQI@N!T32P`V`#C<[:I40
MZ:3&]+ALJ$1L,0(]#H`@\ZT#[8T'O6L6$D&"'0,3B\",S3D.5)L\)0QSK&*Q
MNH'?1>9BSM/(K214PM.A>2#4!BDB:+">%FKWE%A;V6TB5Z]71<QYK+""1>K]
M.YPDE,]C_5C/RBNM>0H`I!OW=\,=ZYIQI!\'J5XENSP<<$75:@@:160LM!"%
M%-9*%+9#,J><&K_..ZB-+$HW_=[]I\%HBKJC/H*_P^E_T7!TX]]]ZDZ'_NB=
MMZG`ZDPE"7W^WK2!4@GJC%6]NN6H7,2%6"ML)A]@%J1LNP'O68X/2OH$XC#O
M)G]^0SDLOA2S<2R-LSV&I<Q?43K]#66=1+R"[!=X:/?\47\PF@SZNC7Q;X?]
M[A1^?.C>=D>]`9I\'`RFDQ/DHQ?SD'#0W-/=C(9Z\?B`F7XM3I:$*#G&L.:K
M)5$4W,J(V1?D9.CB6QA"_WNF^=<39*PT*X;0&9$N4T3`$DX?2&7>5"6<7/RX
MP<7]J'O?'TXS+ERL3*;P1Z]L$^3?('\\N#,+VBG.H%*V?1B7HA='$-\2Y@>D
M.\M_A9:M@DYV7A_&3L__-+X;?`2YX7\&Z-:?G#A+/2R7-RQ^E$,>4M@NJ0H]
M50DG+V\.Y*4[^8AN;OW/I\B'+Q:8TS^,K7M)_/E`*@H[*R)AL_4!2RK]^;@4
M<,;1WB@G;V_USHS*@,4R%01^E-7^&X%B%,]1H1IA'B*C7#\NJT?_2CE.0PIO
MOQ].D,,[$D`L;#64,B5A-S#'2LH78Q%S:`9F7LB,N8:R3KY^VN3+*D.9-K16
MAY[K.W&"(!D)$6JESR^_IS31.<GH</8XDW^YF7P+-=.B`)]XIB=+V);"&D'"
M,5Z5AKWCN2O+G?/-+!M@VR"1A9YXCN](2$B$9XS`SBF*^43%P6\P@,W?<2H`
M*LEG+`2VHWPOA).73G7IL2I1IA,9968R9"VK%^6*3YXUID^'<&Q3JRGD0^)`
MFRU>"UMZG6R\JK)AX,C@45G!B6==CTVJS*H!(S.(S<N1\(`2:8_PVP6<N;_8
MS'U)@QG]O;*.$T__+0WTL8XON@M!RML@5X<SW3]NIKM`HC7TQ+/<(\D2LY@7
M"<F'=N6Q,\.O*P,ZQZT3?.+YG:1)DETD8F:/Q)5OY+N$G+E_4]GNE+0@K09I
M/:BDZ,2Y^$5O)<I?D\H/G#FNG'(-`F60OU$V]3_Z)OF.S)&YHKW2-T?7+4DC
M&%*M_-G2W*'I*^^VOE\[?WO1^0HAG3U%S(IHS367Q8:&S2SDAJV*_&JM_@H9
ME)@3%+PF/>M\RWN!>"#A^\;SG*.CBH;AV;[1`(2PHPL$QO6^@6Q,A9<-Q[.7
MI]!:7ZE"!T02"X5XI>"DKG(BJU6YC0.CI@:B?[4MKJT?M3NOVA>=LR<99H[M
M8;^(:$_[%K>??7<U2D/+%J!-OFY@K+8F9(M-8\\)]`A3TCYIKU4UC;JFQJ+.
M%P<L;Q_@@ZMLI8D399S]<8@;KBJ81GZ4@<6O`SRIU,HT\:(`F=8!UJLE-$W,
MKU%9\P`'-DMRFIBW&-TXQ/1FH4XCVQ9D6OM9WU5?UF0Q8D(\0^D5Z5(O@ITW
MAWC0<"DL65>'6JXO86KJ35G+8*UD/^=JB]V:C`J+T8T#QD2E9*I1&C91!Q#C
M+@O;SXF8CVK\R*M:C2/UQ5G=F50"VYM=O1W[VDP\V].9NM$K>$;Y8JA(I,\;
M+81SJ>N6$JG>\1DIV&/1.)P:7)B*_&3,*6/Z([&5E2F`J4IU[R\B3A-K!$Y@
M$42'*N&5RVF>U;PX8FL@>SR!C8F`\RUF]`]]L,O.N9.8I:6OPB:H'7+E@*(8
MUA0L5JZ0YIC)'3%E?;,LB6!=$#@8OT2HYH-TMHW'K"[678+?0["]6"I_WI3=
M1M+_O[!#,GO)J!L3W4S\.XC[,Z&+)>PAN@]$+/""P+H](\*?FWM+J:LE`EAI
M^Q1BLN6<)@%[XEXP$X?'/.0P6^#PZ(L^R5I#;CZJZ7H$^J"5ER)M)/T]3.Q]
M;E$=+Z=O@Q_/^VH?_Z?D27U@\/P;XR_ALP1D=?A7RC[_R\:^X^+*P76MU/%0
M6KB)"S?#XDNYSO5,Y]I%YM[((Z.Q<C?F(+%&YG@HK#CI8JM.Z,B(*5WG."AQ
M]AX/&27W7#2XNX^7`+?KW\?+VNXZUGN.O#BR=H]2*UT?=KV+M4G8DK%=67%\
M"ZC&,18DP33LDSD1H&;PE.C_L*++A$WM?5=*HF1M)AIJ.,KL>-EG%VC^"5!+
M`0(>`Q0````(`"EQ+3_KF`^48D$``*K;`P`1`!@```````$```"D@0````!C
M<V)R+3(P,3$P-S,Q+GAM;%54!0`#3IQO3G5X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(`"EQ+3\EW+=OPP8``$-7```5`!@```````$```"D@:U!``!C<V)R
M+3(P,3$P-S,Q7V-A;"YX;6Q55`4``TZ<;TYU>`L``00E#@``!#D!``!02P$"
M'@,4````"``I<2T_OHK?">\-``"1S```%0`8```````!````I(&_2```8W-B
M<BTR,#$Q,#<S,5]D968N>&UL550%``-.G&].=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`*7$M/SCD\)I'(0``F.T!`!4`&````````0```*2!_58``&-S
M8G(M,C`Q,3`W,S%?;&%B+GAM;%54!0`#3IQO3G5X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`"EQ+3^B.M7-&A(``*L9`0`5`!@```````$```"D@9-X``!C
M<V)R+3(P,3$P-S,Q7W!R92YX;6Q55`4``TZ<;TYU>`L``00E#@``!#D!``!0
M2P$"'@,4````"``I<2T_ADN;<`4(``!T/```$0`8```````!````I('\B@``
M8W-B<BTR,#$Q,#<S,2YX<V155`4``TZ<;TYU>`L``00E#@``!#D!``!02P4&
2``````8`!@`:`@``3),`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E6GAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 8,839,000<span></span></td>
        <td class="nump">$ 10,457,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">1,236,000<span></span></td>
        <td class="nump">585,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivable</a></td>
        <td class="nump">504,000<span></span></td>
        <td class="nump">517,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">341,000<span></span></td>
        <td class="nump">276,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">10,920,000<span></span></td>
        <td class="nump">11,835,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">212,000<span></span></td>
        <td class="nump">146,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">669,000<span></span></td>
        <td class="nump">669,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">11,801,000<span></span></td>
        <td class="nump">12,650,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES, COMMITMENTS AND CONTINGENCIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">1,498,000<span></span></td>
        <td class="nump">1,580,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump">264,000<span></span></td>
        <td class="nump">302,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">2,077,000<span></span></td>
        <td class="nump">1,618,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">3,839,000<span></span></td>
        <td class="nump">3,500,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability</a></td>
        <td class="nump">795,000<span></span></td>
        <td class="nump">972,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">4,634,000<span></span></td>
        <td class="nump">4,472,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount', window );">Redeemable common stock; $0.001 par value; 12,533,333 contingently puttable common shares outstanding as of July 31, 2011 and April 30, 2011</a></td>
        <td class="nump">8,159,000<span></span></td>
        <td class="nump">8,159,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of July 31, 2011 and April 30, 2011</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 125,000,000 shares authorized, including redeemable common stock, 36,971,667 and 36,956,667 shares issued and 33,930,103 and 33,870,000 shares outstanding as of July 31, 2011 and April 30, 2011, respectively</a></td>
        <td class="nump">37,000<span></span></td>
        <td class="nump">37,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 3,236,000 common shares as of July 31, 2011 and April 30, 2011</a></td>
        <td class="num">(1,252,000)<span></span></td>
        <td class="num">(1,252,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">18,802,000<span></span></td>
        <td class="nump">17,784,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(18,519,000)<span></span></td>
        <td class="num">(16,482,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
        <td class="num">(60,000)<span></span></td>
        <td class="num">(68,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="num">(992,000)<span></span></td>
        <td class="nump">19,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable common stock and stockholders' equity (deficit)</a></td>
        <td class="nump">$ 11,801,000<span></span></td>
        <td class="nump">$ 12,650,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Subparagraph a<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 14, 17, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Staff Position (FSP)<br> -Number FAS115-1/124-1<br> -Paragraph 15D<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 12<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Topic 210<br> -SubTopic 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br> -Section S99<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Concepts (CON)<br> -Number 6<br> -Paragraph 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 18<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Section 45<br> -SubTopic 10<br> -Topic 210<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 9<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 17<br> -Article 9<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 19<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 25<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 3<br> -Section A<br> -Paragraph 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 107<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Staff Position (FSP)<br> -Number FIN39-1<br> -Paragraph 10A, 10B<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 3<br> -Section A<br> -Paragraph 7<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 133<br> -Paragraph 4, 17<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13495-108611<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 45<br> -Subparagraph e<br> -Clause 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 43<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141R<br> -Paragraph 68<br> -Subparagraph l<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 45<br> -Subparagraph e<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141R<br> -Paragraph 34<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141R<br> -Paragraph 72<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrantsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 32<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 25<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 21<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Section A<br> -Paragraph 4<br> -Chapter 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Section 45<br> -SubTopic 10<br> -Topic 210<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Paragraph 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 8<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 12<br> -Paragraph 5<br> -Subparagraph b, c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of common shares (regardless of class), limited partnership units (regardless of class), non-preferential membership interests, or any other form of common equity regardless of investee entity legal form.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=6802392&amp;loc=SL6540498-122764<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -URI http://asc.fasb.org/extlink&amp;oid=6802392&amp;loc=SL6540498-122764<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number D-98<br> -Paragraph 43<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -URI http://asc.fasb.org/extlink&amp;oid=6802392&amp;loc=SL6540498-122764<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number D-98<br> -Paragraph 43<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 27<br> -Appendix A<br> -Subparagraph c<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -URI http://asc.fasb.org/extlink&amp;oid=6802392&amp;loc=SL6540498-122764<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A3<br> -Appendix A<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Technical Bulletin (FTB)<br> -Number 85-6<br> -Paragraph 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.11</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>7</ContextCount>
  <ElementCount>93</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>01 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/DocumentAndEntityInformation</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>02 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>03 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>04 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StatementOfIncomeAlternative</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>05 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StatementOfOtherComprehensiveIncome</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>06 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>07 - Disclosure - Organization, Use of Estimates and Basis of Presentation (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentation</Role>
      <ShortName>Organization, Use of Estimates and Basis of Presentation (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>08 - Disclosure - Recently Issued Accounting Pronouncements (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RecentlyIssuedAccountingPronouncements</Role>
      <ShortName>Recently Issued Accounting Pronouncements (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>09 - Disclosure - Property and Equipment (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10 - Disclosure - Share-Based Payments (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>11 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrant</Role>
      <ShortName>Redeemable Common Stock and Stock Purchase Warrant (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>12 - Disclosure - Related Party Transactions (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>13 - Disclosure - Commitments and Contingencies (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/Commitmentsandcontingencies</Role>
      <ShortName>Commitments and Contingencies (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>14 - Disclosure - Licensing Agreements (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/LicensingAgreements</Role>
      <ShortName>Licensing Agreements (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>15 - Disclosure - Cephalon Agreement (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CephalonAgreement</Role>
      <ShortName>Cephalon Agreement (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>16 - Disclosure - Supplemental Cash Flow Information (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>17 - Disclosure - Grant Income (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/GrantIncome</Role>
      <ShortName>Grant Income (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 02 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jul. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Apr. 30, 2010'</Log>
    <Log type="Info">Process Flow-Through: 03 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 04 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 05 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</Log>
    <Log type="Info">Process Flow-Through: 06 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>csbr-20110731.xml</File>
    <File>csbr-20110731.xsd</File>
    <File>csbr-20110731_cal.xml</File>
    <File>csbr-20110731_def.xml</File>
    <File>csbr-20110731_lab.xml</File>
    <File>csbr-20110731_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>32
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\U,C4V.6(V-E]C-39C7S1C8C%?8C4W-E]F
M9#,R,#DU,F0T-&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3(U
M-CEB-C9?8S4V8U\T8V(Q7V(U-S9?9F0S,C`Y-3)D-#1B+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1$]#54U%3E1?04Y$7T5.5$E465])3D9/4DU!5$E//"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]"04Q!3D-%,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E5.055$251%
M1%]#3TY$14Y3141?0T].4T],241!5#PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E5.055$251%1%]#3TY$14Y3141?0T].4T],241!
M5#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y53D%5
M1$E4141?0T].1$5.4T5$7T-/3E-/3$E$050R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7U5S95]O9E]%<W1I
M;6%T97-?/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4F5C96YT;'E?27-S=65D7T%C8V]U;G1I;F=?4')O/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N
M=%]U;F%U9&ET/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4VAA<F5"87-E9%]087EM96YT<U]U;F%U9&ET960\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y2961E96UA8FQE7T-O;6UO;E]3
M=&]C:U]A;F1?4W0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y296QA=&5D7U!A<G1Y7U1R86YS86-T:6]N<U]U;F$\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?
M0V]N=&EN9V5N8VEE<U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y,:6-E;G-I;F=?06=R965M96YT<U]U;F%U9&ET960\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#97!H86QO;E]!9W)E
M96UE;G1?=6YA=61I=&5D/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W5P<&QE;65N=&%L7T-A<VA?1FQO=U]);F9O<FUA/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1W)A;G1?26YC;VUE
M7W5N875D:71E9#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T
M>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@
M/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C
M=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0
M<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z
M17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*
M("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I
M=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S4R-38Y8C8V7V,U-F-?
M-&-B,5]B-3<V7V9D,S(P.34R9#0T8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\U,C4V.6(V-E]C-39C7S1C8C%?8C4W-E]F9#,R,#DU,F0T-&(O
M5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D1!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY$3T-5345.5"!!3D0@14Y42519($E.1D]234%4
M24]./&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^0TA!35!)3TY3($].0T],3T=9+"!)3D,N/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A
M;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P
M,#`W-S$X-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,#0M,S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE
M<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4VUA
M;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3>6UB;VP\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/F-S8G(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@
M4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#8L,C8X+#0S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`M43QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/DIU;"`S,2P-"@D),C`Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&
M;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^43$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M
M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\U,C4V.6(V-E]C-39C7S1C8C%?8C4W-E]F9#,R,#DU,F0T-&(-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3(U-CEB-C9?8S4V8U\T
M8V(Q7V(U-S9?9F0S,C`Y-3)D-#1B+U=O<FMS:&5E=',O4VAE970P,BYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P139'04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].1$5.
M4T5$($-/3E-/3$E$051%1"!"04Q!3D-%(%-(14544R`H55-$("9N8G-P.R0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;"X@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M07!R+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY!4U-%5%,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`X+#@S.2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XF;F)S<#LD(#$P+#0U-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C,V+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R86YT(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4P-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,3<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H
M97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,T,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-S8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L.3(P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#@S-2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C$R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y';V]D=VEL;#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8Y+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V.2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Q+#@P,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,BPV-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQ)04))3$E42453+"!#
M3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4RP@4D5$145-04),12!#3TU-
M3TX@4U1/0TL@04Y$(%-43T-+2$],1$524R<@15%52519("A$149)0TE4*3PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O
M=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#0Y."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#4X,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#(L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPP-S<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PV,3@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@S.2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y787)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-SDU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDW,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV,S0L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT
M-S(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2961E96UA8FQE(&-O;6UO
M;B!S=&]C:SL@)FYB<W`[)#`N,#`Q('!A<B!V86QU93L@,3(L-3,S+#,S,R!C
M;VYT:6YG96YT;'D@<'5T=&%B;&4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN
M9R!A<R!O9B!*=6QY(#,Q+"`R,#$Q(&%N9"!!<')I;"`S,"P@,C`Q,3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PQ-3DL,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PQ-3DL,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y("AD969I8VET*3H\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R
M<F5D('-T;V-K+"`F;F)S<#LD,3`@<&%R('9A;'5E.R`U-BPP-S4@<VAA<F5S
M(&%U=&AO<FEZ960[(&YO('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG
M(&%S(&]F($IU;'D@,S$L(#(P,3$@86YD($%P<FEL(#,P+"`R,#$Q/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`F
M;F)S<#LD+C`P,2!P87(@=F%L=64[(#$R-2PP,#`L,#`P('-H87)E<R!A=71H
M;W)I>F5D+"!I;F-L=61I;F<@<F5D965M86)L92!C;VUM;VX@<W1O8VLL(#,V
M+#DW,2PV-C<@86YD(#,V+#DU-BPV-C<@<VAA<F5S(&ES<W5E9"!A;F0@,S,L
M.3,P+#$P,R!A;F0@,S,L.#<P+#`P,"!S:&%R97,@;W5T<W1A;F1I;F<@87,@
M;V8@2G5L>2`S,2P@,C`Q,2!A;F0@07!R:6P@,S`L(#(P,3$L(')E<W!E8W1I
M=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4<F5A<W5R>2!S=&]C:RP@870@8V]S="P@,RPR,S8L,#`P(&-O;6UO
M;B!S:&%R97,@87,@;V8@2G5L>2`S,2P@,C`Q,2!A;F0@07!R:6P@,S`L(#(P
M,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,C4R+#`P,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#(U,BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L.#`R+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#<X-"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$X+#4Q.2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,38L-#@R+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!O
M=&AE<B!C;VUP<F5H96YS:79E(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V."PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<W1O8VMH;VQD97)S
M)R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DY,BPP
M,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,L(')E9&5E;6%B;&4@8V]M
M;6]N('-T;V-K(&%N9"!S=&]C:VAO;&1E<G,G(&5Q=6ET>2`H9&5F:6-I="D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,3$L.#`Q
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B9N8G-P.R0@,3(L-C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-3(U-CEB-C9?8S4V8U\T8V(Q7V(U-S9?9F0S
M,C`Y-3)D-#1B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S4R-38Y
M8C8V7V,U-F-?-&-B,5]B-3<V7V9D,S(P.34R9#0T8B]7;W)K<VAE971S+U-H
M965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5"2$%%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R
M;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@6U!A
M<F5N=&AE=&EC86Q=("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2961E96UA8FQE(&-O
M;6UO;B!S=&]C:RP@<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,"XP,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF
M;F)S<#LD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2961E96UA8FQE(&-O;6UO;B!S=&]C:RP@<VAA<F5S
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,BPU,S,L,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3(L-3,S+#,S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L
M=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)FYB<W`[)"`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S
M=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4V+#`W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4V+#`W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R
M97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V
M86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P+C`P,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-BPY-S$L-C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S8L.34V+#8V-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S
M:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,S+#DS,"PQ,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,RPX-S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R>2!S=&]C:RP@<VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(S-BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#(S-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S4R-38Y8C8V7V,U-F-?-&-B,5]B-3<V7V9D,S(P.34R9#0T8@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U,C4V.6(V-E]C-39C7S1C8C%?
M8C4W-E]F9#,R,#DU,F0T-&(O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%-5E!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY53D%51$E4140@
M0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%3E13($]&($]015)!5$E/
M3E,@*%531"`F;F)S<#LD*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6PN(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;"X@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(')E=F5N=64Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<G-O;F%L
M:7IE9"!O;F-O;&]G>2!S;VQU=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B9N8G-P.R0@-C`Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,2PQ,#DL,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5')A;G-L871I;VYA;"!O;F-O;&]G>2!S;VQU=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,#,S+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y,2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O
M<&5R871I;F<@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PV,S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O<W1S(&%N9"!O<&5R
M871I;F<@97AP96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O<W0@;V8@<&5R<V]N86QI>F5D(&]N8V]L;V=Y('-O
M;'5T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@S+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,R-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O<W0@;V8@=')A;G-L871I;VYA;"!O;F-O;&]G>2!S;VQU
M=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q.2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,C(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4T,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3DL,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE<R!A;F0@
M;6%R:V5T:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.#@L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<Q-RPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#0L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@8V]S=',@86YD(&]P97)A=&EN9R!E>'!E;G-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX-#@L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,#,L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S
M<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(L,C$T+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V,#,L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!I;F-O;64@
M*&5X<&5N<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT(&QI86)I
M;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<W+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/=&AE<B!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!I;F-O;64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@8F5F;W)E('!R
M;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R+#`S-RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-3DQ+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R
M(&EN8V]M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,BPP,S<L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4Y,2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R
M92!O=71S=&%N9&EN9RP@:6YC;'5D:6YG(')E9&5E;6%B;&4@8V]M;6]N('-T
M;V-K+"!B87-I8R!A;F0@9&EL=71E9"`H:6X@9&]L;&%R<R!P97(@<VAA<F4I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#`N,#0I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF
M;F)S<#LD("@P+C`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E
M<R!O=71S=&%N9&EN9RP@:6YC;'5D:6YG(')E9&5E;6%B;&4@8V]M;6]N('-T
M;V-K+"!B87-I8R!A;F0@9&EL=71E9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`T-BPT,C`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[
M)"`S,RPW-S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\U,C4V.6(V-E]C-39C7S1C8C%?8C4W-E]F9#,R,#DU,F0T-&(-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3(U-CEB-C9?8S4V8U\T
M8V(Q7V(U-S9?9F0S,C`Y-3)D-#1B+U=O<FMS:&5E=',O4VAE970P-2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14%&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^54Y!541)
M5$5$($-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#3TU0
M4D5(14Y3259%($Q/4U,@*%531"`F;F)S<#LD*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3`\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#(L,#,W+#`P,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@
M*#4Y,2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F]R96EG;B!C=7)R96YC>2!T<F%N<VQA=&EO;B!A9&IU
M<W1M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B9N8G-P.R0@*#(L,#(Y+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#4X-RPP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U,C4V
M.6(V-E]C-39C7S1C8C%?8C4W-E]F9#,R,#DU,F0T-&(-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO-3(U-CEB-C9?8S4V8U\T8V(Q7V(U-S9?9F0S
M,C`Y-3)D-#1B+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%#
M04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^54Y!541)5$5$($-/3D1%3E-%
M1"!#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3("A54T0@
M)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6PN(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@R+#`S-RPP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF
M;F)S<#LD("@U.3$L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O
M;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@
M86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#$T+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E<')E8VEA=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E(&]F
M('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-S<L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@
M87-S971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C4Q+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R
M86YT(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,L(&1E<&]S:71S(&%N9"!O=&AE
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C4L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P.2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#@R+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S."PP,#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#4Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,U-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I
M;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PU,S4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0S-BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5S=&EN9R!A8W1I=FET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.34L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P+#`P,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M8V%S:"!U<V5D(&EN(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Y-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`L,#`P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&
M:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@=')E87-U<GD@<W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,2PP,#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!E>&5R8VES92!O9B!O<'1I;VYS(&%N9"!W87)R86YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A
M<V@@<')O=FED960@8GD@*'5S960@:6XI(&9I;F%N8VEN9R!A8W1I=FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,Q+#`P,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&-H86YG92!R871E(&5F9F5C="!O;B!C87-H(&%N9"!C87-H(&5Q=6EV
M86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$96-R96%S92!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#8Q."PP,#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@T+#`P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',L(&)E9VEN;FEN9R!O9B!P
M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#0U-RPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#4W,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',L(&5N9"!O
M9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P
M.R0@."PX,SDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)FYB<W`[)"`R+#`X."PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S4R-38Y8C8V7V,U-F-?-&-B,5]B
M-3<V7V9D,S(P.34R9#0T8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\U,C4V.6(V-E]C-39C7S1C8C%?8C4W-E]F9#,R,#DU,F0T-&(O5V]R:W-H
M965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%64<^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^3W)G86YI>F%T:6]N+"!5<V4@;V8@17-T:6UA=&5S(&%N9"!"
M87-I<R!O9B!0<F5S96YT871I;VX@*'5N875D:71E9"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG
M(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W)G86YI>F%T:6]N+"!#;VYS;VQI9&%T:6]N
M(&%N9"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',@1&ES
M8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^3F]T92`Q+B8C,38P.R8C,38P.T]R
M9V%N:7IA=&EO;BP@57-E(&]F($5S=&EM871E<R!A;F0@0F%S:7,@;V8@4')E
M<V5N=&%T:6]N#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI
M;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[(#X\8G(@+SX-"CPO9&EV/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z.7!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^0VAA;7!I;VYS($]N
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M960@3VYC;VQO9WD@4V]L=71I;VYS("@F(S@R,C`[4$]3)B,X,C(Q.RDL(&%N
M9"!4<F%N<VQA=&EO;F%L($]N8V]L;V=Y(%-O;'5T:6]N<R`H)B,X,C(P.U1/
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M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.CEP=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M('=A<R!E<W1A8FQI<VAE9"!I;B!.;W9E;6)E<B`R,#$P+B8C,38P.R8C,38P
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M;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
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M:&4@4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H=&AE("8C
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M;&QY(&%C8V5P=&5D(&EN('1H92!5;FET960@4W1A=&5S("@F(S@R,C`[1T%!
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M9&5D($%P<FEL)B,Q-C`[,S`L(#(P,3$L(&%S(&9I;&5D(&]N($9O<FT@,3`M
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M(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@07!R:6PF(S$V,#LS
M,"P@,C`Q,2XF(S$V,#LF(S$V,#M#97)T86EN(')E8VQA<W-I9FEC871I;VYS
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE('!R97!A<F%T
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M<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT
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M;F1I;F<@9F]R('1H92!P97)I;V0N)B,Q-C`[)B,Q-C`[1&EL=71E9"!L;W-S
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M971H;V0N)B,Q-C`[)B,Q-C`[0V]N=&EN9V5N=&QY(&ES<W5A8FQE('-H87)E
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M96YD(&]F('1H92!C;VYT:6YG96YC>2!P97)I;V0N)B,Q-C`[)B,Q-C`[1'5E
M('1O('1H92!N970@;&]S<V5S(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($IU;'D@,S$L(#(P,3$@86YD(#(P,3`L(&)A<VEC(&%N9"!D:6QU=&5D(&QO
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M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
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M;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*
M/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.R`^/'1A8FQE
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,"4@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E
M('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$<&%D9&EN9RUB;W1T
M;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R,B4@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.R<@
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IB;VQD.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#Y4:')E
M92!-;VYT:',@16YD960@2G5L>2`S,2P-"CPO9F]N=#X-"CPO9F]N=#X-"CPO
M9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M
M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IB;VQD.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X-"CPO='(^
M/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@<W1Y;&4],T1P
M861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG
M(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
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M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R
M<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN
M;&EN93L@/C(P,3`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
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M,T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
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M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N
M=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z
M(V-C9F9C8SL@/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
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M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4]
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M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
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M(#XV-3`L,S@U#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD
M+6-O;&]R.B-F9F9F9F8[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-S8E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#Y787)R86YT<PT*/"]F;VYT/@T*/"]D:78^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^-#,Q+#8V.`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
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M;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<V)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O
M;3HR<'@[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E)E
M<W1R:6-T960@<W1O8VL-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O
M;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT
M+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
M:60[=&5X="UA;&EG;CIR:6=H=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/BT-"CPO
M9F]N=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
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M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y
M)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT
M+6%L:6=N.G)I9VAT.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,BPY-S0-"CPO9F]N
M=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP
M861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4]
M,T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[(#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-S8E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
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M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R
M('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<V)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
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M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.G)I
M9VAT.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S
M='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^.#8X+#<R,@T*/"]F;VYT/@T*/"]F
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M:#TS1#$E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG
M:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T
M>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XQ+#$Q-2PV,S(-"CPO9F]N=#X-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG
M+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I
M=CX-"CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\U,C4V.6(V-E]C-39C7S1C8C%?8C4W-E]F9#,R,#DU
M,F0T-&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3(U-CEB-C9?
M8S4V8U\T8V(Q7V(U-S9?9F0S,C`Y-3)D-#1B+U=O<FMS:&5E=',O4VAE970P
M."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15E'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E
M8V5N=&QY($ES<W5E9"!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S("AU;F%U
M9&ET960I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@
M,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^06-C;W5N=&EN9R!#:&%N9V5S(&%N9"!%<G)O<B!#;W)R96-T
M:6]N<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8V]U;G1I;F<@0VAA;F=E<R!A;F0@17)R;W(@0V]R
M<F5C=&EO;G,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
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M<'0[)R`^26X@2G5N92`R,#$Q+"!T:&4@1FEN86YC:6%L($%C8V]U;G1I;F<@
M4W1A;F1A<F1S($)O87)D("@F(S@R,C`[1D%30B8C.#(R,3LI(&ES<W5E9"!!
M8V-O=6YT:6YG(%-T86YD87)D<R!5<&1A=&4@*"8C.#(R,#M!4U4F(S@R,C$[
M*2!.;RX@,C`Q,2TP-2P@)B,X,C(P.U!R97-E;G1A=&EO;B!O9B!#;VUP<F5H
M96YS:79E($EN8V]M928C.#(R,3L@*"8C.#(R,#M!4U4@,C`Q,2TP-28C.#(R
M,3LI+B8C,38P.R8C,38P.T%352`R,#$Q+3`U('!R;W9I9&5S(&9O<B!T:&4@
M;W!T:6]N('1O('!R97-E;G0@=&AE('1O=&%L(&]F(&-O;7!R96AE;G-I=F4@
M:6YC;VUE+"!T:&4@8V]M<&]N96YT<R!O9B!N970@:6YC;VUE(&%N9"!T:&4@
M8V]M<&]N96YT<R!O9B!O=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M92`H)B,X
M,C(P.T]#228C.#(R,3LI(&5I=&AE<B!I;B!A('-I;F=L92!C;VYT:6YU;W5S
M('-T871E;65N="!O9B!C;VUP<F5H96YS:79E(&EN8V]M92!O<B!I;B!T=V\@
M<V5P87)A=&4@8G5T(&-O;G-E8W5T:79E('-T871E;65N=',N(%)E9V%R9&QE
M<W,@;V8@=VAI8V@@9F]R;6%T(&ES(&-H;W-E;BP@=&AE(&%M96YD;65N=',@
M97-T86)L:7-H(&$@<F5Q=6ER96UE;G0@9F]R(&5N=&ET:65S('1O('!R97-E
M;G0@;VX@=&AE(&9A8V4@;V8@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(')E
M8VQA<W-I9FEC871I;VX@861J=7-T;65N=',@9F]R(&ET96US('1H870@87)E
M(')E8VQA<W-I9FEE9"!F<F]M($]#22!T;R!N970@:6YC;VUE(&EN('1H92!S
M=&%T96UE;G0H<RD@=VAE<F4@=&AE(&-O;7!O;F5N=',@;V8@;F5T(&EN8V]M
M92!A;F0@=&AE(&-O;7!O;F5N=',@;V8@3T-)(&%R92!P<F5S96YT960N(%1H
M92!A;65N9&UE;G1S(&EN($%352`R,#$Q+3`U(&%R92!E9F9E8W1I=F4L(&]N
M(&$@<F5T<F]S<&5C=&EV92!B87-I<RP@9F]R('!U8FQI8R!E;G1I=&EE<R!F
M;W(@:6YT97)I;2!A;F0@86YN=6%L('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R
M($1E8V5M8F5R(#$U+"`R,#$Q+B!4:&4@861O<'1I;VX@;V8@=&AI<R!G=6ED
M86YC92!W:6QL(&YO="!H879E(&%N>2!I;7!A8W0@;VX@=&AE($-O;7!A;GDF
M(S@R,3<[<R!F:6YA;F-I86P@<&]S:71I;VX@86YD(')E<W5L=',@;V8@;W!E
M<F%T:6]N<RX-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN
M9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S
M='EL93TS1'1E>'0M:6YD96YT.CEP=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ:G5S=&EF>3L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y);B!-87D@,C`Q,2P@
M=&AE($9!4T(@:7-S=65D($%352!.;RX@,C`Q,2TP-"P@)B,X,C(P.T%M96YD
M;65N=',@=&\@06-H:65V92!#;VUM;VX@1F%I<B!686QU92!-96%S=7)E;65N
M="!A;F0@1&ES8VQO<W5R92!297%U:7)E;65N=',@:6X@52Y3+B!'04%0(&%N
M9"!)1E)3<R8C.#(R,3L@*"8C.#(R,#M!4T,@,C`Q,2TP-28C.#(R,3LI+B8C
M,38P.R8C,38P.U1H92!A;65N9&UE;G1S(&EN($%30R`R,#$Q+3`U('=E<F4@
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M<F5Q=6ER96UE;G1S(&EN($=!05`@9F]R(&UE87-U<FEN9R!F86ER('9A;'5E
M(&%N9"!F;W(@9&ES8VQO<VEN9R!I;F9O<FUA=&EO;B!A8F]U="!F86ER('9A
M;'5E(&UE87-U<F5M96YT<RXF(S$V,#LF(S$V,#M(;W=E=F5R+"!M86YY(&]F
M('1H92!A;65N9&UE;G1S(&EN($%30R`R,#$Q+3`U('=I;&P@;F]T(')E<W5L
M="!I;B!A(&-H86YG92!I;B!T:&4@87!P;&EC871I;VX@;V8@=&AE(')E<75I
M<F5M96YT<R!I;B!!4T,@.#(P+"!&86ER(%9A;'5E($UE87-U<F5M96YT+B!4
M:&4@86UE;F1M96YT<R!I;B!!4U4@,C`Q,2TP-"!A<F4@969F96-T:79E+"!O
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M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV('-T
M>6QE/3-$=&5X="UI;F1E;G0Z.7!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T:69Y.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D1U<FEN9R!$96-E;6)E
M<B8C,38P.S(P,3`L('1H92!&05-"(&ES<W5E9"!!4U4@3F\N)B,Q-C`[,C`Q
M,"TR."P@26YT86YG:6)L97,@+2!';V]D=VEL;"!A;F0@3W1H97(@*"8C.#(R
M,#M!4U4@,C`Q,"TR."8C.#(R,3LI+B!!4U4@,C`Q,"TR."!A9&1R97-S97,@
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M<B!F:7-C86P@>65A<G,@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R
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M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-3(U-CEB-C9?8S4V8U\T
M8V(Q7V(U-S9?9F0S,C`Y-3)D-#1B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S4R-38Y8C8V7V,U-F-?-&-B,5]B-3<V7V9D,S(P.34R9#0T8B]7
M;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$591SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY0<F]P97)T>2!A;F0@17%U:7!M96YT("AU;F%U9&ET
M960I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!$:7-C;&]S=7)E(%M497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX\
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M9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
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M;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC
M96YT97([(#X\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#DP)2!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/'1R/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0W-B4@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
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M="UW96EG:'0Z8F]L9#LG(#Y*=6QY(#,Q+`T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
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M:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD
M.R<@/D%P<FEL(#,P+`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z8F]L9#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^
M#0H\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E('-T
M>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ
M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
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M>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.PT*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^*'5N875D:71E9"D-
M"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X-"CPO
M='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)2!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI
M;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
M;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M1G5R;FET=7)E(&%N9"!F:7AT=7)E<PT*/"]F;VYT/@T*/"]D:78^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[
M)`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/C0T+#`P,`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
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M,"PP,#`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
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M9F]N="US:7IE.C$P<'0[)R`^0V]M<'5T97(@97%U:7!M96YT(&%N9"!S;V9T
M=V%R90T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,38W
M+#`P,`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$Q.2PP,#`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^#0H\+W1R
M/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/DQA
M8F]R871O<GD@97%U:7!M96YT#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
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M>F4Z,3!P=#LG(#XV-RPP,#`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
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M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XU-BPP,#`-
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M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C(L,#`P#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^,BPP,#`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U
M;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W-B4@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
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M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S
M;VQI9#MT97AT+6%L:6=N.G)I9VAT.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,C8L
M,#`P#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O
M;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT
M+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
M:60[=&5X="UA;&EG;CIR:6=H=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/C(T+#`P
M,`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
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M,T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
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M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^
M#0H\+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
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M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C,P-BPP,#`-"CPO9F]N=#X-"CPO
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M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
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M,3!P=#LG(#XR,3$L,#`P#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M3&5S<SH@06-C=6UU;&%T960@9&5P<F5C:6%T:6]N#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C
M:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA
M>3II;FQI;F4[(#XH.30L,#`P#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/BD-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$<&%D
M9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@
M<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA
M8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI
M;F4[(#XH-C4L,#`P#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@
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M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^4')O<&5R='D@86YD(&5Q=6EP
M;65N="P@;F5T#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ-'!X
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI
M9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB
M<W`[)`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE
M.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XR,3(L,#`P
M#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O;3HT
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
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M>F4Z,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,30V
M+#`P,`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
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M<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HY<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y$97!R96-I871I;VX@97AP96YS
M92!W87,@)FYB<W`[)#(Y+#`P,"!A;F0@)FYB<W`[)#$P+#`P,"!F;W(@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!*=6QY)B,Q-C`[,S$L(#(P,3$@86YD(#(P
M,3`L(')E<W!E8W1I=F5L>2X-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4]
M,T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D
M:78^#0H\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-3(U-CEB-C9?8S4V8U\T8V(Q7V(U-S9?9F0S,C`Y
M-3)D-#1B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S4R-38Y8C8V
M7V,U-F-?-&-B,5]B-3<V7V9D,S(P.34R9#0T8B]7;W)K<VAE971S+U-H965T
M,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$591SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M:&%R92U"87-E9"!087EM96YT<R`H=6YA=61I=&5D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@
M3V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S=',L(%-H87)E+4)A<V5D(%!A
M>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&ES8VQO<W5R92!O9B!#;VUP96YS871I;VX@4F5L
M871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6U1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD:78^/&1I
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M;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M:G5S=&EF>3MT97AT+6EN9&5N=#HY<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#Y4:&4@0V]M<&%N>2!H87,@:6X@<&QA8V4@82`R,#$P
M($5Q=6ET>2!);F-E;G1I=F4@4&QA;BP@82`R,#`X($5Q=6ET>2!);F-E;G1I
M=F4@4&QA;B!A;F0@82!$:7)E8W1O<B!#;VUP96YS871I;VX@4&QA;B!O9B`R
M,#$P+"!A;&P@;V8@=VAI8V@@87)E(&1E<V-R:6)E9"!I;B!M;W)E(&1E=&%I
M;"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS($%N;G5A;"!297!O<G0@;VX@1F]R
M;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!!<')I;"8C,38P.S,P+"`R,#$Q
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M;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ
M=7-T:69Y.W1E>'0M:6YD96YT.CEP=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!I;B!T:&4@
M86UO=6YT(&]F("9N8G-P.R0Q+#`Q-"PP,#`@86YD("9N8G-P.R0Q-S`L,#`P
M('=A<R!R96-O9VYI>F5D(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($IU
M;'D@,S$L(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I=F5L>2XF(S$V,#LF(S$V
M,#M3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!W87,@<F5C;V=N
M:7IE9"!A<R!F;VQL;W=S.@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([(#X\=&%B;&4@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DP)2!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@<W1Y
M;&4],T1P861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M8F]L9#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(R)2!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/E1H<F5E($UO
M;G1H<R!%;F1E9"!*=6QY(#,Q+`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(^
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M/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=B
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M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,C`Q,0T*/"]F;VYT/@T*/"]F
M;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'!A9&1I
M;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A
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M.R`^,C`Q,`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<V)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<"`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*
M/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F
M9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)2!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4-"CPO9F]N=#X-
M"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B9N8G-P.R0-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XY,38L,#`P#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/C$T,"PP,#`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS
M1&)A8VMG<F]U;F0M8V]L;W(Z(V9F9F9F9CL@/CQT9`T*('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<V)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I
M<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^4V%L97,@86YD(&UA
M<FME=&EN9PT*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M-S0L,#`P#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^
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M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^."PP,#`-"CPO9F]N=#X-"CPO
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M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&1I=B!S='EL93TS1'1E>'0M
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M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[)R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H
M=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y
M;&4],T1D:7-P;&%Y.FEN;&EN93L@/C(T+#`P,`T*/"]F;VYT/@T*/"]F;VYT
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M1#$E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG:'0[
M)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE
M/3-$9&ES<&QA>3II;FQI;F4[(#XR,BPP,#`-"CPO9F]N=#X-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O
M;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD
M+6-O;&]R.B-F9F9F9F8[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-S8E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
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M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C
M:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<V)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O
M='1O;3HR<'@[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E#0H\+V9O
M;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT
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M93TS1&1I<W!L87DZ:6YL:6YE.R`^,2PP,30L,#`P#0H\+V9O;G0^#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[)R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B9N8G-P.R0-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG
M:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T
M>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XQ-S`L,#`P#0H\+V9O;G0^#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^
M/&)R("\^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II
M=&%L:6,[9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^4W1O8VL@
M3W!T:6]N($=R86YT<PT*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\
M9&EV#0H@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z
M.7!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^0FQA8VLM
M4V-H;VQE<R!A<W-U;7!T:6]N<R!U<V5D('1O(&-A;&-U;&%T92!T:&4@9F%I
M<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960@9'5R:6YG('1H92!T:')E92!M
M;VYT:',@96YD960@2G5L>2`S,2P@,C`Q,2!A;F0@,C`Q,"!W97)E(&%S(&9O
M;&QO=W,Z#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[(#X\8G(@+SX-"CPO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.F-E;G1E<CL@/CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3`E('-T>6QE/3-$)V9O;G0M
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M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^5&AR964@36]N=&AS($5N9&5D
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M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O
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M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQF;VYT('-T>6QE/3-$
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M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T
M<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[(#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
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M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^-BXP#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F
M9F8[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
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M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$N.24@+2`R+C(-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XE#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<-"B!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XR+C`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
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M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
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M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,3`W+C$E("T@
M,3`W+C,-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XE#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^,3`T#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)0T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$
M8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<V)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^1&EV:61E;F0@>6EE;&0-
M"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C`-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XE#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^,`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B4-"CPO
M9F]N=#X-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*
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M(#,Q+"`R,#$Q(&%N9"`R,#$P('=A<R`F;F)S<#LD,"XW-"!A;F0@)FYB<W`[
M)#`N-S4L(')E<W!E8W1I=F5L>2X@5&AE($-O;7!A;GDF(S@R,3<[<R!S=&]C
M:R!O<'1I;VYS(&%C=&EV:71Y(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($IU;'D@,S$L(#(P,3$@:7,@87,@9F]L;&]W<SH-"CPO9F]N=#X-"CPO9&EV
M/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@
M/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R
M.R`^/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Y,"4@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-#`E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M:61T:#TS1#@E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
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M<"`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
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M<#TS1&YO=W)A<"`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M(#Y796EG:'1E9`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T
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M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-
M"CPO=&0^#0H\+W1R/CQT<CX\=&0-"B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0T,"4@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$."4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$."4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQD:78@<W1Y;&4],T1T97AT+6%L
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M86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$."4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
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M,T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L
M9#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQF;VYT('-T
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M(&YO=W)A<#TS1&YO=W)A<"`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N
M=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^079E<F%G90T*/"]F;VYT/@T*
M/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
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M<"`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)R`^4F5M86EN:6YG#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^
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M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T
M<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E
M(&-O;'-P86X],T0R#0H@;F]W<F%P/3-$;F]W<F%P(#X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG(#Y.;VXM
M#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IB;VQD.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z8F]L9#LG(#YA;F0-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N
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M;VYT<F%C='5A;`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T
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M86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^26YT<FEN<VEC#0H\
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M93TS1&1I<W!L87DZ:6YL:6YE.R`^16UP;&]Y965S#0H\+V9O;G0^#0H\+V9O
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M9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
M:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@
M/D5M<&QO>65E<PT*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[
M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
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M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#Y4;W1A;`T*/"]F;VYT/@T*/"]F
M;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
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M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^
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M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
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M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQF;VYT('-T>6QE/3-$)V1I
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQF;VYT('-T
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M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
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M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/D]U='-T86YD:6YG+"!-87D@,2P@,C`Q,0T*/"]F;VYT/@T*/"]D:78^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^,2PV,3`L,#`P#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^,3(L-S$P+#DT.`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$T+#,R,"PY
M-#@-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,"XX.`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
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M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/C@N-#0-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;0T*
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
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M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$
M8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0P)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^1W)A;G1E9`T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0W)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^+0T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
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M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/C(T-2PP,#`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XR-#4L,#`P#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^,"XY,@T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M,T0R(&YO=W)A<#TS1&YO=W)A<"`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R
M;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0P)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^17AE<F-I<V5D#0H\+V9O;G0^#0H\
M+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
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M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^+0T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
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M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
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M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`-"B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
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M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/D9O<F9E:71E9`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^+0T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B@U,"PP,#`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XI#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^*#4P+#`P,`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/BD-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
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M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0X)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^#0H\
M+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,"4@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/D5X<&ER960-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
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M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M+0T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0-"B!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O
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M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4]
M,T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[(#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-#`E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I
M;F<M8F]T=&]M.C)P>#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^0VAA;F=E(&EN(&5M<&QO>65E('-T871U<PT*/"]F;VYT/@T*/"]D
M:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1'!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA
M8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.G)I9VAT.R<@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L
M87DZ:6YL:6YE.R`^+0T*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
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M9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@
M<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA
M8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI
M;F4[(#XM#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O
M='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT
M97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@
M<V]L:60[=&5X="UA;&EG;CIR:6=H=#LG(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/BT-
M"CPO9F]N=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C)P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'!A9&1I;F<M8F]T=&]M
M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
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M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@
M<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[(#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-#`E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<-"B`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0W)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$."4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*
M/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[(#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^3W5T<W1A;F1I;F<L($IU;'D@,S$L(#(P
M,3$-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O;3HT<'@[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
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M9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,2PV,3`L,#`P#0H\+V9O
M;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O;3HT<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
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M(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,3(L.3`U+#DT.`T*
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M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI
M9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B;&4[
M=&5X="UA;&EG;CIR:6=H=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/C$T+#4Q-2PY
M-#@-"CPO9F]N=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'!A9&1I;F<M8F]T=&]M
M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
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M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O
M;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
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M.C$P<'0[)R`^."XQ,PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
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M;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W#0H@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF;F)S<#LD#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*
M/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[(#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
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M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-R4@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
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M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
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M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C
M:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W
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M(#Y697-T960@86YD(&5X<&5C=&5D('1O('9E<W0@87,@;V8@2G5L>2`S,2P@
M,C`Q,0T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
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M9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M
M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XQ+#8Q,"PP,#`-"CPO
M9F]N=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
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M.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-R4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E
M>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XQ,BPX-SDL,C@Q
M#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O;3HT
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
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M,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,30L-#@Y
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
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M:7IE.C$P<'0[)R`^,"XX.`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$<&%D9&EN9RUB
M;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
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M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'!A9&1I;F<M
M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
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M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C
M.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
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M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
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M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
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M9RUB;W1T;VTZ-'!X.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HM.7!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z.7!T
M.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^17AE<F-I<V%B;&4@87,@;V8@2G5L>2`S,2P@,C`Q,0T*/"]F;VYT
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M;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[
M)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)0T*('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIR
M:6=H=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@
M<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/C,L.#4Y+#(U,`T*/"]F;VYT/@T*
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M:61T:#TS1#$E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B;&4[=&5X="UA;&EG
M;CIR:6=H=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O
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M;2!W:61T:#TS1#$E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O
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M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[<&%D9&EN9RUB
M;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C`N
M.#8-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP
M861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M
M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XV
M+C,S#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T1P861D:6YG+6)O='1O;3HT<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
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M<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M
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M:7IE.C$P<'0[)R`^02!S=6UM87)Y(&]F('1H92!A8W1I=FET>2!R96QA=&5D
M('1O(')E<W1R:6-T960@<W1O8VL@9W)A;G1S(&ES(&%S(&9O;&QO=W,Z#0H\
M+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I
M<W!L87DZ8FQO8VL[(#X\8G(@+SX-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.F-E;G1E<CL@/CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$-S`E('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\='(^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8T)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O
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M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG(#Y796EG:'1E9`T*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
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M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T
M)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQD:78@<W1Y;&4],T1T
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M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<-"B!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
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M:#TS1#$T)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQD:78@<W1Y
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M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<"`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M9'1H/3-$,30E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[
M)R`^1&%T92!&86ER#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG
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M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
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M;W1A;`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L
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M,B!N;W=R87`],T1N;W=R87`@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E
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M)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG
M(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<CX\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ
M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O
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M1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/E-H87)E
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$T)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQF;VYT('-T>6QE
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M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*
M/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[(#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
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M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG#0H@/C$P,"PP,#`-"CPO9F]N=#X-"CPO
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M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF;F)S<#LD#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/C`N.3`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
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M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
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M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XM#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.PT*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N
M9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8T)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^5F5S=&5D#0H\+V9O;G0^#0H\+V1I=CX-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
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M86X[9F]N="US:7IE.C$P<'0[)R`^-3`L,#`P#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/C`N.3`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M
M8V]L;W(Z(V9F9F9F9CL@/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V
M-"4@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[
M)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI
M9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF
M;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XM#0H\+V9O;G0^#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
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M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I
M;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1&)A
M8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0V-"4@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
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M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
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M('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8T)2!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/DYO;G9E<W1E9"!A<R!O9B!*=6QY(#,Q+"`R,#$Q#0H\
M+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ
M<FEG:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT
M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XU,"PP,#`-"CPO9F]N=#X-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG
M+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)2!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O
M;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,"XY,`T*
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M:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S
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M+"`R,#$Q('=A<R`F;F)S<#LD-#,L,#`P+@T*/"]F;VYT/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R
M("\^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II
M=&%L:6,[9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^4W1O8VL@
M4'5R8VAA<V4@5V%R<F%N=',-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4]
M,T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D
M:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N
M=#HY<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y!<R!O
M9B!*=6QY(#,Q+"`R,#$Q+"!T:&4@0V]M<&%N>2!H87,@=V%R<F%N=',@;W5T
M<W1A;F1I;F<@9F]R('1H92!P=7)C:&%S92!O9B`Q+#@Y-RPP,3D@<VAA<F5S
M(&]F(&ET<R!C;VUM;VX@<W1O8VLL(&%L;"!O9B!W:&EC:"!A<F4@97AE<F-I
M<V%B;&4N)B,Q-C`[)B,Q-C`[3V8@=&AE<V4@=V%R<F%N=',L(#$L,C8V+#8V
M-R!W97)E(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($%P<FEL(#(P
M,3$@9FEN86YC:6YG(&%R<F%N9V5M96YT(&%N9"!A<F4@86-C;W5N=&5D(&9O
M<B!A<R!L:6%B:6QI=&EE<R!A<R!F=7)T:&5R(&1I<V-U<W-E9"!I;B!.;W1E
M(#4N(#$U+#`P,"!W87)R86YT<R!W97)E(&5X97)C:7-E9"!O;B!*=6QY(#$Q
M+"`R,#$Q+B8C,38P.R8C,38P.T%S(&]F($IU;'D@,S$L(#(P,3$L('1H92!W
M96EG:'1E9"!A=F5R86=E(&5X97)C:7-E('!R:6-E(&]F('1H97-E('=A<G)A
M;G1S('=A<R`F;F)S<#LD,"XW,R!A;F0@=&AE('=E:6=H=&5D(&%V97)A9V4@
M8V]N=')A8W1U86P@;&EF92!W87,@,RXT-B!Y96%R<RX-"CPO9F]N=#X-"CPO
M9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%64<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4F5D965M86)L92!#;VUM;VX@4W1O8VL@86YD(%-T;V-K(%!U<F-H87-E(%=A
M<G)A;G0@*'5N875D:71E9"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5L+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY2961E96UA8FQE($-O;6UO;B!3=&]C:R!A
M;F0@4W1O8VL@4'5R8VAA<V4@5V%R<F%N="!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E9&5E;6%B;&4@
M0V]M;6]N(%-T;V-K(&%N9"!3=&]C:R!0=7)C:&%S92!787)R86YT(%M497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX\
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M<'0[)R`^3VX@36%R8V@@,C0L(#(P,3$L('1H92!#;VUP86YY(&5N=&5R960@
M:6YT;R!A(%-E8W5R:71I97,@4'5R8VAA<V4@06=R965M96YT('=I=&@@<V5V
M97)A;"!A8V-R961I=&5D(&EN=F5S=&]R<R!F;W(@=&AE('-A;&4@=&\@=&AE
M(&EN=F5S=&]R<R!O9B!A;B!A9V=R96=A=&4@,3(L-3,S+#,S,R!S:&%R97,@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!#;VUM;VX@4W1O8VL@870@82!P=7)C
M:&%S92!P<FEC92!O9B`F;F)S<#LD,"XW-2!P97(@<VAA<F4L(&]R(&%N(&%G
M9W)E9V%T92!O9B`F;F)S<#LD.2PT,#`L,#`P+"!O9B!W:&EC:"P@)FYB<W`[
M)#4P,"PP,#`@=V%S('-O;&0@=&\@;V9F:6-E<G,@86YD(&1I<F5C=&]R<R!O
M9B!T:&4@0V]M<&%N>2XF(S$V,#LF(S$V,#M!<R!P87)T(&]F('1H:7,@=')A
M;G-A8W1I;VXL('1H92!#;VUP86YY(&%L<V\@:7-S=65D('=A<G)A;G1S('1O
M('!U<F-H87-E(&%N(&%G9W)E9V%T92`Q+#(V-BPV-C<F(S$V,#LF(S$V,#MS
M:&%R97,@;V8@0V]M;6]N(%-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F
M("9N8G-P.R0P+CDP('!E<B!S:&%R92XF(S$V,#LF(S$V,#M4:&5S92!W87)R
M86YT<R!E>'!I<F4@9FEV92!Y96%R<R!A9G1E<B!T:&4@8VQO<VEN9R!D871E
M+"!W:&EC:"!O8V-U<G)E9"!O;B!!<')I;"`T+"`R,#$Q+B8C,38P.R8C,38P
M.U1H92!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="!C;VYT86EN<R!C
M97)T86EN(&%N=&DM9&EL=71I;VX@<')O=&5C=&EO;G,@9F]R('1H92!I;G9E
M<W1O<G,@86YD(&-E<G1A:6X@<F5G:7-T<F%T:6]N(')I9VAT<R!W:71H(')E
M<W!E8W0@=&\@=&AE('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@:7-S=65D('1O
M('1H92!I;G9E<W1O<G,N)B,Q-C`[)B,Q-C`[1G5R=&AE<FUO<F4L(&EN=F5S
M=&]R<R!W:6QL(&AA=F4@=&AE(')I9VAT('1O(')E<75I<F4@=&AE($-O;7!A
M;GD@=&\@<F5D965M('1H92!P=7)C:&%S960@8V]M;6]N('-H87)E<R!H96QD
M(&)Y('-U8V@@:6YV97-T;W)S("AT:&4@)B,X,C(P.U!U="!/<'1I;VXF(S@R
M,C$[*2!F;W(@8V%S:"!F;W(@)FYB<W`[)#`N-S4@<&5R('-H87)E('5P;VX@
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M:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S
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M-C`[)B,Q-C`[56YD97(@=&AE<V4@<')O=FES:6]N<RP@=&AE(&5X97)C:7-E
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M<'0[)R`^5&AE($-O;7!A;GD@:&%S(&=R86YT960@9&5M86YD(')E9VES=')A
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M<&5C:69I960@=&EM92!P97)I;V0N)B,Q-C`[)B,Q-C`[268@=&AE($-O;7!A
M;GD@:7,@;F]T(&%B;&4@=&\@8V]M<&QY('=I=&@@=&AE<V4@<F5G:7-T<F%T
M:6]N(')E<75I<F5M96YT<RP@=&AE($-O;7!A;GD@=VEL;"!B92!R97%U:7)E
M9"!T;R!P87D@8V%S:"!P96YA;'1I97,@97%U86P@=&\@,2XP)2!O9B!T:&4@
M86=G<F5G871E(%!U<F-H87-E(%!R:6-E('!A:60@8GD@=&AE(&EN=F5S=&]R
M<R!F;W(@96%C:"`S,"UD87D@<&5R:6]D(&EN('=H:6-H(&$@4F5G:7-T<F%T
M:6]N($1E9F%U;'0L(&%S(&1E9FEN960@:6X@=&AE(%-E8W5R:71I97,@4'5R
M8VAA<V4@06=R965M96YT+"!E>&ES=',N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A
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M96YT(&%R<F%N9V5M96YT(&ES("9N8G-P.R0T,2PP,#`@9F]R(&5A8V@@,S`M
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M,T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D
M:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N
M=#HY<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y4:&4@
M0V]M<&%N>2!H87,@86-C;W5N=&5D(&9O<B!T:&4@=V%R<F%N=',@:7-S=65D
M(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@4V5C=7)I=&EE<R!0=7)C:&%S92!!
M9W)E96UE;G0@87,@;&EA8FEL:71I97,@8F%S960@;VX@=&AE(&5X97)C:7-E
M('!R:6-E(')E<V5T('!R;W9I<VEO;G,@9&5S8W)I8F5D(&%B;W9E+B8C,38P
M.R8C,38P.U1H:7,@;&EA8FEL:71Y+"!W:&EC:"!I<R!R96-O<F1E9"!A="!F
M86ER('9A;'5E(&]N('1H92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D(&-O;F1E
M;G-E9"!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E=',L('1O=&%L960@)FYB
M<W`[)#DS-BPP,#`@870@=&AE('1I;64@;V8@=&AE(&-L;W-E(&]F('1H92!3
M96-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="XF(S$V,#LF(S$V,#M!<R!O
M9B!!<')I;"`S,"P@,C`Q,2P@=&AE(&9A:7(@=F%L=64@;V8@=&AE<V4@=V%R
M<F%N=',@:6YC<F5A<V5D("9N8G-P.R0S-BPP,#`@=&\@)FYB<W`[)#DW,BPP
M,#`N)B,Q-C`[)B,Q-C`[1'5R:6YG('1H92!Q=6%R=&5R(&5N9&5D($IU;'D@
M,S$L(#(P,3$L('1H92!F86ER('9A;'5E(&]F('1H97-E('=A<G)A;G1S(&1E
M8W)E87-E9"!B>2`F;F)S<#LD,3<W+#`P,"!T;R`F;F)S<#LD-SDT+#`P,"XF
M(S$V,#LF(S$V,#M4:&4@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=&AE<V4@
M=V%R<F%N=',@:&%S(&)E96XL(&%N9"!W:6QL(&)E+"!R96-O9VYI>F5D(&%S
M(&]T:&5R(&EN8V]M92`H97AP96YS92D@;VX@=&AE($-O;7!A;GDF(S@R,3<[
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M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.R`^/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,"4@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.PT*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"`^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^2G5L>2`S
M,2P-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT
M97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG(#Y!<')I;"`S,"P-"CPO9F]N=#X-
M"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<V)2!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C)P
M>#L-"B`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O
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M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@/CQF;VYT('-T>6QE/3-$
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M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T
M<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[(#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
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M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XU+C`-"CPO
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M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/E)I<VLM9G)E92!I;G1E<F5S="!R871E<PT*/"]F;VYT/@T*/"]D
M:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O
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M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,2XT#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)0T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C(N
M,`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
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M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/C$P,PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B4-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O
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M;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
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M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D1I=FED
M96YD('EI96QD#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
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M,T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)0T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/C`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
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M.C$P<'0[)R`^5&AE($-O;7!A;GD@=VEL;"!C;VYT:6YU92!T;R!A9&IU<W0@
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M<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O
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M9"!U;F1E<B!T:&4@8V%P=&EO;B`F(S@R,C`[4F5D965M86)L92!C;VUM;VX@
M<W1O8VLF(S@R,C$[(&]N('1H92!A8V-O;7!A;GEI;F<@0V]N9&5N<V5D($-O
M;G-O;&ED871E9"!"86QA;F-E(%-H965T<RXF(S$V,#LF(S$V,#M4:&4@=&]T
M86P@86UO=6YT(&%L;&]C871E9"!T;R!T:&5S92!C;VUM;VX@<VAA<F5S('=A
M<R`F;F)S<#LD."PQ-3DL,#`P+B8C,38P.R8C,38P.U1H:7,@86QL;V-A=&EO
M;B!I<R!E<75A;"!T;R!T:&4@=&]T86P@<')O8V5E9',@;V8@)FYB<W`[)#DL
M-#`P+#`P,"P@;&5S<R!T:&4@86UO=6YT(&%L;&]C871E9"!T;R!T:&4@=V%R
M<F%N=',@;V8@)FYB<W`[)#DS-BPP,#`@86YD(&ES(&%L<V\@;F5T(&]F(&1I
M<F5C="!A;F0@:6YC<F5M96YT86P@8V]S=',@87-S;V-I871E9"!W:71H('1H
M92!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="!O9B`F;F)S<#LD,S`U
M+#`P,"X-"CPO9F]N=#X-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%64<^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@
M*'5N875D:71E9"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5L+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS($1I<V-L;W-U<F4@6U1E
M>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
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M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
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M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0^
M#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T
M:69Y.W1E>'0M:6YD96YT.CEP=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0^#0H\+V9O;G0^#0H\+V1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT
M.CEP=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^1'5R
M:6YG('1H92!T:')E92!M;VYT:',@96YD960@2G5L>2`S,2P@,C`Q,2!A;F0@
M,C`Q,"P@=&AE($-O;7!A;GD@<&%I9"!O;F4@;V8@:71S(&1I<F5C=&]R<R!A
M;F0@9F]R;65R($-H:65F($5X96-U=&EV92!/9F9I8V5R+"`F;F)S<#LD,3@L
M,#`P(&%N9"`F;F)S<#LD,34L,#`P+"!R97-P96-T:79E;'DL(&EN(&-O;G-U
M;'1I;F<@9F5E<RXF(S$V,#LF(S$V,#M$=7)I;F<@=&AE('1H<F5E(&UO;G1H
M<R!E;F1E9"!*=6QY(#,Q+"`R,#$Q(&%N9"`R,#$P+"!T:&4@0V]M<&%N>2!P
M86ED(&-E<G1A:6X@;65M8F5R<R!O9B!I=',@0F]A<F0@;V8@1&ER96-T;W)S
M("9N8G-P.R0Q-BPP,#`@86YD("9N8G-P.R0Q,"PP,#`L(')E<W!E8W1I=F5L
M>2P@9F]R(&-O;G-U;'1I;F<@<V5R=FEC97,@=6YR96QA=&5D('1O('1H96ER
M(&1U=&EE<R!A<R!B;V%R9"!M96UB97)S+B8C,38P.R8C,38P.U1H92!#;VUP
M86YY(&EN8W5R<F5D("9N8G-P.R0T+#`P,"!I;B!E>'!E;G-E<R!F;W(@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!*=6QY(#,Q+"`R,#$Q(&9R;VT@82!S=6)S
M=&%N=&EA;"!S=&]C:VAO;&1E<B!O9B!T:&4@0V]M<&%N>2!F;W(@8V]N<W5L
M=&EN9R!F965S+B`F;F)S<#LD,BPP,#`@=V%S('!A>6%B;&4@=&\@=&AI<R!S
M=&]C:VAO;&1E<B!A<R!O9B!*=6QY(#,Q+"`R,#$Q+B!!<R!O9B!T:&4@9&%T
M92!O9B!T:&ES(&9I;&EN9RP@=&AE($-O;7!A;GD@:&%S('-A=&ES9FEE9"!T
M:&ES(&]B;&EG871I;VXN($YO('-U8V@@97AP96YS97,@=V5R92!I;F-U<G)E
M9"!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!*=6QY(#,Q+"`R,#$P+@T*
M/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)R`^4F5V96YU90T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL
M93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\
M+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD
M96YT.CEP=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D1U
M<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($IU;'D@,S$L(#(P,3$L('1H
M92!#;VUP86YY(')E8V]G;FEZ960@)FYB<W`[)#(P+#`P,"!I;B!R979E;G5E
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M;'D@,S$L(#(P,3`N#0H\+V9O;G0^#0H\+V1I=CX-"CPO9&EV/@T*/"]D:78^
M#0H\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-3(U-CEB-C9?8S4V8U\T8V(Q7V(U-S9?9F0S,C`Y-3)D
M-#1B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S4R-38Y8C8V7V,U
M-F-?-&-B,5]B-3<V7V9D,S(P.34R9#0T8B]7;W)K<VAE971S+U-H965T,3,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$591SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H=6YA=61I=&5D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI
M=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S($1I<V-L;W-U<F4@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX\
M9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T
M:69Y.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^3F]T92`W+B!#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE
M<PT*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV('-T>6QE/3-$
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T:69Y.R`^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^3W!E<F%T:6YG($QE87-E<PT*/"]F;VYT/@T*/"]D
M:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.R`^/&)R("\^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z.7!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[=&5X="UA;&EG;CIJ=7-T:69Y.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/D%S(&]F($IU;'D@,S$L(#(P,3$L('1H92!#;VUP86YY(&QE
M87-E<R!O9F9I8V4@86YD(&QA8F]R871O<GD@<W!A8V4@=6YD97(@82!N;VXM
M8V%N8V5L86)L92!O<&5R871I;F<@;&5A<V4@:6X@0F%L=&EM;W)E+"!-87)Y
M;&%N9"P@=VAI8V@@97AP:7)E<R!I;B!!<')I;"`R,#$T+"!O9F9I8V4@<W!A
M8V4@=6YD97(@82!N;VXM8V%N8V5L86)L92!O<&5R871I;F<@;&5A<V4@:6X@
M4F$F(S@R,3<[86YA;F$L($ES<F%E;"P@=VAI8V@@97AP:7)E<R!I;B!*=6QY
M(#(P,3(L(&%N9"!O9F9I8V4@<W!A8V4@:6X@2&%C:V5N<V%C:RP@3F5W($IE
M<G-E>2!U;F1E<B!A(&YO;BUC86YC96QL86)L92!O<&5R871I;F<@;&5A<V4L
M('=H:6-H(&5X<&ER97,@:6X@,C`Q-"X\9F]N="!S='EL93TS1&1I<W!L87DZ
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^)B,Q-C`[#0H\+V9O;G0^4F5N="!E
M>'!E;G-E('5N9&5R(&%L;"!L96%S92!A9W)E96UE;G1S('=A<R!A<'!R;WAI
M;6%T96QY("9N8G-P.R0S-BPW,#`@86YD("9N8G-P.R0Q-"PR,#`@9F]R('1H
M92!T:')E92!M;VYT:',@96YD960@2G5L>2`S,2P@,C`Q,2!A;F0@,C`Q,"P@
M<F5S<&5C=&EV96QY+@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\
M9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T
M:69Y.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^4F5S96%R8V@@86YD($1E=F5L
M;W!M96YT($UA=&5R:6%L<R!0=7)C:&%S92!!9W)E96UE;G0-"CPO9F]N=#X-
M"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT
M.CEP=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.W1E>'0M86QI9VXZ:G5S=&EF>3L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#Y);B!&96)R=6%R>2`R,#$P+"!T:&4@0V]M<&%N>2!E
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M<F]X:6UA=&5L>2`F;F)S<#LD,S<L,#`P(&9O<B`Q."!M;VYT:',L(&-O;6UE
M;F-I;F<@36%R8V@@,2P@,C`Q,"XF(S$V,#LF(S$V,#M&=71U<F4@<&%Y;65N
M=',@9'5E('5N9&5R('1H92!A9W)E96UE;G0@=&]T86P@)FYB<W`[)#$T-"PP
M,#`@870@2G5L>2`S,2P@,C`Q,2!A;F0@87)E(&1U92!D=7)I;F<F(S$V,#MT
M:&4@<F5M86EN9&5R(&]F('1H92!F:7-C86P@>65A<B!E;F1I;F<@07!R:6P@
M,S`L(#(P,3(N#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI
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M="US:7IE.C$P<'0[)R`^5&AE($-O;7!A;GD@:7,@<&%R='D@=&\@8V5R=&%I
M;B!L96=A;"!M871T97)S(&%R:7-I;F<@:6X@=&AE(&]R9&EN87)Y(&-O=7)S
M92!O9B!I=',@8G5S:6YE<W,N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@:&%S
M(&5V86QU871E9"!I=',@<&]T96YT:6%L(&5X<&]S=7)E('1O('1H97-E(&QE
M9V%L(&UA='1E<G,L(&%N9"!H87,@8V]N8VQU9&5D('1H870@=&AE<F4@=V5R
M92!N;R!R96%S;VYA8FQY('!O<W-I8FQE(&]R('!R;V)A8FQE(&QI86)I;&ET
M:65S(&%T($IU;'D@,S$L(#(P,3$@86YD($%P<FEL(#,P+"`R,#$Q+B8C,38P
M.R8C,38P.U1H92!#;VUP86YY(&ES(&YO="!A=V%R92!O9B!A;GD@;W1H97(@
M;6%T=&5R<R!T:&%T('=O=6QD(&AA=F4@82!M871E<FEA;"!I;7!A8W0@;VX@
M=&AE($-O;7!A;GDF(S@R,3<[<R!F:6YA;F-I86P@<&]S:71I;VX@;W(@<F5S
M=6QT<R!O9B!O<&5R871I;VYS+@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL
M93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\
M+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^4F5G:7-T<F%T:6]N(%!A
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE
M($-O;7!A;GD@:&%S(&5N=&5R960@:6YT;R!R96=I<W1R871I;VX@<FEG:'1S
M(&%G<F5E;65N=',@:6X@8V]N;F5C=&EO;B!W:71H(&$@<')I=F%T92!P;&%C
M96UE;G0@;V8@:71S('-E8W5R:71I97,L('=H:6-H(&-L;W-E9"!D=7)I;F<@
M07!R:6P@,C`Q,2!A;F0@:7,@9&ES8W5S<V5D(&UO<F4@9G5L;'D@:6X@3F]T
M92`U+B8C,38P.R8C,38P.U1H:7,@<F5G:7-T<F%T:6]N(')I9VAT<R!A9W)E
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M=&EA;"!P96YA;'1I97,@87,@;V8@2G5L>2`S,2P@,C`Q,2X-"CPO9F]N=#X-
M"CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\U,C4V.6(V-E]C-39C7S1C8C%?8C4W-E]F9#,R,#DU,F0T
M-&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3(U-CEB-C9?8S4V
M8U\T8V(Q7V(U-S9?9F0S,C`Y-3)D-#1B+U=O<FMS:&5E=',O4VAE970Q-"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15E'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQI8V5N
M<VEN9R!!9W)E96UE;G1S("AU;F%U9&ET960I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EC96YS:6YG($%G<F5E
M;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,:6-E;G-I;F<@06=R965M96YT<R!$:7-C;&]S=7)E
M(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^1'5R:6YG(&9I<V-A;"`R,#$Q
M+"!T:&4@0V]M<&%N>2!W87,@82!P87)T>2!T;R!S979E<F%L(&1I9F9E<F5N
M="!L:6-E;G-I;F<@86=R965M96YT<RP@86QL(&]F('=H:6-H(&%R92!D97-C
M<FEB960@:6X@;6]R92!D971A:6P@:6X@=&AE($-O;7!A;GDF(S@R,3<[<R!!
M;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@
M07!R:6PF(S$V,#LS,"P@,C`Q,2XF(S$V,#LF(S$V,#M$=7)I;F<@07!R:6P@
M,C`Q,2P@=&AE($-O;7!A;GD@=&5R;6EN871E9"!A;&P@;V8@=&AE<V4@;&EC
M96YS:6YG(&%G<F5E;65N=',@=VET:"!T:&4@97AC97!T:6]N(&]F('1H92!,
M:7!O<V]M92!/<'1I;VX@06=R965M96YT+"!W:&EC:"!I<R!D97-C<FEB960@
M9G5R=&AE<B!B96QO=RXF(S$V,#LF(S$V,#M!;&P@<FEG:'1S(')E;&%T960@
M=&\@86QL(&]T:&5R(&QI8V5N<VEN9R!A9W)E96UE;G1S('1H870@=V5R92!T
M97)M:6YA=&5D(&1U<FEN9R!!<')I;"`R,#$Q('=E<F4@<F5T=7)N960@=&\@
M=&AE('5N9&5R;'EI;F<@8V]M<&%N:65S(&%N9"!N;R!A;6]U;G1S('=E<F4@
M9'5E('5N9&5R('1H97-E(&]T:&5R(&%G<F5E;65N=',@87,@;V8@07!R:6P@
M,S`L(#(P,3$N#0H\+V9O;G0^#0H\+V1I=CX\9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z.7!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&)R("\^#0I);B!&96)R=6%R>2`R
M,#$P+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@97AC;'5S:79E(&]P
M=&EO;B!A9W)E96UE;G0@=VET:"!A($-A;F%D:6%N(&-O;7!A;GD@9F]R('=H
M:6-H(&ET('!A:60@86YD(&5X<&5N<V5D("9N8G-P.R0T,"PP,#`@9'5R:6YG
M('1H92!#;VUP86YY)B,X,C$W.W,@9FES8V%L(#(P,3`@>65A<BXF(S$V,#LF
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M:"!!<')I;"`R,#$Q+B8C,38P.R8C,38P.T1U<FEN9R!T:&4@;W!T:6]N('EE
M87(L('1H92!#;VUP86YY('!E<F9O<FUE9"!V87)I;W5S('1U;6]R9W)A9G0@
M=&5S=&EN9R!O;B!T:&4@;F%N;W!A<G1I8VQE(&-O;7!O=6YD+B!);B!-87)C
M:"`R,#$Q+"!T:&4@0V]M<&%N>2!E>&5R8VES960@:71S(&]P=&EO;B!T;R!L
M:6-E;G-E($ER:6YO<&AO<F4@0RP@82!L:7!O<V]M86P@9F]R;75L871I;VX@
M;V8@27)I;F]T96-A;BX@56YD97(@=&AE('1E<FUS(&]F('1H92!A9W)E96UE
M;G0L('1H92!C;VUP86YY)B,X,C$W.W,@97AE<F-I<V4@;V8@=&AE(&]P=&EO
M;B!R97-U;'1E9"!I;B!A;6]U;G1S(&1U92!T;R!T:&4@0V%N861I86X@8V]M
M<&%N>2!O9B`F;F)S<#LD.#4L,#`P(&-O;7!R:7-E9"!O9B!T:&4@;W!T:6]N
M(&5X97)C:7-E('!R:6-E(&%N9"!R96EM8G5R<V5M96YT('1O('1H92!#86YA
M9&EA;B!C;VUP86YY(&9O<B!P87-T('!A=&5N="!C;W-T<RP@=VAI8V@@:7,@
M<F5C;W)D960@87,@82!L:6%B:6QI='D@87,@;V8@2G5L>2`S,2P@,C`Q,2!A
M;F0@07!R:6P@,S`L(#(P,3$N)B,Q-C`[)B,Q-C`[07,@;V8@=&AE(&1A=&4@
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M<V5D('5P;VX@<F5V96YU97,N)B,Q-C`[)B,Q-C`[)B,Q-C`[0V]M;65N8VEN
M9R!W:71H('1H92!S96-O;F0@86YN:79E<G-A<GD@;V8@=&AE(&%G<F5E;65N
M="`H36%R8V@@,C`Q,RDL('1H92!#;VUP86YY('=I;&P@8F4@;V)L:6=A=&5D
M('1O('!A>2!A(&UI;FEM=6T@86YN=6%L(')O>6%L='D@;V8@)FYB<W`[)#$P
M+#`P,"`H0V%N861I86XI+@T*/"]F;VYT/@T*/"]D:78^#0H\+V1I=CX\9&EV
M('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[(#X\8G(@
M+SX-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%64<^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V5P:&%L;VX@06=R965M96YT("AU;F%U9&ET960I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V5P:&%L
M;VX@06=R965M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V5P:&%L;VX@06=R965M96YT(%M497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX\
M9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T
M:69Y.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^3F]T92`Y+B!#97!H86QO;B!!9W)E96UE;G0-"CPO9F]N=#X-
M"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT
M.CEP=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.W1E>'0M86QI9VXZ:G5S=&EF>3L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#Y/;B!-87)C:"8C,38P.S$V+"`R,#$Q+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D(&EN=&\@86X@86=R965M96YT('=I=&@@0V5P:&%L;VXL
M($EN8RXL("@F(S@R,C`[0V5P:&%L;VXF(S@R,C$[*2P@<'5R<W5A;G0@=&\@
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M86X@:6YI=&EA=&EO;B!F964@;V8@)FYB<W`[)#$L,SDP+#`P,"!T;R!T:&4@
M0V]M<&%N>2!W:&EC:"!I<R!R969L96-T960@=VET:&EN(&1E9F5R<F5D(')E
M=F5N=64@;VX@=&AE($-O;F1E;G-E9"!#;VYS;VQI9&%T960@0F%L86YC92!3
M:&5E=',@87,@;V8@2G5L>2`S,2P@,C`Q,2!A;F0@07!R:6P@,S`L(#(P,3$N
M(%1H92!#;VUP86YY(&%N=&EC:7!A=&5S('1H870@=&AE('-T=61I97,@=VEL
M;"!B92!C;VUP;&5T960@=VET:&EN(#$R(&UO;G1H<R!O9B!T:&4@97AE8W5T
M:6]N(&]F('1H92!A9W)E96UE;G0N)B,Q-C`[)B,Q-C`[07,@;6]D96QS+"!A
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M=6QY(#,Q+"`R,#$Q+"!A<R!N;R!M;V1E;',@=V5R92!D96QI=F5R960N(%1H
M92!#;VUP86YY(&5X<&5C=',@=&AE(&UO9&5L<R!W:6QL(&)E9VEN(&)E:6YG
M(&1E;&EV97)E9"!I;B!T:&4@<V5C;VYD('%U87)T97(@;V8@;W5R(&9I<V-A
M;"!Y96%R(&5N9&EN9R!!<')I;"`S,"P@,C`Q,BX@0V5P:&%L;VX@=VEL;"P@
M=6YD97(@8V5R=&%I;B!C;VYD:71I;VYS+"!A;'-O('!A>2!T:&4@0V]M<&%N
M>2!V87)I;W5S(&%M;W5N=',@=7!O;B!A8VAI979I;F<@8V5R=&%I;B!M:6QE
M<W1O;F5S+B!0;W1E;G1I86P@;6EL97-T;VYE('!A>6UE;G1S('5N9&5R('1H
M92!!9W)E96UE;G0@=&]T86P@)FYB<W`[)#(W)B,Q-C`[;6EL;&EO;BX@26X@
M861D:71I;VXL('5N9&5R(&-E<G1A:6X@8V]N9&ET:6]N<RP@0V5P:&%L;VX@
M=VEL;"!P87D@=&AE($-O;7!A;GD@<F]Y86QT:65S(&]N(&%N>2!C;VUM97)C
M:6%L:7IE9"!P<F]D=6-T<R!D979E;&]P960@=6YD97(@=&AE($%G<F5E;65N
M="X-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D:78^#0H\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%64<^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W5P<&QE;65N=&%L($-A<V@@1FQO=R!)
M;F9O<FUA=&EO;B`H=6YA=61I=&5D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!#87-H($9L
M;W<@16QE;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H($9L;W<L(%-U<'!L96UE;G1A;"!$
M:7-C;&]S=7)E<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^3F]T92`Q,"X@4W5P<&QE;65N
M=&%L($-A<V@@1FQO=R!);F9O<FUA=&EO;B`-"CPO9F]N=#X-"CPO9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB
M<B`O/@T*#0H\+V1I=CX\9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[=&5X="UI;F1E;G0Z.7!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^5&AE<F4@=V%S(&YO(&-A<V@@<&%I9"!F;W(@:6YT97)E<W0@
M;W(@:6YC;VUE('1A>&5S(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($IU;'D@,S$L(#(P,3$@86YD(#(P,3`N#0H\+V9O;G0^#0H\+V1I=CX-"CPO
M9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%64<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1W)A;G0@26YC;VUE("AU;F%U9&ET960I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1W)A;G0@26YC;VUE(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1W)A;G0@26YC;VUE(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[=&5X="UA;&EG;CIJ=7-T:69Y.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^3F]T92`Q,2X@1W)A;G0@
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M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@3V-T;V)E<B`R.2P@
M,C`Q,"P@=&AE($-O;7!A;GD@=V%S(&YO=&EF:65D('1H870@:70@=V%S(&%W
M87)D960@=&]T86P@8V%S:"!G<F%N=',@;V8@87!P<F]X:6UA=&5L>2`F;F)S
M<#LD,2XU(&UI;&QI;VX@=6YD97(@=&AE(%%U86QI9GEI;F<@5&AE<F%P975T
M:6,@1&ES8V]V97)Y(%!R;VIE8W0@<')O9W)A;2!A9&UI;FES=&5R960@=6YD
M97(@<V5C=&EO;B`T.$0@;V8@=&AE($EN=&5R;F%L(%)E=F5N=64@0V]D92P@
M;V8@=VAI8V@@87!P<F]X:6UA=&5L>2`F;F)S<#LD,2XP(&UI;&QI;VX@<F5L
M871E9"!T;R!Q=6%L:69Y:6YG(&5X<&5N<V5S('1H92!#;VUP86YY(&AA9"!P
M<F5V:6]U<VQY(&EN8W5R<F5D(&1U<FEN9R!F:7-C86P@,C`Q,"!A;F0@)FYB
M<W`[)#`N-2!M:6QL:6]N(')E;&%T960@=&\@<75A;&EF>6EN9R!E>'!E;G-E
M<R!W:&EC:"!T:&4@0V]M<&%N>2!E>'!E8W1E9"!T;R!I;F-U<B!D=7)I;F<@
M9FES8V%L(#(P,3$N)B,Q-C`[)B,Q-C`[26X@3F]V96UB97(@,C`Q,"P@=&AE
M($-O;7!A;GD@<F5C96EV960@87!P<F]X:6UA=&5L>2`F;F)S<#LD,2XP(&UI
M;&QI;VX@86YD(&5X<&5C=',@=&\@<F5C96EV92`F;F)S<#LD,"XU(&UI;&QI
M;VX@<F5L871E9"!T;R!T:&4@,C`Q,2!E>'!E;F1I='5R97,@9'5R:6YG('1H
M92!#;VUP86YY)B,X,C$W.W,@9FES8V%L('EE87(N)B,Q-C`[)B,Q-C`[5&\@
M9&%T92P@=&AE("9N8G-P.R0P+C4@;6EL;&EO;B!H87,@;F]T(&)E96X@<F5C
M96EV960N#0H\+V9O;G0^#0H\+V1I=CX\8G(@+SX-"CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-3(U-CEB-C9?8S4V
M8U\T8V(Q7V(U-S9?9F0S,C`Y-3)D-#1B#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S4R-38Y8C8V7V,U-F-?-&-B,5]B-3<V7V9D,S(P.34R9#0T
M8B]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B
M=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\
M;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*/"]X;6P^#0HM+2TM
M+2T]7TYE>'1087)T7S4R-38Y8C8V7V,U-F-?-&-B,5]B-3<V7V9D,S(P.34R
(9#0T8BTM#0H`
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
